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A B S T R A C T
Background
Prolonging kidney transplant survival is an important clinical priority. Induction immunosuppression with antibody therapy is recom-
mended at transplantation and non-depleting interleukin-2 receptor monoclonal antibodies (IL2Ra) are considered first line. It is suggest-
ed that recipients at high risk of rejection should receive lymphocyte-depleting antibodies but the relative benefits and harms of the avail-
able agents are uncertain.
Objectives
We aimed to: evaluate the relative and absolute effects of different antibody preparations (except IL2Ra) when used as induction therapy
in kidney transplant recipients; determine how the benefits and adverse events vary for each antibody preparation; determine how the
benefits and harms vary for different formulations of antibody preparation; and determine whether the benefits and harms vary in specific
subgroups of recipients (e.g. children and sensitised recipients).
Search methods
We searched the Cochrane Kidney and Transplant's Specialised Register to 29 August 2016 through contact with the Information Specialist
using search terms relevant to this review.
Selection criteria
Randomised controlled trials (RCTs) comparing monoclonal or polyclonal antibodies with placebo, no treatment, or other antibody ther-
apy in adults and children who had received a kidney transplant.
Data collection and analysis
Two authors independently extracted data and assessed risk of bias. Dichotomous outcomes are reported as relative risk (RR) and contin-
uous outcomes as mean difference (MD) together with their 95% confidence intervals (CI).
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Main results
We included 99 studies (269 records; 8956 participants; 33 with contemporary agents). Methodology was incompletely reported in most
studies leading to lower confidence in the treatment estimates.
Antithymocyte globulin (ATG) prevented acute graB rejection (17 studies: RR 0.63, 95% CI 0.51 to 0.78). The benefits of ATG on graB rejec-
tion were similar when used with (12 studies: RR 0.61, 0.49 to 0.76) or without (5 studies: RR 0.65, 0.43 to 0.98) calcineurin inhibitor (CNI)
treatment. ATG (with CNI therapy) had uncertain effects on death (3 to 6 months, 3 studies: RR 0.41, 0.13 to 1.22; 1 to 2 years, 5 studies:
RR 0.75, 0.27 to 2.06; 5 years, 2 studies: RR 0.94, 0.11 to 7.81) and graB loss (3 to 6 months, 4 studies: RR 0.60, 0.34 to 1.05; 1 to 2 years,
3 studies: RR 0.65, 0.36 to 1.19). The effect of ATG on death-censored graB loss was uncertain at 1 to 2 years and 5 years. In non-CNI stud-
ies, ATG had uncertain effects on death but reduced death-censored graB loss (6 studies: RR 0.55, 0.38 to 0.78). When CNI and older non-
CNI studies were combined, a benefit was seen with ATG at 1 to 2 years for both all-cause graB loss (7 studies: RR 0.71, 0.53 to 0.95) and
death-censored graB loss (8 studies: RR 0.55, 0.39 to 0.77) but not sustained longer term. ATG increased cytomegalovirus (CMV) infection
(6 studies: RR 1.55, 1.24 to 1.95), leucopenia (4 studies: RR 3.86, 2.79 to 5.34) and thrombocytopenia (4 studies: RR 2.41, 1.61 to 3.61) but
had uncertain effects on delayed graB function, malignancy, post-transplant lymphoproliferative disorder (PTLD), and new onset diabetes
after transplantation (NODAT).
Alemtuzumab was compared to ATG in six studies (446 patients) with early steroid withdrawal (ESW) or steroid minimisation. Alemtuzumab
plus steroid minimisation reduced acute rejection compared to ATG at one year (4 studies: RR 0.57, 0.35 to 0.93). In the two studies with
ESW only in the alemtuzumab arm, the effect of alemtuzumab on acute rejection at 1 year was uncertain compared to ATG (RR 1.27, 0.50
to 3.19). Alemtuzumab had uncertain effects on death (1 year, 2 studies: RR 0.39, 0.06 to 2.42; 2 to 3 years, 3 studies: RR 0.67, 95% CI 0.15
to 2.95), graB loss (1 year, 2 studies: RR 0.39, 0.13 to 1.30; 2 to 3 years, 3 studies: RR 0.98, 95% CI 0.47 to 2.06), and death-censored graB
loss (1 year, 2 studies: RR 0.38, 0.08 to 1.81; 2 to 3 years, 3 studies: RR 2.45, 95% CI 0.67 to 8.97) compared to ATG. Creatinine clearance was
lower with alemtuzumab plus ESW at 6 months (2 studies: MD -13.35 mL/min, -23.91 to -2.80) and 2 years (2 studies: MD -12.86 mL/min,
-23.73 to -2.00) compared to ATG plus triple maintenance. Across all 6 studies, the effect of alemtuzumab versus ATG was uncertain on all-
cause infection, CMV infection, BK virus infection, malignancy, and PTLD. The effect of alemtuzumab with steroid minimisation on NODAT
was uncertain, compared to ATG with steroid maintenance.
Alemtuzumab plus ESW compared with triple maintenance without induction therapy had uncertain effects on death and all-cause graB
loss at 1 year, acute rejection at 6 months and 1 year. CMV infection was increased (2 studies: RR 2.28, 1.18 to 4.40). Treatment effects were
uncertain for NODAT, thrombocytopenia, and malignancy or PTLD.
Rituximab had uncertain effects on death, graB loss, acute rejection and all other adverse outcomes compared to placebo.
Authors' conclusions
ATG reduces acute rejection but has uncertain effects on death, graB survival, malignancy and NODAT, and increases CMV infection, throm-
bocytopenia and leucopenia. Given a 45% acute rejection risk without ATG induction, seven patients would need treatment to prevent
one having rejection, while incurring an additional patient experiencing CMV disease for every 12 treated. Excluding non-CNI studies, the
risk of rejection was 37% without induction with six patients needing treatment to prevent one having rejection.
In the context of steroid minimisation, alemtuzumab prevents acute rejection at 1 year compared to ATG. Eleven patients would require
treatment with alemtuzumab to prevent 1 having rejection, assuming a 21% rejection risk with ATG.
Triple maintenance without induction therapy compared to alemtuzumab combined with ESW had similar rates of acute rejection but
adverse effects including NODAT were poorly documented. Alemtuzumab plus steroid withdrawal would cause one additional patient
experiencing CMV disease for every six patients treated compared to no induction and triple maintenance, in the absence of any clinical
benefit. Overall, ATG and alemtuzumab decrease acute rejection at a cost of increased CMV disease while patient-centred outcomes (re-
duced death or lower toxicity) do not appear to be improved.
P L A I N   L A N G U A G E   S U M M A R Y
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
What is the issue?
A kidney transplant is the best treatment for many people who have severe kidney disease to allow patients to return to work and feel bet-
ter. Patients who receive a kidney transplant receive drugs to prevent their own body from rejecting the transplant - the aim of treatment
is to prolong the function of the kidney transplant while minimising common long-term side effects of treatment such as cancer, infection,
and diabetes. For some patients who have a much higher risk of rejection, additional treatment is given at the time of the operation (which
may lower the body's ability to attack the kidney transplant and increase kidney function but can increase the risk of complications such
as infection and cancer).
What did we do?
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We searched the Cochrane Kidney and Transplant's Specialised Register to 29 August 2016 for randomised controlled trials (RCTs) compar-
ing monoclonal or polyclonal antibodies with placebo, no treatment, or other antibody therapy in adults and children who had received
a kidney transplant.
What did we find?
We identified 99 studies (265 records; 8956 participants; 33 with contemporary agents). From the available studies in this area, an antibody
against human immune cells (ATG) reduces the chances of a patient having a kidney rejection by one-third, but it is uncertain whether
this prolongs the function of the kidney transplant or survival for the patient. ATG significantly increases viral infections including cy-
tomegalovirus. In addition, the effects of ATG treatment on cancer are not well understood. Alemtuzumab is another treatment which
has been compared to ATG in patients who have received less or no steroid therapy as part of their transplant treatment. Treatment with
alemtuzumab with lower steroid doses or no steroid treatment at all may lower a patient's risk of kidney rejection within a year after
transplantation when compared to ATG but overall the information about treatment benefits and harms of alemtuzumab in many clini-
cal situations are not certain. This means we are not confident about the effects of alemtuzumab on kidney function, patient survival or
treatment side-effects.
Conclusions
Overall the available research on antibody treatment for kidney transplantation is limited when clinicians and patients make joint deci-
sions about antibody therapy at the time of a kidney transplant because of the uncertain long term benefits and hazards of these treat-
ments.
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Summary of findings for the main comparison.
ATG compared with placebo or no induction for kidney transplant recipients
Patient or population: kidney transplant recipients
Settings:
Intervention: ATG
Comparison: placebo/no treatment
Illustrative comparative
risks* (95% CI)
Assumed risk Correspond-
ing risk
Outcomes
Placebo/no
treatment
ATG
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Medium risk populationDeath (including CNI)
Follow-up: median 24 months (IQR
12-24)
31 per 1000 23 per 1000
(8 to 64)
RR 0.75
(0.27 to 2.06)
632 (5) ⊕⊕⊝⊝
low1,2
 
Medium risk populationAll-cause graB loss (including CNI)
Follow-up: median 1 year (IQR 12-24) 109 per 1000 71 per 1000
(39 to 129)
RR 0.65
(0.36 to 1.19)
549 (3) ⊕⊕⊝⊝
low1,2
 
Medium risk populationDelayed graB function
Follow-up: N/A (immediate) 283 per 1000 263 per 1000
(221 to 311)
RR 0.93 (0.78 to 1.10) 1304 (9) ⊕⊕⊝⊝
low1,2
 
Medium risk populationAcute rejection (including CNI)
Follow-up: median 1 year (IQR 6-24) 365 per 1000 222 per 1000
(179 to 277)
RR 0.61
(0.49 to 0.76)
1491 (12) ⊕⊕⊕⊝
moderate1
 
Infection: CMV infection Medium risk population RR 1.55 1072 (6) ⊕⊕⊕⊝  
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Follow-up: median 1 year (IQR
4.5-13.5) 176 per 1000 273 per 1000(218 to 343)
(1.24 to 1.95) moderate1
Medium risk populationMalignancy
Follow-up: median 18 months (IQR
12-60)
15 per 1000 14 per 1000
(5 to 44)
RR 0.94
(0.30 to 2.94)
891 (7) ⊕⊕⊝⊝
low1,2,3
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval: RR: Risk Ratio; IQR: interquartile range.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 At risk of selection bias as more than 50% of studies rated as allocation concealment and/or random sequence generation unclear or high risk of causing bias.
2 Confidence interval includes range of plausible values below clinical significance or including harm.
3Based on few events across all studies.
 
 
Summary of findings 2.
Alemtuzumab plus ESW or steroid minimisation versus ATG for induction therapy for kidney transplant recipients
Patient or population: kidney transplant recipients
Settings:
Intervention: alemtuzumab plus ESW or steroid minimisation
Comparison: ATG ± ESW or steroid minimisation
Illustrative comparative
risks* (95% CI)
Assumed risk Correspond-
ing risk
Outcomes
ATG Alemtuzum-
ab
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
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Medium risk populationDeath (ESW both arms)
Follow-up: median 1 year (IQR 12-36) 102 per 1000 27 per 1000
(7 to 108)
RR 0.27 (0.07 to 1.06) 180 (3) ⊕⊕⊝⊝
low1,2
 
Medium risk populationAll-cause graB loss (ESW both arms)
Follow-up: median 18 months (IQR 12-30) 148 per 1000 89 per 1000
(50 to 160)
RR 0.60
(0.34 to 1.08)
360 (4) ⊕⊕⊝⊝
low1,2
 
Medium risk populationAcute rejection (ESW both arms)
Follow-up: median 18 months (IQR 12-30) 208 per 1000 119 per 1000
(73 to 193)
RR 0.57
(0.35 to 0.93)
360 (4) ⊕⊕⊕⊝
moderate1
 
Medium risk populationBiopsy-proven CAN (ESW with alemtuzumab
only)
Follow-up: median 30 months (IQR 24-36)
116 per 1000 284 per 1000
(118 to 689)
RR 2.45
(1.02 to 5.94)
86 (2) ⊕⊕⊝⊝
low1,2
 
Medium risk populationCMV infection (all studies)
Follow-up: median 30 months
(IQR 24-36)
80 per 1000 86 per 1000
(37 to 205)
RR 1.08
(0.46 to 2.56)
225 (3) ⊕⊕⊝⊝
low1,2
 
Medium risk populationNODAT (ESW alemtuzumab only)
Follow-up: median 30 months (IQR 24-36) 237 per 1000 97 per 1000
(28 to 332)
RR 0.41
(0.12 to 1.40)
69 (2) ⊕⊕⊝⊝
low1,2
 
Medium risk populationMalignancy (all studies)
Follow-up: median 36 months (IQR 12-36) 11 per 1000 54 per 1000
(6 to 452)
RR 4.93
(0.59 to 41.11)
187 (3) ⊕⊝⊝⊝
very low1,2,3
All reported
events from
single study
(other 2 stud-
ies reported 0
events)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval: RR: Risk Ratio; IQR: interquartile range.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
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Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 At risk of selection bias as more than 50% of studies rated as allocation concealment and/or random sequence generation unclear or high risk of causing bias.
2 Confidence interval includes range of plausible values below clinical significance or including harm.
3Based on few events across all studies.
 
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
Kidney transplantation is the treatment of choice for many patients
with end-stage kidney disease (ESKD) but demand exceeds supply
from organ donors. Increasing this supply and prolonging kidney
transplant survival are therefore important for patients and health
systems (Tonelli 2011).
Description of the intervention
Immunosuppressive therapy consists of initial induction and main-
tenance regimens to prevent rejection. Induction may be defined
as treatment with a biologic agent either before, at the time of,
or immediately after transplantation to deplete or modulate T cell
responses at the time of antigen presentation. Maintenance im-
munosuppression protocols usually involve three drugs acting on
different parts of the T-cell activation or proliferation cascade: cal-
cineurin inhibitors (CNI) (e.g. cyclosporin (CSA), tacrolimus), an-
tiproliferative agents (e.g. azathioprine, mycophenolate mofetil)
and corticosteroids (e.g. prednisolone) (Denton 1999; Hong 2000).
Induction immunosuppression with antibody therapy is now rec-
ommended at the time of transplantation for all patients (KDI-
GO 2009). Antibody therapies are monoclonal or polyclonal, and
depleting or non-depleting of lymphocytes. Non-depleting inter-
leukin-2 receptor monoclonal antibodies (IL2Ra) are considered
first line but it is suggested that recipients at high risk of rejec-
tion (e.g. children, subsequent transplants, certain racial groups
such as African-Americans, and other sensitised patients) should
receive lymphocyte-depleting antibodies. Depleting antibodies are
also used for those at risk of delayed graB function to delay the in-
troduction of full dose CNI, which can prolong the duration of acute
tubular necrosis (Denton 1999). Depleting antibodies include poly-
clonal antibodies against the human lymphocyte (antilymphocyte
globulin (ALG); antithymocyte globulin (ATG)).
How the intervention might work
Depleting antibodies bind to target immune effector cells leading
to complement mediated destruction. Non-depleting antibodies
bind to targets on effector cells preventing their interaction with
other cells rendering them ineffective, but do not lead to cell de-
struction.
Most antibodies used in transplantation have been directed at T
cells. Significant reduction in circulating T-effector cells is rapidly
observed, leading to impaired cell mediated immunity (the desired
effect to prevent kidney transplant rejection). A number of different
preparations of ATG have been produced over the last few decades.
These can be broadly divided into horse ATG (hATG), derived from
horse serum after immunisation of horses with human thymocytes,
and rabbit ATG (rATG), derived from rabbit serum. There are cur-
rently two or three standardised preparations available globally.
Historical ATG preparations used in early studies were less stan-
dardised compared to the preparations currently available. Even
though both hATG and rATG contain antibodies to a wide variety of
T-cell antigens and MHC antigens, it is likely that the effects are not
equal given that the two types are prepared differently. One study
assessing both efficacy and safety clearly showed differences be-
tween these two preparations (Brennan 1999).
Monomurab-CD3 is a murine monoclonal antibody against the CD3
receptor on activated T cells (Orthoclone OKT3) which became
available in the late 1980s. OKT3 removes the functional T-cell pop-
ulation from circulation, producing immunosuppression useful for
both induction therapy and the management of acute rejection.
However, this profound immunosuppression is associated with im-
mediate toxicity (cytokine release syndrome) and higher rates of
infection and malignancy than standard triple therapy (Soulillou
2001). Use of these preparations may also be limited by the devel-
opment of neutralising antibodies to their xenogeneic components
(Kreis 1992). Use of OKT3 for both induction and treatment of acute
rejection has declined in many countries over recent years due to
the side effect profile. Janssen-Cilag discontinued the manufacture
of OKT3 in 2010 due to a combination of declining sales and evi-
dence from a Cochrane review on treatment of acute rejection con-
firming that OKT3 was associated with increased side effects com-
pared to newer biologic agents (Webster 2006).
More recently, the IL2Ra basiliximab and daclizumab have been
used in the induction phase. IL2Ra are IgG monoclonal antibodies
to the interleukin-2 receptor found only on activated T cells. IL2Ra
are more specific immunosuppressants, with no immediate toxici-
ty, and are increasingly used as induction agents, but not for treat-
ing acute rejection (Cibrik 2001). These agents are investigated in
a separate Cochrane review (Webster 2010) and so will not be con-
sidered here.
Other antibodies have also been introduced for kidney transplan-
tation induction such as alemtuzumab. This humanised CD-52 spe-
cific complement fixing monoclonal antibody was first used for in-
duction by Calne 1999. Alemtuzumab causes profound depletion
of T-cells from peripheral blood and also less marked depletion of
other mononuclear cells.
Although the majority of current anti-rejection therapies are target-
ed at T-cell mechanisms, there is increasing evidence that B-cells
may have a role due to their ability to act as antigen presenting
cells and T-cell activators (Zand 2007). For this reason the B-cell de-
pleting anti-CD20 antibody, rituximab is also being used in kidney
transplantation.  Initially this was used in studies for ABO-incom-
patible kidney transplants at induction (Tyden 2003) but is now be-
ing considered for selected patients in some centres.
Why it is important to do this review
Favoured antibody preparations and rates of use differ from coun-
try to country and among transplant units. In 2007 in the USA, 78%
of recipients received an antibody preparation as part of induc-
tion immunosuppression. Forty five per cent of kidney recipients
received ATG, 1% OKT3, 27% IL2Ra and 10% received alemtuzum-
ab (UNOS 2011). In Australia, 93% of patients received an IL2Ra in
2008 and 5% to 10% received an additional or alternative antibody
preparation (ANZDATA 2009). There has clearly been an increase in
use of antibody induction therapy over the last decade (ANZDATA
2009; UNOS 2011) but there is still a large amount of variability in
the type of antibody preparation used. This reflects local policies to
some extent but there is also uncertainty, in particular in patients
at high risk of rejection, as to whether one agent is superior to an-
other. In patients at higher risk of rejection, increased risk of side
effects may be acceptable if a treatment is more effective at reduc-
ing the risk of acute rejection, leading to improved rates of allograft
and patient survival.
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The aim of this systematic review is to summarise the relative short
and long-term beneficial and adverse effects of different antibody
preparations (except IL2Ra) used as induction in kidney transplant
recipients. A previous Cochrane review looks at the use of antibod-
ies for treatment of acute rejection episodes (Webster 2006).
O B J E C T I V E S
• To evaluate the relative and absolute effects of different anti-
body preparations (except IL2Ra) when used as induction ther-
apy in kidney transplant recipients.• To determine how the benefits and adverse events vary for each
antibody preparation.• To determine how the benefits and harms vary for different for-
mulations of antibody preparation.• To determine whether the benefits and harms vary in specific
subgroups of recipients (e.g. children and sensitised recipients).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in
which allocation to treatment was obtained by alternation, use of
alternate medical records, date of birth or other predictable meth-
ods) looking at different antibody preparations (except IL2Ra) used
as induction in kidney transplant recipients.
Types of participants
Adults and children who are kidney transplant recipients.
Recipients of multi-organ transplants were excluded from this re-
view.
Types of interventions
We included studies using antibody preparations given in combina-
tion with any other immunosuppressive agents for induction ther-
apy.
Exclusions were IL2Ra, as they are the subject of a separate
Cochrane Review (Webster 2010). The authors also note that the
manufacture of OKT3 was discontinued in January 2010 but have
decided to include this agent in the interventions for historical pur-
poses.
We examined the following comparisons.
• ATG versus placebo/no treatment• ATG versus ALG• ATG versus a different ATG (e.g. rabbit versus horse)• ATG versus monomurab-CD3• ALG versus placebo/no treatment• ALG versus monomurab-CD3• Monomurab-CD3 versus placebo/no treatment• Alemtuzumab/anti-CD52 versus placebo/no treatment• Alemtuzumab/anti-CD52 versus other poly- or monoclonal anti-
body• Rituximab/anti-CD20 versus placebo/no treatment
• Rituximab/anti-CD20 versus other poly- or monoclonal anti-
body• Other poly- or monoclonal antibody versus placebo/no treat-
ment• Other poly- or monoclonal antibody versus other poly- or mon-
oclonal antibody• Antibody versus non-antibody intervention
The 'class effect' of anti-lymphocyte preparations was initially as-
sumed but differences in formulation were also examined (e.g.
rabbit versus horse-based ATG formulations). All dosage regimens
were included and low versus high dose regimens were examined.
Types of outcome measures
Where possible, outcome events were assessed at one, three and
six months, and at one, two, three and five years post-transplanta-
tion.
Primary outcomes• Death (all cause)• GraB loss (defined as dependence on dialysis, graB loss cen-
sored for death with a functioning allograft)• GraB loss including death with a functioning graB• Incidence of acute rejection of kidney (analysed as combined
outcome for clinical suspicion, biopsy-proven and steroid resis-
tant).
Secondary outcomes• Kidney allograft function: glomerular filtration rate (GFR), serum
creatinine (SCr), creatinine clearance (CrCl), or as defined by au-
thors• Incidence of delayed graB function• Incidence of bacterial, fungal and viral infectious complications
specifically including cytomegalovirus (CMV) (both asympto-
matic CMV viraemia and true cases of CMV infection with tissue
invasion were analysed as reported by the individual studies)
and Polyoma BK virus• Incidence of new-onset diabetes after transplantation (NODAT)• Incidence of any malignancy• Incidence of post-transplant lymphoproliferative disorders
(PTLD) and lymphoma• Incidence of treatment-related adverse reactions (gastrointesti-
nal, neurological, haematological, biochemical) and recognised
syndromes (e.g. serum sickness, cytokine release syndrome).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised Reg-
ister up to 29 August 2016 through contact with the Information
Specialist using search terms relevant to this review. The Cochrane
Kidney and Transplant Specialised Register contains studies iden-
tified from the following sources
1. Quarterly searches of the Cochrane Central Register of Con-
trolled Trials CENTRAL
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals & the proceedings of
major kidney conferences
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients (Review)
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4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney-journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal & ClinicalTrials.gov
Studies contained in the Specialised register are identified through
search strategies for CENTRAL, MEDLINE, and EMBASE based on the
scope of Cochrane kidney and Transplant. Details of these strate-
gies as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts are available in the 'Specialised
Register' section of information about the Cochrane Kidney and
Transplant.
See Appendix 1 for search terms used in strategies for this review.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and ab-
stracts of studies that might have been relevant to the review. The
titles and abstracts were screened independently by two authors,
who discarded studies that were not applicable. However, stud-
ies and reviews that might include relevant data or information
on studies were retained initially. Two authors independently as-
sessed retrieved abstracts and, if necessary the full text, of these
studies to determine which studies satisfy the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by two authors us-
ing standard data extraction forms. Studies reported in non-English
language journals were translated before assessment. Where more
than one publication of one study existed, records were grouped
together and the publication with the most complete data was used
in the analyses. Where relevant outcomes were only published in
earlier versions these data were used. Any discrepancy between
published versions was to be highlighted. Where duplicate publi-
cation was suspected authors were contacted for clarification and
if duplication was confirmed the initial full publication together
with any subsequent publication which adds additional informa-
tion (e.g. longer term follow-up data) was included in the review.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately pre-
vented during the study?* Participants and personnel (performance bias)* Outcome assessors(detection bias)• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e>ect
For dichotomous outcomes (e.g. rejection) results were expressed
as risk ratios (RR) with 95% confidence intervals (95% CI).
Where continuous scales of measurement were used to assess
the effects of treatment (e.g. CrCl), the mean difference (MD) was
used, or the standardised mean difference (SMD) if different scales
were used. For count data (such as total number of infections/per-
son-year of follow-up) the rate ratio was used. Where time-to-event
data could not be dichotomised, survival analysis methods were
used and the results expressed as hazard ratio (HR).
Where outcomes were not amenable to meta-analysis, i.e. if report-
ed idiosyncratically (e.g. drug-related specific adverse reactions),
they were tabulated and assessed with descriptive techniques, and
the risk difference (RD) with 95% CI was calculated. Quality of life
and economic data was analysed using descriptive techniques.
Assessment of heterogeneity
Clinical and methodological heterogeneity was analysed using a
Cochran Q test (Chi2 with N-1 degrees of freedom and a P value of
0.05 used for statistical significance) and with the I2 test (Higgins
2003). I2 values of 25%, 50% and 75% correspond to low, medium
and high levels of heterogeneity.
Assessment of reporting biases
Funnel plots were used to assess for the potential existence of small
study bias (Higgins 2011).
Data synthesis
Data was pooled using the random effects model (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was used to explore possible clinical sources of
heterogeneity.
• Baseline maintenance immunosuppression• Antibody formulation (e.g. rabbit versus horse ATG)• Duration and dose of antibody treatment.
'Summary of findings' tables
We have presented the main results of the review in 'Summary of
findings' tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the in-
terventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The 'Summary of findings'
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008). The GRADE approach defines the quality of a body
of evidence as the extent to which one can be confident that an es-
timate of effect or association is close to the true quantity of spe-
cific interest. The quality of a body of evidence involves considera-
tion of within-trial risk of bias (methodological quality), directness
of evidence, heterogeneity, precision of effect estimates and risk of
publication bias (Schünemann 2011b). We presented the following
outcomes in the 'Summary of findings' tables.
• Death• GraB loss
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients (Review)
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• Delayed graB function• Acute rejection• CMV infection• Malignancy• NODAT
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of exclud-
ed studies; Characteristics of studies awaiting classification; Char-
acteristics of ongoing studies.
Results of the search
After searching the Specialised Register we identified 452 records.
After duplicates were removed and titles and abstracts screened
we retrieved 285 full-text articles for further assessment. Of
these, 99 studies (268 records) were included and five studies
(8 records) were excluded. Three ongoing studies (NCT00733733;
NCT01154387; ReMIND Study 2013) were identified, and five stud-
ies (NCT00089947; NCT00861536; NCT01046955; NCT01354301;
Stevens 2016) were identified prior to publication. These eight stud-
ies and will be assessed in a future update of this review (Figure 1).
 
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
11
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 1.   Flow diagram of included and excluded studies.
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Figure 1.   (Continued)
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Included studies
Of the 99 included studies, 92 had data that could be used for meta-
analysis and these combined studies represented a total of 8802
randomised participants. ATG was used in 41 studies, alemtuzumab
in 11, OKT3 in 27, ALG in 26, rituximab in 3 and other antibodies in
5 studies.
There were 19 comparisons of an antibody versus placebo or anti-
body versus other antibody that were studied in a single study on-
ly. These are briefly discussed in the text below but have not been
meta-analysed.
Interventions
Number of studies (participants) in included studies by compar-
ison
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients (Review)
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  ATG ALG Alemtuzumab Rituximab OKT3 Othera Placebo
ATG 9 (513)b 1 (50) 6 (446) - 6 (571) 2 (141) 17 (2044)
ALG - 3 (254)b - - 7 (644) - 16 (1809)
Alemtuzumab - - - - - - 4 (296)
Rituximab - - - - - - 3 (447)
OKT3 - - - - 2 (55)b - 12 (1184)
Othera - - - - 1 (20) - 3 (328)
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a Includes the following; anti CD2 rat monoclonal antibody, an-
ti CD7 monoclonal antibody, anti-LFA-1 monoclonal antibody, an-
ti-ICAM-1 monoclonal antibody, rituximab combined with ATG,
bortezomib combined with ATG, both rituximab and bortezomib
combined with ATG.
b Indicates studies comparing different doses or formulations of
same agent.
ATG versus placebo/no treatment
Twelve studies (1491 participants) compared ATG with placebo or
no treatment in a CNI-based regimen (Banhegyi 1991; Charpentier
2002; Kasiske 1997; Khosroshahi 2008; Martins 2004; Mourad 1998;
Samsel 1999; Sheashaa 2008; Thibaudin 1998; TRIMS Study 2010;
van den Hoogen 2013; Yussim 2000), and a further five studies (553
participants) in a non-CNI-based regimen (Cosimi 1976; Diethelm
1979; Kountz 1977; Kreis 1986; Wechter 1979).
Rabbit ATG versus horse ATG
Three studies (155 participants) compared rATG with hATG in a CNI-
based regimen (Bock 1999; Brennan 1999; Rostaing 2010).
ATG versus alemtuzumab
Six studies (446 participants) compared ATG with alemtuzumab.
Four studies had early steroid withdrawal (ESW) or steroid minimi-
sation in both arms in a CNI-based regimen (Farney 2008; Hanaway
2011; Lu 2011; Thomas 2007) and two studies had ESW in the alem-
tuzumab arm only (Ciancio 2005; Ciancio 2010) and triple mainte-
nance in the ATG groups.
Alemtuzumab versus placebo/no treatment
Four studies (296 participants) compared alemtuzumab with place-
bo or no treatment. Three of four studies used ESW with either sin-
gle or double agent maintenance immunosuppression in the alem-
tuzumab group (CAMPASIA Study 2005; Margreiter 2008; Sharaf El
Din 2006) versus triple therapy maintenance in the control group,
and one study (Friend 1987) used ESW and single agent CSA main-
tenance in both groups.
Rituximab versus placebo
Three studies (447 participants) compared rituximab with placebo
(Smeekens 2013; Tsai 2012; Tyden 2009).
ATG versus OKT3
Six studies (571 participants) compared ATG with OKT3 (Bock 1995;
Cole 1994; Fukuuchi 1996; Kumar 1998a; Perez-Tamajon 1996;
Raffaele 1991). Maintenance immunosuppression was CNI-based
triple therapy and the same in both arms for all six studies.
OKT3 versus placebo/no treatment
Twelve studies (1184 participants) compared OKT3 with placebo or
no treatment (Abramowicz 1992; Ackermann 1988; Benfield 1999;
Debure 1987; De Pauw 1990; Henry 2001; Kreis 1986; Morales 1994a;
Norman 1988; Norman 1993; Shield 1993; Vigeral 1986).
ALG versus OKT3
Six studies (593 participants) compared ALG with OKT3 (Broyer
1993; Frey 1991; Grino 1991; Hanto 1991; Niaudet 1990; Vela 1994).
ALG versus placebo/no treatment
Sixteen studies (1809 participants) compared ALG with placebo or
no treatment (Belitsky 1991; Bell 1983; Cantarovich 2008; Condie
1985; Gianello 1987; Grundmann 1984; Halloran 1982; Jakobsen
1981; Grino 1990; Launois 1977; Maiorca 1984; Minnesota Study
1982; Novick 1983; Sansom 1976; Slakey 1993; Taylor 1976).
Other antibodies
Five studies looked at single antibody comparisons each: anti-CD2
rat monoclonal antibody versus placebo (40 participants, Squif-
flet 1997), anti-CD7 monoclonal antibody versus OKT3 (20 par-
ticipants, Lazarovits 1993), anti-LFA-1 monoclonal antibody ver-
sus placebo (22 participants, Spillner 1998), anti-LFA-1 monoclon-
al antibody versus ATG (101 participants, Hourmant 1996), and an-
ti-ICAM-1 monoclonal antibody versus placebo (266 participants,
EARTS Study 1999). One small pilot study compared ATG with 3 oth-
er combination induction regimens; ATG + rituximab, ATG + borte-
zomib; ATG + rituximab + bortezomib (40 participants, Ejaz 2013).
Other comparisons
A further thirteen studies looked at other ATG, OKT3 or ALG com-
parisons but each of these had only a single study for each compar-
ison. The ATG studies were:
• Single versus divided dose ATG (142 participants, Stevens 2008)• Two versus four doses (same total) of ATG (17 participants, Buch-
ler 2013)• rATG Fresenius versus rATG Merieux (90 participants, Norrby
1997)• ATG adjusted for CD3 count versus fixed dose (45 participants,
Abouna 1995)• ATG adjusted for CD3 count versus adjusted for total lymphocyte
count (21 participants, Ata 2013)• standard versus low dose ATG (43 participants, Grafals 2014)• ATG versus ALG (50 participants, Toledo-Pereyra 1985).
The OKT3 studies were:
• Standard versus low dose (26 participants, Norman 1993a)• Standard versus high dose (29 participants, Abramowicz 1994)• OKT3 versus ALG given only for delayed graB function (51 partic-
ipants, Steinmuller 1991).
The remaining ALG studies were:
• Low versus high dose (83 participants, Sakhrani 1992)• Low potency versus high potency ALG (71 participants, Thomas
1977)• Fourteen versus 7 days induction (100 participants, Grundmann
1987).
Reported outcome measures
The reporting of outcome measures was variable across studies:
83 reported patient death, 70 reported all-cause graB loss and 24
death-censored graB loss while 84 reported acute rejection and 42
reported delayed graB function (see Figure 1). Acute rejection was
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reported in a further seven studies but could not be used in meta-
analysis as rejection was either reported without actual figures or
reported as total number of episodes rather than number of par-
ticipants. GraB function was reported at a variety of time points
in 33 studies. Some studies reporting graB function could not be
included in meta-analysis as there was no SD or SE reported. Re-
porting of harms was more limited and inconsistent among studies.
Participants with any serious infection were reported in 61 (66%)
studies, however a further 7 studies also assessed infection, but ex-
pressed their results as ‘infectious episodes’, or reported no actual
figures and so this data could not be easily meaningfully combined.
CMV infection was reported in 35 studies and BKV infection in on-
ly 7 studies. Malignancy and PTLD were reported in only 30 studies
and NODAT in 12. Haematological effects were reported in very few
studies; 16 reported leucopenia and 12 thrombocytopenia. Very
small numbers of studies reported other adverse outcomes includ-
ing serum sickness, tremor, headache, chronic allograft nephropa-
thy (on biopsy) and failure to complete induction therapy.
Excluded studies
Five studies were excluded (Alloway 1993; Kirsch 2006; Kumar
2002b; NCT00000936; NCT01312064). The reasons for exclusion
were:
• Mixed population and data could not be separated (Alloway
1993)• No outcomes of interest were reported (Kirsch 2006)• Not a true randomisation (Kumar 2002b)• Study terminated and no results published (NCT00000936;
NCT01312064).
Risk of bias in included studies
Reporting of details of study methodology was incomplete for the
majority of studies. Details are summarised in Figure 2 and Figure 3.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
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Figure 2.   (Continued)
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Figure 2.   (Continued)
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Figure 2.   (Continued)
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Allocation
Twenty studies reported adequate sequence generation, and 27
reported adequate allocation concealment. Five studies used in-
adequate methods of sequence generation and four used inade-
quate allocation concealment. The remainder (74 studies for se-
quence generation and 68 for allocation concealment) used un-
clear methodology.
Blinding
Seventy-six studies adequately reported blinding of participants
and personnel, and 54 studies adequately reported blinding of out-
come assessment. Two studies had inadequate blinding of partic-
ipants and personnel and six studies had inadequate blinding of
outcome assessment. The remainder had unclear methods.
Incomplete outcome data
Incomplete outcome data was adequately addressed in 68 studies,
and inadequately in eight studies. The remainder were unclear.
Selective reporting
Forty-five studies were free of selective reporting, 43 studies were
inadequate, while the remainder of studies were unclear.
Other potential sources of bias
Thirteen studies declared their funding source to be independent
or academic funding body, and so were judged free of other poten-
tial biases. Twenty-eight studies were deemed to be high risk of oth-
er bias due to funding from a pharmaceutical company or author
links to industry or other reasons not covered by above bias assess-
ments. Others did not disclose the funding source of the study or
gave limited information about funding and were judged unclear.
E>ects of interventions
See: Summary of findings for the main comparison; Summary of
findings 2
ATG versus placebo/no induction treatment
ATG had little or no effect on death at 1 to 2 years compared to
placebo or no treatment in older studies without CNI maintenance
(Analysis 1.1.3 (6 studies, 621 participants): RR 1.03, 95% CI 0.86 to
1.22; I2 = 0%) and uncertain effect in more contemporary studies
including CNI maintenance (Analysis 1.1.2 (5 studies, 632 partici-
pants): RR 0.75, 95% CI 0.27 to 2.06; I2 = 0%). In the CNI studies, there
was also uncertain effect on death at 3 to 6 months (Analysis 1.1.1
(3 studies, 523 participants): RR 0.41, 95% CI 0.13 to 1.22; I2 = 0%)
and at 5 years (Analysis 1.1.4 (2 studies, 159 participants): RR 0.94,
95% CI 0.11 to 7.81; I2 = 48%).
Treatment with ATG had uncertain effect on all-cause graB loss in
CNI studies at 3 to 6 months (Analysis 1.2.1 (4 studies, 638 partici-
pants): RR 0.60, 95% CI 0.34 to 1.05; I2 = 0%), at 1 to 2 years (Analysis
1.2.2 (3 studies, 549 participants): RR 0.65, 95% CI 0.36 to 1.19; I2 =
6%) and at 5 years (Analysis 1.2.4 (2 studies, 159 participants): RR
1.13, 95% CI 0.62 to 2.05; I2 = 0%). However, ATG reduced graB loss
in the non-CNI studies at 1 to 2 years (Analysis 1.2.3 (4 studies, 500
participants): RR 0.70, 95% CI 0.49 to 1.01; I2 = 50%). When CNI and
non-CNI studies were combined, ATG reduced all-cause graB loss
at 1 to 2 years (Analysis 1.2.5 (7 studies, 1049 participants): RR 0.71,
95% CI 0.53 to 0.95; I2 = 35%).
Death-censored graB loss was reduced at 1 to 2 years in non-CNI
studies (Analysis 1.3.2 (6 studies, 299 participants): RR 0.55, 95% CI
0.38 to 0.78; I2 = 0%) but there was uncertain effect in CNI studies
at 2 years (Analysis 1.3.1 (2 studies, 82 participants): RR 0.57, 95%
CI 0.19 to 1.75; I2 = 0%) and at 5 years (Analysis 1.3.3 (2 studies, 148
participants): RR 1.64, 95% CI 0.20 to 13.18; I2 = 71%). Again, if CNI
and non-CNI studies were combined then death censored graB loss
was significantly reduced with ATG at 1 to 2 years (Analysis 1.3.4 (8
studies, 381 participants): RR 0.55, 95% CI 0.39 to 0.77; I2 = 0%).
ATG prevented acute rejection (Analysis 1.4 (17 studies, 2044 partic-
ipants): RR 0.63, 95% CI 0.51 to 0.78; I2 = 65%). The relative reduc-
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tion in risk of rejection was similar in studies including CNI mainte-
nance (Analysis 1.4.1 (12 studies, 1491 participants): RR 0.61, 95% CI
0.49 to 0.76; I2 = 35%) compared to non-CNI studies (Analysis 1.4.2
(5 studies, 553 participants): RR 0.65, 95% CI 0.43 to 0.98; I2 = 73%)
(P = 0.79; I2 = 0% for subgroup analysis).
ATG had little or no effect on delayed graB function (Analysis 1.5 (9
studies, 1304 participants): RR 0.93, 95% CI 0.78 to 1.10; I2 = 0%).
ATG increased CMV infection (Analysis 1.6.2 (6 studies, 1072 partici-
pants): RR 1.55, CI 1.24 to 1.95; I2 = 0%) but had uncertain effects on
all-cause viral infection (Analysis 1.6.4 (3 studies, 197 participants):
RR 1.38, 95% CI 0.56 to 3.39; I2 = 46%) and bacterial infection (Analy-
sis 1.6.5 (5 studies, 775 participants): RR 1.15, 95% CI 0.96 to 1.37;
I2 = 0%).
Leucopenia (Analysis 1.7 (4 studies, 920 participants): RR 3.86, 95%
CI 2.79 to 5.34; I2 = 0%) and thrombocytopenia (Analysis 1.8 (4 stud-
ies, 848 participants): RR 2.41, 95% CI 1.61 to 3.61; I2 = 0%) were
both increased by ATG.
ATG had uncertain effects on both early malignancy at 1 to 2 years
(Analysis 1.9.1 (3 studies, 611 participants): RR 0.94, 95% CI 0.22 to
3.94; I2 = 0%) and on late malignancy at 5 years (Analysis 1.9.2 (2
studies, 159 participants): RR 0.94, 95% CI 0.14 to 6.23; I2 = 0%). The
single study (151 participants) that reported PTLD had no events at
1 year in either arm (Analysis 1.9).
ATG had uncertain effect on development of NODAT (Analysis 1.10.1
(6 studies, 935 participants): RR 1.01, 95% CI 0.56 to 1.84; I2 = 39%).
There was no difference in SCr at 6 months (Analysis 1.11.1 (2 stud-
ies, 503 participants): MD -5.34 µmol/L, 95% CI -13.44 to 2.75; I2 =
0%), 1 year (Analysis 1.11.2 (2 studies, 222 participants): MD -10.56
µmol/L, 95% CI -21.81 to 0.69) or 5 years (Analysis 1.11.5 (1 study,
55 participants): MD -32.70 µmol/L, 95% CI -68.98 to 3.58) following
ATG therapy in studies including CNI maintenance. There was also
no difference in SCr at 1 year in the single non CNI study that as-
sessed graB function (Turcotte 1973). GraB function measured by
eGFR was only assessed in one study (Sheashaa 2008) and was sim-
ilar between treatment groups at 5 years (1 study, 71 participants:
MD 4.80 mL/min, 95% CI -2.57 to 12.17).
Rabbit ATG versus horse ATG
There was sparse data for meta-analyses comparing rATG versus
hATG. rATG had uncertain effects on death at 1 year (Analysis 2.1.1
(2 studies, 139 participants): RR 0.41, 95% CI 0.07 to 2.30; I2 = 0%)
and on long-term death at 10 years (Analysis 2.2.2 (1 study, 72 par-
ticipants): RR 0.75, 95% CI 0.35 to 1.59) compared to hATG. The ef-
fect on all-cause graB loss was also uncertain at both 1 year (Analy-
sis 2.1.3 (2 studies, 139 participants: RR 0.31, 95% CI 0.08 to 1.27; I2
= 14%) and at 10 years (Analysis 2.1.4 (1 study, 72 participants: RR
0.96, 95% CI 0.58 to 1.58).
rATG prevented acute rejection (2 studies, 88 participants: RR 0.17,
95% CI 0.04 to 0.76) compared to hATG although one study reported
no events (Rostaing 2010).
Single studies reported uncertain effects of rATG compared to hATG
with respect to delayed graB function (Rostaing 2010) (Analysis
2.1.7, 16 participants: RR 0.50, 95% CI 0.06 to 4.47), all-cause infec-
tion (Rostaing 2010) (Analysis 2.2.1, 16 participants: RR 1.67, 95%
CI 0.59 to 4.73), and malignancy (Brennan 1999) (Analysis 2.2.4, 72
participants: RR 0.40, 95% CI 0.12 to 1.35).
Brennan 1999 reported CMV disease was reduced with rATG at 1
year (Analysis 2.2.2, 72 participants: RR 0.38, 95% CI 0.15 to 0.96),
more leucopenia with rATG compared to hATG (analysis 2.2.3, 72
participants: RR 13.50, 95% CI 1.95 to 93.46), and graB function was
better at 10 years with a lower SCr in the hATG group (Analysis 2.3,
35 participants: MD 44.0 µmol/L, 95% CI 20.41 to 67.59).
Alemtuzumab versus ATG
The effects of alemtuzumab (with ESW or minimisation) compared
to ATG on death were uncertain both at 1 year (Analysis 3.1.1 (2 stud-
ies, 41 participants): RR 0.39, 95% CI 0.06 to 2.42; I2 = 0%) and at 2
to 3 years (Analysis 3.1.2 (3 studies, 225 participants): RR 0.67, 95%
CI 0.15 to 2.95; I2 = 33%). Similarly, alemtuzumab had uncertain ef-
fect on all-cause graB loss at 1 year (Analysis 3.1.3 (2 studies, 41 par-
ticipants): RR 0.39, 95% CI 0.12 to 1.30; I2 = 0%) and at 2 to 3 years
(Analysis 3.1.4 (3 studies, 379 participants): RR 0.98, 95% CI 0.47 to
2.06; I2 = 42%) and on death-censored graB loss at 1 year (Analysis
3.1.5 (2 studies, 37 participants): RR 0.38, 95% CI 0.08 to 1.81; I2 =
0%) and at 2 to 3 years (Analysis 3.1.6 (2 studies, 186 participants):
RR 2.45, 95% CI 0.67 to 8.97; I2 = 17%) compared to ATG. There was
also uncertain effect of alemtuzumab versus ATG on delayed graB
function (Analysis 3.1.7 (2 studies, 86 participants): RR 0.62, 95% CI
0.13 to 3.07; I2 = 0%).
Alemtuzumab had uncertain effect on acute rejection in the first 6
months (Analysis 3.2.1 (3 studies, 341 participants): RR 0.47, 95%
CI 0.17 to 1.30; I2 = 32%) and at 1 year or more (Analysis 3.2.2 (6
studies, 446 participants: RR 0.68, 95% CI 0.44 to 1.05; I2 = 0%).
Two of these 6 studies favoured ATG (Ciancio 2005; Ciancio 2010)
while the other four favoured alemtuzumab (Farney 2008; Hanaway
2011; Lu 2011; Thomas 2007). This difference may be explained by
ESW in the alemtuzumab group but not the ATG group in two stud-
ies (Ciancio 2005; Ciancio 2010), compared to ESW in both arms
in the other four studies. Subgroup analysis of these four studies
showed acute rejection was reduced at 1 year and beyond by alem-
tuzumab compared to ATG in studies with ESW in both arms (Analy-
sis 3.2.3 (4 studies, 360 participants: RR 0.57, 95% CI 0.35 to 0.93;
I2 = 0%) (test for subgroup differences, P = 0.13). Subgroup analy-
sis of the two studies with alemtuzumab plus ESW versus ATG and
steroid continuation showed the effect of alemtuzumab and ESW
on acute rejection at 1 year was uncertain (Analysis 3.2.4 (2 studies,
86 participants): RR 1.27, 95% CI 0.50 to 3.19; I2 = 0%). The results
of all outcomes other than acute rejection were not significantly al-
tered when subgroup analysis was done including only studies with
steroid avoidance in both the alemtuzumab and ATG arms.
There was an increased rate of chronic allograft nephropathy (CAN)
on biopsy with alemtuzumab plus ESW but this was only assessed
in the 2 studies that had triple maintenance immunosuppression
in the ATG arms (Analysis 3.2.5 (2 studies, 86 participants): RR 2.64,
95% CI 1.09 to 6.36; I2 = 0%). The classification of CAN is a histor-
ical one, present in the original BanI 1997 diagnostic categories
(Racusen 1999) but removed in the 2005 update (Solez 2007).
Alemtuzumab had uncertain effect on all-cause infection (Analysis
3.3.1 (4 studies, 247 participants): RR 0.94, 95% CI 0.63 to 1.41; I2 =
0%), CMV infection (Analysis 3.3.2 (3 studies, 225 participants): RR
1.08, 95% CI 0.46 to 2.56; I2 = 0%), and BKV infection (Analysis 3.3.3
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(2 studies, 86 participants: RR 3.00 95% CI 0.13 to 70.83; I2 = 0%),
when compared to ATG.
Risk of leucopenia was assessed in one study (Ciancio 2005) and
was increased at one month with alemtuzumab compared to ATG
(Analysis 3.4.1 (60 participants): RR 21.00, 95% CI 1.29 to 342.93) but
not at two years (Analysis 3.4.2 (53 participants): RR 3.12, 95% CI
0.13 to 70.83).
The effect of alemtuzumab plus ESW and dual maintenance
(tacrolimus and mycophenolate) versus ATG and triple mainte-
nance (CNI, steroid and either azathioprine or mycophenolate) on
NODAT was uncertain (Analysis 3.4.3 (2 studies, 69 participants): RR
0.41, 95% CI 0.12 to 1.40; I2 = 0%).
There was uncertain effect of alemtuzumab compared to ATG for
other harms including malignancy (Analysis 3.4.4 (3 studies, 187
participants): RR 4.93, 95% CI 0.59 to 41.11), PTLD (Analysis 3.4.5 (2
studies, 165 participants): no events), cytokine release syndrome
(Analysis 3.4.6 (1 study, 22 participants): RR 0.20, 95% CI 0.01 to
3.74), or occurrence of any serious adverse event (Analysis 3.4.7 (1
study, 139 participants): RR 0.81, 95% CI 0.59 to 1.12).
GraB function measured by CrCl was lower with alemtuzumab plus
ESW and dual maintenance at six months (Analysis 3.5.1 (2 studies,
83 participants): MD -13.35 mL/min, 95% CI -23.91 to -2.80; I2 = 0%)
and two years (Analysis 3.5.2 (2 studies, 77 participants): MD -12.86
mL/min, 95% CI -23.73 to -2.00; I2 = 0%) compared to ATG plus triple
maintenance.
Alemtuzumab (and ESW) versus no induction
Three of the four studies used triple maintenance immunosuppres-
sion including steroids in the control group (CAMPASIA Study 2005;
Margreiter 2008; Sharaf El Din 2006), Friend 1987 used only CSA.
Sensitivity analyses excluding Friend 1987 did not significantly alter
the summary risk ratio for any outcomes for the remaining studies.
Results are therefore reported including all four studies.
Alemtuzumab and ESW had uncertain effect on death (Analysis
4.1.1 (4 studies, 296 participants): RR 1.54, 95% CI 0.60 to 4.00; I2
= 0%) and all-cause graB loss (Analysis 4.1.2 (4 studies, 296 partici-
pants): RR 0.86, 95% CI 0.47 to 1.59; I2 = 0%) at 6 to 12 months com-
pared to no induction.
Alemtuzumab and ESW had little or no effect on acute rejection
within 6 months compared with no induction (Analysis 4.1.3 (3
studies, 213 participants): RR 0.72, 95% CI 0.48 to 1.08; I2 = 0%) and
had uncertain effect at 1 year or later (Analysis 4.1.4 (4 studies, 244
participants): RR 0.89, 95% CI 0.42 to 1.87; I2 = 32%).
CAMPASIA Study 2005 showed uncertain effects of alemtuzumab
on delayed graB function (Analysis 4.1.5 (30 participants): RR 2.00,
95% CI 0.26 to 15.62)
The risk of CMV infection was increased with alemtuzumab (Analy-
sis 4.2.1 (2 studies, 161 participants): RR 2.28, 95% CI 1.18 to 4.40;
I2 = 0%) compared with control.
The effect of alemtuzumab was imprecise for all-cause infection
(Analysis 4.2.2 (3 studies, 213 participants): RR 1.15, 95% CI 0.46 to
2.89; I2 = 71%), NODAT (Analysis 4.2.3 (2 studies, 161 participants):
RR 0.57, 95% CI 0.13 to 2.46; I2 = 0%), and thrombocytopenia (Analy-
sis 4.2.4 (1 study, 30 participants): RR 1.33, 95% CI 0.45 to 3.96).
Malignancy and PTLD were assessed in CAMPASIA Study 2005 and
there were no events reported in either group.
There was little or no effect on graB function measured by SCr with
alemtuzumab and ESW compared to no induction both at 6 months
(Analysis 4.3.1 (1 study, 27 participants): MD -5.00 µmol/L, 95% CI
-28.90 to 18.90) and 1 year (Analysis 4.3.2 (2 studies, 108 partici-
pants): MD -2.89 µmol/L, 95% CI -43.29 to 37.52; I2 = 0%).
Rituximab versus placebo
Only death and acute rejection were reported in all three studies
comparing rituximab versus placebo.
Rituximab had uncertain effect on death both at 6 months (Analysis
5.1.1 (3 studies, 447 participants): RR 0.55, 95% CI 0.18 to 1.71; I2 =
0%) and at 3 to 4 years (Analysis 5.1.2 (2 studies, 381 participants):
RR 2.06, 95% CI 0.27 to 15.64; I2 = 74%) when compared to placebo.
There was uncertain effects of rituximab on all-cause graB loss
(Analysis 5.1.3 (2 studies, 416 participants): RR 0.58, 95% CI 0.26 to
1.28; I2 = 0%) and death-censored graB loss (Analysis 5.1.4 (2 stud-
ies, 405 participants): RR 0.55, 95% CI 0.21 to 1.46; I2 = 0%) at 6
months.
Acute rejection was not reduced at 6 months with rituximab com-
pared to placebo (Analysis 5.1.5 (3 studies, 447 participants): RR
0.73, 95% CI 0.48 to 1.10; I2 = 0%).
Leucopenia at 6 months was increased (Analysis 5.2.4 (2 studies,
416 participants): RR 8.15, 95% CI 2.00 to 33.15; I2 = 21%) with rit-
uximab compared to placebo.
The effect of rituximab on CMV infection, BKV infection, fungal in-
fection and malignancy was also uncertain (Analysis 5.2).
There was little or no effect of rituximab on graB function (eGFR)
at 6 months (Analysis 5.3 (2 studies, 388 participants): MD 0.32 mL/
min, 95% CI -3.34 to 3.97; I2 = 0%).
ATG versus OKT3
ATG had uncertain effect on death at 6 to 12 months compared with
OKT3 (Analysis 6.1.1 (5 studies, 451 participants): RR 1.29, 95% CI
0.64 to 2.60; I2 = 0%) and no effect on death-censored graB loss at
6 to 12 months (Analysis 6.1.2 (5 studies, 439 participants): RR 1.00,
95% CI 0.64 to 1.57; I2 = 0%).
There was little or no effect on acute rejection with ATG compared
to OKT3 at 1 year (Analysis 6.1.3 (4 studies, 450 participants): RR
0.76, 95% CI 0.53 to 1.09; I2 = 67%) and on delayed graB function
(Analysis 6.1.4 (3 studies, 235 participants): RR 0.80, 95% CI 0.52 to
1.24; I2 = 0%).
ATG had no effect compared to OKT3 on CMV infection (Analysis
6.2.1 (3 studies, 274 participants): RR 1.13, 95% CI 0.88 to 1.46; I2
= 4%) and uncertain effects on bacterial infection (Analysis 6.2.2 (1
study, 50 participants): RR 0.51, 95% CI 0.20 to 1.32), leucopenia
(Analysis 6.2.3 (1 study, 104 participants): RR 1.92, 95% CI 0.78 to
4.74), thrombocytopenia (Analysis 6.2.4 (1 study, 104 participants):
RR 4.81, 95% CI 0.24 to 97.91), and the inability to complete induc-
tion due to side effects (Analysis 6.2.6 (2 studies, 131 participants):
RR 1.96, 95% CI 0.10 to 39.72; I2 = 50%). Malignancy was only report-
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ed in Bock 1995 and there were no events reported in either group
(Analysis 6.2.5).
Bock 1995 reported ATG had uncertain effects compared to OKT3
on graB function at 1 year (SCr) (Analysis 6.3 (88 participants): MD
0.00 µmol/L, 95% CI -3.56 to 3.56).
OKT3 versus placebo/no treatment
A reduction in death was seen with OKT3 compared to no induction
at 1 to 2 years (Analysis 7.1.1 (6 studies, 491 participants): RR 0.41,
95% CI 0.18 to 0.97; I2 = 0%) but the benefit was uncertain at 3 to
5 years (Analysis 7.1.2 (5 studies, 768 participants): RR 0.72, 95% CI
0.37 to 1.44; I2 = 38%).
The effect of OKT3 compared to no induction on graB loss was un-
certain both at 1 to 2 years (Analysis 7.1.3 (7 studies, 416 partici-
pants): RR 0.55, 95% CI 0.30 to 1.02; I2 = 0%) and at 3 to 5 years
(Analysis 7.1.4 (5 studies, 768 participants): RR 0.73, 95% CI 0.47 to
1.14; I2 = 65%).
Acute rejection was decreased with OKT3 compared to no induc-
tion for CNI studies (Analysis 7.1.5 (8 studies, 968 participants): RR
0.60, 95% CI 0.43 to 0.83; I2 = 79%) but the effect was uncertain in
non CNI studies (Analysis 7.1.6 (3 studies, 85 participants): RR 0.70,
95% CI 0.33 to 1.46; I2 = 86%).
The effect of OKT3 compared to placebo on delayed graB function
was uncertain (Analysis 7.1.7 (6 studies, 494 participants): RR 1.08,
95% CI 0.70 to 1.65; I2 = 63%)
Abramowicz 1992 showed an increased risk of all-cause infection
with OKT3 (Analysis 7.2.1 (108 participants): RR 1.38, 95% CI 1.04
to 1.82). OKT3 had uncertain effects on all other infection subtypes
including bacterial infection (Analysis 7.2.2 (3 studies, 366 partici-
pants): RR 1.01, 95% CI 0.76 to 1.34; I2 = 0%), all-cause viral infection
(Analysis 7.2.3 (2 studies, 353 participants: RR 0.99, 95% CI 0.72 to
1.37; I2 = 0%), CMV infection (Analysis 7.2.4 (3 studies, 332 partici-
pants): RR 1.52, 95% CI 0.82 to 2.84; I2 = 0%), Herpes Simplex virus
infection (Analysis 7.2.5 (1 study, 215 participants): RR 1.45, 95% CI
0.89 to 2.38), and fungal infection (Analysis 7.2.6 (3 studies, 568 par-
ticipants): RR 1.26, 95% CI 0.33 to 4.89; I2 = 68%).
The effect of OKT3 compared to placebo on malignancy and PTLD
was uncertain (Analysis 7.2.7 (3 studies, 610 participants): RR 1.34,
95% CI 0.52 to 3.50; I2 = 0%).
There was no difference in graB function measured by SCr with
OKT3 compared to placebo both at 3 months (Analysis 7.3.1 (3 stud-
ies, 226 participants): MD -0.93 µmol/L, 95% CI -15.78 to 13.93; I2 =
0%) and at 1 year (Analysis 7.3.2 (2 studies, 261 participants): MD
-6.22 µmol/L, 95% CI -18.21 to 5.76; I2 = 0%). The effect on graB func-
tion at 3 to 4 years was uncertain with only 2 studies reporting for a
total of 38 participants at this time point (Analysis 7.3.3 (2 studies,
38 participants): -21.10 µmol/L, 95% CI -49.81 to 7.61; I2 = 60%).
ALG versus OKT3
ALG had uncertain effects on death at 1 to 2 years (Analysis 8.1.1 (3
studies, 300 participants): RR 2.00, 95% CI 0.62 to 6.47; I2 = 0%) and
3 years (Analysis 8.1.2 (2 studies, 265 participants): RR 1.03, 95% CI
0.13 to 8.09; I2 = 41%) and also uncertain effect on all-cause graB
loss at 1 to 2 years (Analysis 8.1.3 (3 studies, 300 participants): RR
1.01, 95% CI 0.57 to 1.80; I2 = 18%) and 3 years (Analysis 8.1.4 (2 stud-
ies, 265 participants): RR 1.08, 95% CI 0.68 to 1.70 ; I2 = 0%) com-
pared with OKT3.
There was little or no effect on acute rejection with ALG compared
to OKT3 (Analysis 8.1.5 (6 studies, 593 participants): RR 0.97, 95% CI
0.83 to 1.13; I2 = 0%).
Delayed graB function was less with ALG compared to OKT3 (Analy-
sis 8.1.6 (3 studies, 310 participants): RR 0.78, 95% CI 0.61 to 0.99;
I2 = 0%)
ALG had uncertain effect on CMV infection (Analysis 8.2.1 (4 studies,
431 participants): RR 1.53, 95% CI 0.82 to 2.85; I2 = 57%) and all other
infection outcomes (Analysis 8.2).
ALG treatment was associated with lower SCr values at 1 year
(Analysis 8.3.1 (2 studies, 245 participants): MD -15.85 µmol/L, 95%
CI -28.55 to -3.15; I2 = 0%) but this was not sustained at 2 years
(Analysis 8.3.2 (2 studies, 223 participants): MD 12.50 µmol/L, 95%
CI -13.52 to 38.52; I2 = 59%).
ALG versus placebo/no treatment
ALG had little or no effect on all-cause death or all-cause graB loss
at any time point after transplantation compared to placebo or no
induction (Analysis 9.1).
Acute rejection was prevented with ALG compared to placebo or
no induction (Analysis 9.1.7 (13 studies, 1575 participants): RR 0.69,
95% CI 0.53 to 0.92; I2 = 87%) and ALG reduced delayed graB func-
tion (Analysis 9.1.8 (5 studies, 615 participants): RR 0.55, 95% CI 0.31
to 0.97; I2 = 73%).
ALG markedly increased both CMV infection (Analysis 9.2.1 (3 stud-
ies, 289 participants): RR 2.45, 95% CI 1.23 to 4.85; I2 = 0%) and all-
cause viral infections (Analysis 9.2.2 (2 studies, 324 participants):
RR 2.71, 95% CI 1.86 to 3.95; I2 = 0%), and may increase bacterial
infection rates (Analysis 9.2.3 (4 studies, 742 participants): RR 1.18,
95% CI 0.92 to 1.52; I2 = 43%). The treatment effect on fungal infec-
tion rates was uncertain (Analysis 9.2.4 (1 study, 230 participants):
RR 1.11, 95% CI 0.63 to 1.95).
ALG markedly increased thrombocytopenia (Analysis 9.2.5 (1 study,
67 participants): RR 12.19, 95% CI 3.10 to 47.92) and leucopenia
(Analysis 9.2.6 (2 studies, 297 participants): RR 20.31, 95% CI 0.61 to
676.54; I2 = 83%). ALG had uncertain effects on malignancy or PTLD
(Analysis 9.2.7 (4 studies, 623 participants): RR 0.60, 95% CI 0.27 to
1.31; I2 = 0%) and NODAT (Analysis 9.2.8 (1 study, 105 participants):
RR 0.93, 95% CI 0.22 to 3.93).
ALG had uncertain effect on both early graB function at 1-2 years
and long term graB function at 10-20 years compared to placebo or
no induction (Analysis 9.3).
Other studies
The remainder of comparisons (Figure 1) involved only a single
study and therefore could not be used for meta-analysis. The re-
sults are summarised briefly below.
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Dose comparisons
Stevens 2008 assessed single versus divided dose ATG. There were
no differences in any reported outcomes. Abouna 1995 compared
ATG adjusted for the CD3 count with fixed dose ATG and again there
was no difference in outcomes. One very small study by Ata 2013
compared ATG with dose adjusted by CD3 count compared to dose
adjusted for total lymphocyte count and there was no difference in
outcomes. Grafals 2014 compared 'standard' dose ATG (3.75 mg/
kg total) with low dose ATG (2.25 mg/kg total) and found no signif-
icant difference in outcomes. Another very small study by Buchler
2013 compared a split of four versus two doses of ATG (same total
dose of 6 mg/kg) and found no difference in outcomes. Two stud-
ies compared different OKT3 dose regimens: standard versus low
dose (Norman 1993a) and standard versus high dose (Abramowicz
1994). There were no significant differences in either of these small
studies. Low versus high dose ALG was also assessed in Sakhrani
1992 and seven days versus 14 days ALG was addressed in Grund-
mann 1987. There were no differences in the low versus high dose
study. Treatment was frequently stopped early in the 14 day group
but there were no other differences in outcomes. One older study
by Thomas 1977 comparing low potency ALG with high potency ALG
found increased acute rejection at three months (RR 4.14, 95% CI
1.55 to 11.00) and increased graB loss at 1 year (RR 2.53, 95% CI 1.30
to 4.90) with the low potency ALG.
Table summarising single studies of di>erent dose comparisons
 
Comparison / Study ID (number of participants) Outcome RR 95% CI
lower
limit
95% CI
upper
limit
rATG: single 6 mg/kg versus 4 x 1.5 mg/kg doses (same total dose)
Death at 6
months
0.34 0.01 8.27
GraB loss
(all cause)
at 6 months
0.21 0.01 4.21
Acute rejec-
tion
0.69 0.26 1.83
Delayed
graB func-
tion
2.40 0.65 8.91
Malignan-
cy/PTLD
0.21 0.01 4.21
BKV 0.15 0.01 2.79
Severe
febrile
reaction
(anaphylax-
is requiring
ICU)
1.03 0.15 7.10
Serum sick-
ness
0.21 0.01 4.21
Stevens 2008 (142)
NODAT 0.82 0.47 1.42
ATG: 2 x3 mg/kg versus 4 x 1.5 mg/kg doses (same total)
Buchler 2013 (17) ** - - -
ATG: adjusted for CD3 count versus fixed dose of 15 mg/kg/d
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Death at 2
years
0.96 0.06 14.37
GraB loss
(all cause) 2
years
0.72 0.18 2.85
Acute rejec-
tion
0.96 0.5 1.84
Leucopenia 0.36 0.11 1.18
Thrombo-
cytopenia
0.14 0.01 2.51
Viral infec-
tion (all
cause)
0.96 0.15 6.21
Abouna 1995 (45)
Bacterial
infection
(all cause)
0.64 0.21 1.96
ATG: adjusted by CD3 count versus adjusted by total lymphocytes
Ata 2013 (21) ** - - -
ATG: standard (3.75 mg/kg total) versus low dose (2.25 mg/kg total)
Acute re-
jection at 1
year
0.57 0.12 2.81
Leucopenia 0.69 0.31 1.56
Severe in-
fection
0.77 0.14 4.14
CMV infec-
tion
0.23 0.01 4.50
BKV infec-
tion
0.38 0.02 8.86
Death at 1
year
8.00 0.44 146.08
Delayed
graB func-
tion
3.07 0.94 10.02
Malignancy
at 1 year
2.30 0.23 23.51
PTLD at 1
year
0 events not estimable
Grafals 2014 (43)
GraB func-
tion at 1
6.00* 1.07 10.93
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year (SCr,
µmol/L)
OKT3: standard dose (5 mg) versus low dose (2 mg)
Death at 1
year
0 events not estimable
GraB loss at
1 year
3 0.13 67.51
Acute rejec-
tion
0.2 0.01 3.8
Delayed
graB func-
tion
1.25 0.43 3.63
CMV 4 0.51 31.13
Herpes
Simplex
virus
0.5 0.05 4.86
Bacterial 0.86 0.4 1.86
Fungal 1 0.16 6.07
Norman 1993a (26)
Malignancy 4.72 0.23 96.59
OKT3: standard dose (5 mg) versus high dose (10 mg)
Death at 3
months
0 events not estimable
GraB loss at
3 months
4.69 0.24 89.88
Acute re-
jection to 3
months
0.47 0.1 2.16
Abramowicz 1994 (29)
Delayed
graB func-
tion
0.93 0.34 2.54
ALG: low versus high dose
Death at 1
year
0.89 0.41 1.97
Acute rejec-
tion
0.86 0.48 1.55
Leucopenia 0.5 0.18 1.41
Sakhrani 1992 (83)
Severe in-
fection
1.05 0.52 2.11
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ALG: 14 days versus 7 days
Death 1
year
0 events not estimable
GraB loss
(all cause) 1
year
0.29 0.06 1.31
Acute rejec-
tion
0.5 0.05 5.34
Delayed
graB func-
tion
0.62 0.28 1.35
Pneumonia 3 0.13 71.92
Wound in-
fection
0 events not estimable
Treatment
stopped
due to side
effects
63 3.96 1002.01
Grundmann 1987 (100)
GraB func-
tion at 1
year (SCr,
µmol/L)
-35.4* -78.72 7.92
ALG: high versus low potency
Acute re-
jection at 3
months
4.14 1.55 11.00Thomas 1977 (71)
GraB loss at
1 year
2.53 1.30 4.90
 
* MD and SD for continuous variables (not RR and 95% CI).
** Results not converted to RR for extremely small studies with 10 or fewer par-
ticipants in each group.
Significant results shown in bold.
Other antibody preparations
Anti-CD2 rat monoclonal antibody was compared with no induc-
tion treatment in Squifflet 1997. This small study (40 participants)
showed acute rejection was decreased by anti-CD2 (RR 0.42, 95%
CI 0.18 to 0.96) but no difference in any other outcomes. Another
small study compared anti CD7 with OKT3 (Lazarovits 1993) and
there were no differences. Two studies assessed anti-LFA-1 mono-
clonal antibody: one in comparison with no induction agent (Spill-
ner 1998) and the other in comparison with ATG (Hourmant 1996).
Other than decreased fever with anti-LFA-1 compared to ATG, dif-
ferences were not significant in either of these studies. One small
pilot study (Ejaz 2013) comparing four different interventions (ATG
versus ATG + rituximab versus ATG + bortezomib versus ATG + rit-
uximab + bortezomib) did not show any significant differences in
outcomes other than an increase in new-onset peripheral neuropa-
thy in the bortezomib groups. There were only 10 participants in
each group and follow-up only reported to one year at the time of
this review. One final study compared anti-ICAM-1 monoclonal an-
tibody with placebo (EARTS Study 1999) but again there were no
differences in outcomes.
Norrby 1997 compared two rabbit ATG preparations made by dif-
ferent manufacturers. There was no difference for the only report-
ed outcomes of acute rejection and CMV infection. One small (51
participants) study by Steinmuller 1991 compared OKT3 with ALG
but antibody therapy was only given for patients with delayed graB
function. For this reason it was considered separately from the oth-
er studies comparing OKT3 and ALG. Side effects were reduced with
ALG compared to OKT3 (RR 0.41, 95% CI 0.24 to 0.72) but there
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were no other significant differences in outcomes. Finally Tole-
do-Pereyra 1985 compared ATG with ALG also showed no significant
differences in outcomes.
Table summarising single studies of other antibody preparations
 
Comparison / Study ID (number of participants) Outcome RR 95% CI
lower
limit
95% CI
upper
limit
Rabbit ATG Fresenius versus rabbit ATG Merieux
Acute re-
jection
0.87 0.63 1.20Norrby 1997 (90)
CMV infec-
tion
0.56 0.29 1.07
ALG versus ATG
Death at 1
year
0.5 0.10 2.49
GraB loss
at 1 year
0.92 0.50 1.67
Acute re-
jection
0.95 0.73 1.24
Thrombo-
cytopenia
1 0.15 6.55
Leucope-
nia
0.07 0 1.11
Toledo-Pereyra 1985 (50)
HSV infec-
tion
2 0.19 20.67
ALG vs OKT3 (given only if delayed graB functionpost-operatively)
Death at 6
months
0.48 0.05 4.98
GraB
loss (all
cause) at
6 months
0.96 0.27 3.43
Acute re-
jection
0.61 0.28 1.32
Side ef-
fects (any
reported)
0.41 0.24 0.72
Any infec-
tion
0.89 0.51 1.55
Steinmuller 1991 (51)
CMV 0.89 0.51 1.55
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Anti-CD7 versus OKT3
Death 5
years
1 0.07 13.87
GraB loss
5 years
0.11 0.01 1.83
Acute re-
jection
1.4 0.67 2.94
Lazarovits 1993 (20)
Serious
infection
0.25 0.03 1.86
Anti-CD2 rat monoclonal antibody versus no induction
Death at 6
months
0.2 0.01 3.92
GraB loss
(death
cen-
sored) at 6
months
0 events Not estimable
Acute re-
jection
0.42 0.18 0.96
Delayed
graB func-
tion
0.17 0.02 1.26
Bacterial
infection
0.25 0.03 2.05
CMV 0.5 0.05 5.08
EB virus 3 0.13 69.52
Herpes
Simplex
virus
4 0.49 32.72
Other viral
infection
0.33 0.01 7.72
Malignan-
cy
3 0.13 69.52
Squifflet 1997 (40)
GraB func-
tion at 6
months
(SCr,
µmol/L)
8* -20.99 36.99
Anti-LFA-1 monoclonal antibody versus no induction1
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
33
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Death at 1
year
3 0.14 66.53
GraB loss
(all cause)
at 1 year
1 0.17 5.89
Serious
infection
1 0.07 14.05
CMV infec-
tion
1 0.17 5.89
Delayed
graB func-
tion
1.5 0.31 7.3
Spillner 1998 (22)
GraB func-
tion at 1
year (SCr,
µmol/L)
-17.6* -62.69 27.49
Anti-LFA-1 monoclonal antibody versus ATG
Death at 1
year
4.72 0.23 95.86
GraB loss
(death
censored)
at 1 year
0.39 0.08 1.93
Acute re-
jection
1.05 0.62 1.78
Delayed
graB func-
tion
0.55 0.28 1.09
Any
episode of
infection
1.05 0.74 1.48
CMV dis-
ease
0.94 0.5 1.77
Treat-
ment
stopped
due to
side ef-
fects
0.24 0.03 2.04
Leucope-
nia
0.4 0.11 1.47
Hourmant 1996 (101)
Thrombo-
cytopenia
0.57 0.22 1.44
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Fever (1st
10 days)
0.58 0.36 0.94
Anti-ICAM-1 monoclonal antibody versus placebo
Death at 1
year
1.71 0.7 4.22
GraB loss
at 1 year
1.4 0.76 2.59
Acute re-
jection at
3 months
1.18 0.88 1.57
Acute re-
jection at
1 year
1.07 0.82 1.41
Primary
non func-
tion
1.2 0.38 3.83
Delayed
graB func-
tion
1.21 0.82 1.77
Any infec-
tion
1.13 0.98 1.3
Sepsis 1.3 0.59 2.86
EARTS Study 1999 (266)
Malignan-
cy
0.5 0.05 5.45
ATG versus ATG + rituximab vs ATG + bortezomib versus ATG + rituximab + bortezomib
Ejaz 2013 (40) ** - - -
 
* MD and SD for continuous variables (not RR and 95% CI).
** Results not converted to RR for extremely small studies with 10 or fewer par-
ticipants in each group
Significant results shown in bold.
1. Acute rejection was reported for anti-LFA 1 versus no induction but was re-
ported as total number of episodes rather than total number of patients with
any episode (results were 5 episodes with anti-LFA 1 versus 12 episodes with
no induction)
D I S C U S S I O N
Summary of main results
Many antibody preparations are now available for induction im-
munosuppression in kidney transplantation and we sought to sum-
marise the evidence in this review to help inform clinical decision
making and policy. Our inclusion criteria were deliberately broad
resulting in 28 different pairwise comparisons and studies span-
ning over many decades. This review provides the best summary
available of all RCTs (excluding IL2Ra) and highlights several issues.
Firstly, the evidence basis for decision making is poorly informed
by studies in this area. The effects of polyclonal antibody induction
remain uncertain for many important outcomes including graB loss
and death. Many relevant, well recognised potential harms are not
reported frequently in RCTs and more well designed studies report-
ing patient-centred outcomes (benefits and harms) are required.
Some effects of antibody induction could be quantified.
ATG reduced acute rejection rates by roughly one third when com-
pared to placebo or no treatment, at the cost of approximately 50%
increase in the risk of CMV complications and an uncertain impact
on future malignancy risk. rATG reduces acute rejection compared
to hATG but data supporting this is weak as all events were only re-
ported in a single study. The only significant difference seen in com-
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parisons between alemtuzumab and ATG in steroid avoidance stud-
ies was that alemtuzumab reduces rejection at one year; in compar-
ison alemtuzumab increased CMV infection but had similar rejec-
tion rates when compared to no induction and triple maintenance.
NODAT was not reduced with alemtuzumab plus ESW compared to
triple maintenance. OKT3 decreases acute rejection compared to
placebo or no treatment but has been withdrawn from clinical use
due to a poor side effect profile. ALG prevented acute rejection and
led to better kidney function at one year post-transplant compared
with placebo or no treatment but increased the rates of all viral in-
fections.
See Summary of findings for the main comparison; Summary of
findings 2.
Overall completeness and applicability of evidence
A decision was made to include any co-intervention immunosup-
pression regimens to ensure all relevant studies were included. As a
result, a large number of studies from the pre-CNI era were includ-
ed which may not be relevant to clinical practice today. Where pos-
sible, results were separated into CNI or non-CNI maintenance as
combining these groups was not felt to be clinically useful. As a re-
sult, there were multiple subgroups for outcomes of death and graB
loss for most comparisons as studies frequently reported these out-
comes at a variety of time points. There were no benefits seen for
improved patient or graB survival with ATG despite decreased re-
jection rates when CNI and non-CNI studies were separated. This
lack of benefit may be due to small numbers of studies in each sub-
group. When CNI and non-CNI studies were combined, a reduction
in both all-cause graB loss and death-censored graB loss was seen
at one to two years post-transplant. This benefit was not sustained
however in the studies that assessed longer term graB survival at
five years. Results for acute rejection were generally more robust as
this was reported in nearly all studies and time points were more
standardised resulting in larger subgroups and greater statistical
power. New studies are required to see if the absence of benefit is
due to a lack of power or whether there really is no effect of one
antibody compared to another antibody or placebo on patient and
graB survival.
The main aim of using alemtuzumab has been to try to reduce the
doses of maintenance immunosuppression required to prevent re-
jection, especially steroids. It is hoped that this will reduce some of
the long term side effects of steroids, including NODAT. However,
NODAT was not reduced with alemtuzumab plus ESW compared to
ATG and triple maintenance or with alemtuzumab plus ESW com-
pared to triple maintenance alone. This may be partly due to small
numbers in these studies or may be due to the role of CNI, especial-
ly tacrolimus also causing increased rates of NODAT. Other steroid
side effects have generally not been well reported in these studies.
In the absence of any data to confirm a reduction in side effects, it
is difficult to support the use of alemtuzumab and ESW currently
compared to another antibody with triple maintenance.
The applicability of the results of this meta-analysis to the general
transplant population may be limited by the individual studies. The
majority of studies included patient groups with mixed immuno-
logical risk and a small number studied higher risk groups. Benefits
and harms of individual treatments generally seemed homogenous
across studies despite these apparent differences in risk. Harms are
frequently under-reported in clinical studies compared to benefits
and this review may therefore underestimate some of the potential
harms of treatments due to possible under-reporting in the individ-
ual studies.
Quality of the evidence
Overall, the quality of the evidence was generally low to only mod-
erately good by GRADE criteria. Figure 2 shows the individual biases
for each study. The most common problem was potential selection
bias due to unclear methods of both randomisation and allocation
concealment. Only 20% to 27% of included studies were low risk of
bias for either random sequence generation or allocation conceal-
ment (see Figure 3).
For the main comparison of ATG versus placebo, quality of evidence
according to GRADE criteria was moderate for outcomes of acute
rejection and CMV infection but low for all other outcomes. The ev-
idence for acute rejection and CMV was graded as moderate rather
than high as more than 50% of studies rated methods of allocation
concealment and/or random sequence generation as ‘unclear’ or
‘high risk’ as a potential source of bias. For the comparison of alem-
tuzumab plus ESW versus ATG with and without ESW, the evidence
for acute rejection was rated as moderate quality but evidence for
all other outcomes was either low or very low quality by GRADE
criteria. Again the main reason for acute rejection evidence being
graded as moderate rather than high was a significant risk of se-
lection bias due to poor reporting of randomisation and allocation
concealment.
Potential biases in the review process
The review was conducted with standard Cochrane methodology
and there were no changes from the original protocol.
Agreements and disagreements with other studies or
reviews
One study of registry data of transplant recipients in the US al-
so failed to show any improvement in all-cause graB survival de-
spite decreasing rates of acute rejection (Meier-Kriesche 2004).
More alarmingly, this study showed a trend towards worsening
death censored graB survival, despite more potent maintenance
immunosuppression. However, given these trends are taken from
registry data, it is hard to interpret what this really means, especial-
ly with older and more co-morbid patients being transplanted in
recent years.
Many antibody therapies have now shown a reduction in acute re-
jection but it remains uncertain as to whether this translates into
increased patient or graB survival for any of the antibodies in this
review. In comparison, there was a reduction in graB loss at one
year (but not after) for IL2Ra compared to placebo (24 studies, 4672
participants: RR 0.75, 95% CI 0.62 to 0.90) in a systematic review
by Webster 2010. However, there was no difference for graB loss
when IL2Ra and ATG were compared in the same review and clini-
cally diagnosed acute rejection rates were also similar for IL2Ra and
ATG. However, ATG increased early malignancy at one year com-
pared to IL2Ra (7 studies, 1067 participants: RR 0.25, 95% CI 0.07 to
0.87) but had no effect on malignancy at other time points (Webster
2010). It is possible that malignancy is influenced more by mainte-
nance immunosuppression than induction agents given it is a rela-
tively late complication after transplantation. However, under-re-
porting of late harms is common in RCTs and malignancy rates may
therefore be grossly underestimated in existing studies of induc-
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tion agents leading to insufficient power to determine true cancer
risk.
In steroid avoidance studies, alemtuzumab reduced acute rejection
compared to ATG when ESW was used in both arms. These results
would support using alemtuzumab over ATG in patients deemed to
be at particularly high risk of steroid side effects and where main-
tenance with ESW is planned. Further studies of alemtuzumab and
ESW compared to no induction and triple maintenance showed
similar rates of acute rejection but an increased risk of CMV infec-
tion with alemtuzumab. There was no other difference in harms but
this may need larger studies to show potential benefits of alem-
tuzumab relating to steroid avoidance. Reduction of maintenance
immunosuppression certainly has theoretical benefits, including
reduction in antihypertensives, antihyperlipidaemics, cholesterol,
cataracts and NODAT requiring treatment as well as possible reduc-
tion of late complications such as malignancy. However, none of
the studies to date have been long enough duration or large enough
to confirm any of these suggested benefits.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Given a 45% acute rejection risk with no induction (assumed risk
from control group in Analysis 1.4), seven patients would need ATG
to prevent one from experiencing acute transplant rejection, while
one additional patient would experience CMV disease for every 12
patients treated with ATG. Where only studies including CNI main-
tenance were assessed, the acute rejection rate was 37% with no
induction and six patients would need treatment with ATG to pre-
vent one person having acute rejection. In steroid withdrawal stud-
ies, 11 patients would require alemtuzumab to prevent one pa-
tient experiencing rejection given a 21% rejection risk with ATG.
Alemtuzumab treatment combined with steroid withdrawal would
cause one additional patient experiencing CMV disease for every six
patients treated when compared with no antibody induction and
triple maintenance, and without apparent benefits to patient-cen-
tred outcomes. ATG and alemtuzumab decreased acute rejection at
a cost of increased CMV while patient-centred outcomes including
survival or side effects do not appear to be improved.
In kidney transplant recipients deemed to be at high risk of rejec-
tion, the evidence remains unclear as to whether one particular an-
tibody preparation is better than any other at preventing acute re-
jection. However, this review does suggest that the perceived ben-
efit of induction immunosuppression in reducing acute rejection
may not actually lead to any long-term benefits or improvements
in patient-centred outcomes.
Implications for research
Longer term follow-up is always a problem when assessing study
data. Although some of the studies in this review have reported
fairly long-term data, the numbers are generally too small to draw
conclusions. Longer term follow-up is needed to really establish
whether the benefit of reduced acute rejection with ATG has a
significant impact on graB survival or indeed patient survival. In
the absence of this information, is it possible to say that decreas-
ing acute rejection is truly a benefit? Reducing the risk of acute
rejection becomes less important to an individual patient if this
fails to improve long-term graB or patient survival, especially if the
treatment causes potential severe side effects and other harms.
We need to find better ways of monitoring long-term harmful out-
comes such as malignancy in any future studies. This may require
an ongoing observational cohort study of patients once the initial
RCT phase of a study is completed. Another response to this issue is
follow up within established registries combined with core patient
outcome sets.
If ESW or steroid minimisation is planned in an individual patient,
the data in this review would support use of alemtuzumab over
ATG due to a reduction in acute rejection. Further studies with long-
term follow-up or ongoing follow-up of existing studies are need-
ed to show if there is sustained benefit to steroid reduction thera-
py and indeed if the benefits outweigh risks of increased chronic
rejection and potential increased long-term graB loss.
When assessing outcomes in transplantation it is difficult to sep-
arate the contribution of induction immunosuppression versus
maintenance immunosuppression. The appropriate question for
future studies may relate to maintenance rather than induction im-
munosuppression. Increasing knowledge in the field of transplant
immunology has led to continual reassessment of the BanI diag-
nostic criteria and a much greater understanding of antibody-me-
diated rejection over recent years. Future studies comparing differ-
ent immunosuppression regimens need to assess for not only dif-
ferences in all cause rejection but also differences in the different
subgroups of rejection. Ideally study designs should also include
some measure of adherence to maintenance immunosuppression
as this is particularly relevant for antibody-mediated rejection in
the presence of de novo donor-specific antibodies. Adherence can
be difficult to measure and is generally poorly reported or not mea-
sured at all in studies. However, this may be the area that really
needs to be studied if we want to increase long term patient and
graB survival in kidney transplantation.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods • Study design: parallel RCT• Study duration: February 1993 to June 1994• Study follow-up: 2 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group (23); control group (22)• Mean age ± SD (years): treatment group (43 ± 9); control group (53 ± 12)• Sex (M/F): treatment group (17/6); control group (17/5)• Exclusion criteria: not reported
Interventions Treatment group 1
• ATG: 15 mg/kg on day 1 then adjusted as per CD3 cell count (to maintain count 50 to 100/µL)* ATG given for at least 3 days after CSA started or at least 7 days post-transplant
Treatment group 2
• ATG: fixed dose (15 mg/kg/d)
Immunosuppression (both groups)
• CSA: 8 mg/kg and started when SCr ≤ 3 mg/dL• PRED: dosage not reported• AZA: dosage not reported
Outcomes • Death• GraB loss• GraB function• Acute rejection• Leucopenia• Thrombocytopenia• Viral infection• Bacterial infection
Notes • Funding source: "This work was supported by the Upjohn Company, Kalamazoo, MI"
Risk of bias
Abouna 1995 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes included
Other bias High risk Study supported by Upjohn Company
Abouna 1995  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: September 1987 to September 1989• Study follow-up: 36 months
Participants • Country: Belgium• Setting: single centre (Brussels)• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group 1 (56); treatment group 2 (52)• Mean age ± SEM (years): treatment group 1 (34 ± 1.3); treatment group 2 (35.3 ± 1.2)• Sex (M/F): treatment group 1 (39/47); treatment group 2(37/15)• Exclusion criteria: not reported
Interventions Treatment group 1
• OKT3: 5 mg/d for 14 days post-op, CSA started day 11* Dose increased to 10 mg/d if serum level < 500 ng/mL• AZA: 2 mg/kg/d, then 1 mg/kg/d by day 14• MP: 1.3 mg/kg before 1st OKT3 dose for 1st 31 patients, increased to 8 mg/kg for next 25 patients to
try to decrease cytokine release syndrome• PRED: 0.3 mg/kg day 1 to 14
Treatment group 2
• CSA: day 1 post-op, dose 6 mg/kg/d, then as per trough level (150 to 250 ng/mL)• AZA: 1 mg/kg/d
Abramowicz 1992 
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• MP: 1.5 mg/kg on day 0; 1 mg/kg on day 1; 0.5 mg/kg on day 2; 0.4 mg/kg on day 14; 0.17 mg/kg after
3 months
Outcomes • Death• GraB loss• Acute rejection• GraB function• Infection• Malignancy
Notes • CSA delayed until day 11 in OKT3 group• Funding source: "This work was supported by Cilag Benelux and the Fonds de la Recherche Scien-
tifique Medicale (Belgium)"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Baseline imbalance. PRA, donor age and HLA mismatch all higher in OKT3
group; funded by Cilag
Abramowicz 1992  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: only reported to 3 months
Participants • Country: Belgium• Setting: single centre (Brussels)• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group 1 (15); treatment group 2 (14)• Mean age ± SEM (years): treatment group 1 (40.6 ± 1.9); treatment group 2 (40.6 ± 3.5)
Abramowicz 1994 
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• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• OKT3: 5 mg for 1st 3 doses
Treatment group 2
• OKT3: 10 mg for 1st 3 doses
Dose adjustment as per level from day 3 post-op
• Above 1000 ng/mL: next dose 5 mg• 800 to 1000 ng/mL: next dose 10 mg• Below 800 ng/mL: evening 5 mg dose, then 10 mg next day
Immunosuppression (both groups)
• As per Abramowicz 1992
Outcomes • Death• GraB loss• DGF• Acute rejection
Notes • Short-term data only (to 3 months)• Mean OKT3 dose given was similar• Funding source: "This work was supported by Cilag Benelux and the Fonds de la Recherche Scien-
tifique Medicale (Belgium)"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk No blinding but the review authors judge that the outcomes are not likely to be
influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Unclear risk Short-term follow-up reported only
Other bias High risk Supported by Cilag Bennelux
Abramowicz 1994  (Continued)
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Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 3 to 12 months
Participants • Country: USA• Setting: single centre (Florida)• Inclusion criteria: adult (> 16 years) DD kidney transplant recipients (100%); financial resources for
CSA therapy after discharge• Number: treatment group (33); control group (33)• Mean age ± SD (years): not reported• Sex (M/F): treatment group (21/12); control group (23/12)• Ethnicity (other/African American): treatment group (23/10); control group (21/12)• Exclusion criteria: fluid overload (unresolved by dialysis); previous exposure to OKT3, pregnant or lac-
tating women
Interventions Treatment group
• OKT3: 5 mg/d IV for 14 days• CSA: started day 11, target trough 300 to 500 ng/mL
Control group
• CSA: twice daily started day 1 (unsure), target trough level 300 to 500 ng/mL
Immunosuppression (both groups)
• AZA: 2.5 mg/kg (adjusted per WCC and kidney function)• MP-PRED: 2 g IV intra-op then PRED 0.25 mg/kg/d
Outcomes • Death• GraB loss• Acute rejection• DGF• Infection• GraB function
Notes • Outcomes reported for 3 months only as some patients only followed to 3 months at time of reporting
(some but NOT all patients followed for 12 months)• Funding source: "Supported by a grant from Othro Pharmaceutical Corp (Raritan, NJ)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Low risk 'Randomized by sealed envelope draw'
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Unblinded but not likely to influence most outcomes; may influence reporting
of infections
Ackermann 1988 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not certain if acute rejection was biopsy-proven or clinically diagnosed
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Grant from Ortho Pharmaceutical Corp (OKT3 manufacturer)
Ackermann 1988  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 2009 to January 2012• Study follow-up: 3 months
Participants • Country: Turkey• Setting: single centre (Istanbul)• Inclusion criteria: adults DD kidney transplant recipients• Number: treatment group 1 (11); treatment group 2 (10)• Mean age ± SD (years): treatment group 1 (43.6 ± 4); treatment group 2 (37 ± 3.8)• Sex (M/F): treatment group 1 (3/8); treatment group 2 (4/6)• Exclusion criteria: not reported
Interventions Treatment group 1
• ATG modified by CD3 count: 1 mg/kg at time of transplant* Continued daily for 10 days with dose as follows as per CD3 count□ > 150/mL: no adjustment□ 50 to 150/mL: half dose□ < 50/mL: dose skipped
Treatment group 2
• ATG standard dose: 1 mg/kg at time of transplant* Continued same dose daily for 10 days* Dose skipped if lymphocyte count < 300/mL
Maintenance immunosuppression
• Not specified for either group
Outcomes • ATG dose• Side effects• GraB function at 3 months• Acute rejection• Infection• Cost (CD3+ analysis + ATG)
Notes • Brief report only• Funding source: not reported
Ata 2013 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not reported but likely not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported but likely not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Unclear risk Brief report only
Other bias Unclear risk Funding not reported
Ata 2013  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: September 1989 to June 1990• Study follow-up: 6 months
Participants • Country: Austria• Setting: single centre (Vienna)• Inclusion criteria: adults DD 1st kidney transplant recipients• Number: treatment group (55); control group (60)• Mean age (years): treatment group (49.7); control group (47.3)• Sex (M/F): treatment group (32/23); control group (35/25)• Exclusion criteria: not reported
Interventions Treatment group
• ATG (Thymozytenglobuline-Biotest)* 200 mg during implantation, repeat dose days 1, 2, 4, 6 and 8 (100 mg if low weight)• CSA started day 8 at 4 mg/kg/d• Steroids: IV DEX 40 mg, 32, 24, 16, 8 then PRED 20 mg once daily
Control group
• CSA: 2 mg/kg/d IV infusion, starting during implantation* Switch to oral CSA day 2 to 3; 4 mg/kg/d• Steroids as for treatment group
Banhegyi 1991 
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CSA adjusted according to levels in both groups
Outcomes • DGF• Acute rejection• GraB failure
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Acute rejection episodes were not biopsy-proven
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk 7 patients excluded: vascular complications (2), trauma (1), ABO-incompatible
transplant (1), ‘therapy protocol not followed’ (2).
Not clear which group these patients were from; possibly all from one group
This appears to be a preliminary report, however no further publication has
been identified
Banhegyi 1991  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: June 1987 to March 1990• Study follow-up: 2 to 3 years
Participants • Country: Canada• Setting: single centre• Inclusion criteria: adults and children (> 10 years); 1st kidney transplant; all DD• Number: treatment group (57); control group (53)• Mean age, range: 41.5, 10 to 65 years• Sex (M/F): 72/38• Exclusion criteria: not reported
Belitsky 1991 
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Interventions Treatment group
• ALG (Lymphoglobuline, Merieux) at 10 mg/kg/d until serum Cr < 300• Then switched to CSA as per control
Control group
• CSA: IV 3 to 4 mg/kg started post-op, continuous IV infusion for 5 days then oral 5 mg/kg twice daily,
target levels 300 to 450 ng/mL for 3 months, then 100 to 250 ng/mL there after
Immunosuppression (both groups)
• AZA: 2 mg/kg IV during surgery, then 1.5 mg/kg orally for 30 days only• MP: 500 mg in OT, then oral PRED 1mg/kg, decrease to 20mg over 2 to 3 weeks, decrease further
at 60 days, stopped at 105 days• If Cr > 200 at 105 days, CSA reduced. If no benefit, PRED and/or AZA re-added
Outcomes • GraB survival• Death• Acute rejection (confirmed by biopsy or FNA)• Kidney function• Infection• Complications
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding source not reported
Belitsky 1991  (Continued)
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Methods • Study design: parallel RCR• Study duration: not reported• Study follow-up: 2 years
Participants • Country: UK• Setting: multicentre (5)• Inclusion criteria: adult LD or DD kidney transplant recipients• Number: treatment group (86); control group (87)• Mean age, range (years): treatment group (39.6, 17 to 63); control group (33.7, 16 to 66)• Sex (M/F): treatment group (56/30); control group (51/36)• DD/LD: treatment group (70/16); control group (70/17)• 1st graB/2nd graB: treatment group (76/10); control group (80/7)• Exclusion criteria: identical matches for HLA-A and HLA-B antigens; ABO blood group donor/recipient
incompatibility; circulating donor-specific leukocytotoxicity; oxalosis; not available follow-up due to
geographical reasons
Interventions Treatment group
• ALG: IV infusion (30 mg/kg/d, max 2g) for 10 days (in 15 mL/kg in 5% dextrose); IV infusion stopped if
severe vasomotor disturbance
Control group
• Placebo: 15 mL/kg in 5% dextrose for 10 days
Immunosuppression (both groups)
• AZA: 5 mg/kg day 1, then 1 to 2 mg/kg, increased every 10 days up to 3 to 4 mg/kg (depending on WCC
and platelet count)• MP: 1 g at operation, then PRED 150, 100, 80, 60, 50, 40 down to 20 mg by 3 months, then further to
10 mg
Outcomes • Death• GraB failure• Acute rejection• Infection
Notes • Randomisation balanced within each centre and for DD versus LD• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk 'Random number code' stated, no other information provided
Allocation concealment
(selection bias)
Low risk Pharmacy controlled; fluids supplied by pharmacists, under double-blind con-
ditions
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blinded
Blinding of outcome as-
sessment (detection bias) 
Low risk Unlikely to influence outcomes
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding not reported
Bell 1983  (Continued)
 
 
Methods • Study design: parallel 2 x 2 factorial RCT• Study duration: April 1995 to August 1999• Study follow-up: 4 years
Participants • Country: USA• Setting: multicentre (21)• Inclusion criteria: children; LD and DD kidney transplant recipients• Number: treatment group (147); control group (140)• Mean age ± SD (years): not reported• Sex (M/F): treatment group (92/55); control group (84/56)• White/black/Hispanic/other (%): treatment group (54/22/19/4); control group (59/19/15/7)• DD/LD: treatment group (82/65); control group (77/63)• Exclusion criteria: recipients of more than 1 organ; pregnant females; females of child-bearing age
who were not willing to practice an acceptable method of birth control during the 1st year after trans-
plantation; HIV positive; positive Hep B surface antigen
Interventions Treatment group
• OKT3: 2.5 to 5 mg/kg (< or > 30 kg) IV infusion peri-op then daily for 10 days• Oral CSA: day 7 at 250 mg/m2• PRED and AZA until 1996 then MMF and PRED from 1996
Control group
• IV CSA: 165 mg/m2 or 4.5 mg/m2 (< or > 6 years), continuous IV infusion over 24 hours, continued for
3 days due to concern over GI absorption• Oral CSA day 3 at 500 mg/m2 (< 6 years) or 15 mg/kg (> 6 years)
Outcomes • Kidney function at 1 year• Death• GraB loss• Acute rejection• infection• PTLD
Notes • Different maintenance of AZA early on and MMF later• Some also switched induction therapy• 292 patients randomised, 287 transplanted• CSA group: 12/140 (9%) received OKT3 in 1st week, 2 for early acute rejection• OKT3 group: OKT3 was stopped early in 21/147 (14%), 6 due to early graB failure
Benfield 1999 
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• ITT analysis used• Funding source: National Institutes of Health, National Institute of Allergy and Infectious Diseases,
5UO1AI37206
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Randomization in a 1:1 ratio occurred preoperatively by contacting the cen-
tral data center"
Allocation concealment
(selection bias)
Low risk "Central data center"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not clear for outcome of acute rejection; not all episodes were biopsy-proven
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Low risk Appears free of other biases
Benfield 1999  (Continued)
 
 
Methods • Study design: parallel RCT; stratified according to immunological risk ('R' at risk; 'N' normal risk)• Study duration: not reported• Study follow-up: 1 year
Participants • Country: Switzerland• Setting: single centre• Inclusion criteria: adults, LD or DD kidney transplant recipients• Number: treatment group 1 (53); treatment group 2 (51)• Mean age ± SEM (years): treatment group 1 (46 ± 2); treatment group 2 (49 ± 2)• Sex (M/F): treatment group 1 (35/18); treatment group 2 (30/21)• DD/LD: treatment group 1 (46/7); treatment group 2 (44/7)• Exclusion criteria: HLA-identical LD; pre-existing antibodies against mouse globulin
Interventions Treatment group 1
• rATG (Fresenius): 4 mg/kg/d* N patients received 7 doses, R patients received 14 doses• IV MP: higher doses in R patients• PRED tapered by 5 mg every 2 weeks until 15 mg then 2.5 mg reductions; tapered to 0 unless R patients
or those with vascular rejection• AZA: given for 8 weeks for N patients or 8 months in R patients
Bock 1995 
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• CSA adjusted as per level, R patients had higher target level than N patients• Maintenance of AZA and PRED from day 0, CSA from day 4
Treatment group 2
• OKT3: 5 mg/d• Doses and other immunosuppression as per treatment group 1
Outcomes • GraB survival• Death• Acute rejection• Infection• Malignancy• GraB function• Low WCC• Low platelets• DGF
Notes • Immunological risk: high risk (previous acute rejection causing graB loss in 1st year or > 80% PRA at
time of transplantation (R)); all others considered normal risk (N)• Funding source: Cilag AG and Fresenius AG each funded half the study costs
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequences established prior to start of study such that within each set
of 4 consecutive patients 2 received ATGF and 2 received OKT3
Allocation concealment
(selection bias)
Low risk "assigned treatments were kept in sealed envelopes that were opened when
the patient was admitted to the hospital for transplantation."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Funded by Cilag and Fresenius
Bock 1995  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported
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• Study follow-up: 6 months
Participants • Country: Switzerland• Setting: single centre• Inclusion criteria: not reported• Number: treatment group 1 (35); treatment group 2 (32)• Mean age ± SD (years): not reported• Sex (M/F): treatment group 1 not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• hATG (ATGAM): 15 mg/kg/d for 7 days from day 0 to 6 (or 14 days if ‘high risk’)• Triple maintenance immunosuppression with CSA, AZA, PRED
Treatment group 2
• rATG (Fresenius): 4 mg/kg/d for 7 days (or 14 days if 'high risk')• Triple Immunosuppression with CSA, AZA, PRED
Outcomes • Death• GraB loss• Acute rejection• Side effects (headache)• Infection
Notes • Abstract only publication• No table 1 but abstract states baseline and risk characteristics were similar• Acute rejection reported as mean number of episodes/patient (1.1 for ATG and 0.6 for ATG-Fresenius).
Total number of patients with acute rejection in each group not given, therefore results not included
in analyses of this review• Infection reported as 'similar' in both groups but figures not given• Side effects other than headache reported as no significant difference between groups• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Incomplete outcome data
(attrition bias) 
Unclear risk Insufficient information to permit judgement
Bock 1999  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
High risk Abstract only, limited outcomes reported and not able to be included in meta-
analyses
Other bias Unclear risk Insufficient information to permit judgement; funding source not reported
Bock 1999  (Continued)
 
 
Methods • Study design: parallel RCT; 2:1 randomisation (thymoglobulin:ATG)• Study duration: May 1996 to March 1997• Study follow-up: 10 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: all patients eligible for induction agent; adult LD and DD kidney transplant recipients• Number: treatment group 1 (48); treatment group 2 (24)• Mean age ± SD (years): treatment group 1 (45 ± 14); treatment group 2 (52 ± 12)• Sex (M/F): treatment group 1 (30/18); treatment group 2 (15/7)• Ethnicity (white/black/other): treatment group 1 (30/18/0); treatment group 2 (17/6/1)• DD/LD: treatment group 1 (35/13); treatment group 2 (19/5)• Exclusion criteria: previous treatment with horse or rabbit anti-T-cell polyclonal agents; had a known
allergy to rabbit or horse proteins; documentation of malignancy within 2 years, with the exception
of skin malignancies; pregnant women, nursing mothers or women of childbearing potential or who
were not practicing a reliable form of birth control; serological evidence of infection with HIV-1, human
T-lymphotropic virus-1; presence of serum Hep B surface antigen
Interventions Treatment group 1
• rATG: 1.5 mg/kg IV for at least 7 days, 1st dose intra-op through central line
Treatment group 2
• hATG (ATGAM): 15 mg/kg IV for at least 7 days
Immunosuppression (both groups)
• AZA: IV then oral* MMF instead of AZA if on allopurinol or 2nd transplant or ESKD due to immunologic cause• MP then PRED: tapered over 9 months to 0.1 mg/kg• CSA: started 2/7 pre-op if LD or after good urine output if DD; adjust as per levels; TAC if CSA not tol-
erated
Outcomes • Death• GraB failure• Acute rejection• CMV• PTLD/malignancy• GraB function
Notes • Funding source: not reported
Risk of bias
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random sequence used but not reported
Allocation concealment
(selection bias)
Low risk Not reported, however appears to be coordinated by the pharmacist
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk "Only the pharmacist was unblinded and responsible
for maintaining that the investigator, staI, laboratory, and pathologists re-
mained blinded to patient study drug
group for greater than 1 year after transplantation"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "Only the pharmacist was unblinded and responsible
for maintaining that the investigator, staI, laboratory, and pathologists re-
mained blinded to patient study drug
group for greater than 1 year after transplantation"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding not reported
Brennan 1999  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: September 1987 to December 1990• Study follow-up: 3 years
Participants • Country: France• Setting: single centre (Paris)• Inclusion criteria: children; all 1st transplant, all DD• Number: treatment group 1 (77); treatment group 2(71)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• OKT3 (Orthoclone): 0.1 mg/kg/d start dose, adjusted as per circulating CD3 cells; given for 21 days,
later reduced to 15 days (after 6 months into study)
Treatment group 2
• ALG (Lymphoglobuline, Merieux): 1 to 5 mg/kg/d, to maintain total lymphocyte count < 500 mm3; giv-
en for 15 to 21 days
Immunosuppression (both groups)
• AZA: 3 mg/kg, decreased to 1.5 mg/kg after CSA started• CSA started when OKT3 stopped; dose 150 mg/mL/d (trough level not reported)
Broyer 1993 
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• PRED: 60 mg, tapered to 30 mg by one month, tapered to 7.5 mg at 6 months
Outcomes • Death• GraB loss• Acute rejection• DGF• Infection• GraB function
Notes • No table 1; reported as no significant differences in age, donor age, cold ischaemia time, HLA mis-
match, blood transfusions, or PRA• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Most outcomes unlikely to influence outcomes but unclear whether acute re-
jection was biopsy proven or clinically diagnosed
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Insufficient information to permit judgement; funding source not reported
Broyer 1993  (Continued)
 
 
Methods • Study design: parallel, open-label RCT• Study duration: October 2009 to October 2010• Study follow-up: 12 months
Participants • Country: France• Setting: single centre• Inclusion criteria: 1st or 2nd DD kidney transplant recipients• Number: treatment group (9); control group (9)• Mean age ± SD (years): treatment group 1 (47 ± 9); treatment group 2 (56 ± 9)• Sex (M/F): treatment group 1 (4/5); treatment group 2 (7/1)• Pre-emptive transplant: treatment group 1 (4); treatment group 2 (2)
Buchler 2013 
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• Dialysis vintage (months): treatment group 1 (13.7 ± 10); treatment group 2 (32.7 ± 25)• Exclusion criteria: <18 years; previous exposure to lymphocyte-depleting therapies, evidence of HIV
infection, active Hep B or C or tuberculosis; PRA > 20%, and recent or current exposure to other inves-
tigational drugs
Interventions Treatment group 1
• ATG: 2 x 3 mg/kg doses day 0 and 3 (started intra-op), 24 h IV infusion• MP: 250 mg pretransplant, second dose before 2nd ATG
Treatment group 2
• ATG: 4 x 1.5 mg/kg doses day 0, 1, 2, 3, 12 h IV infusion• MP: 250 mg pretransplant
Maintenance immunosuppression (both groups)
• PRED: 1 mg/kg/d• MMF: 1000 mg twice/d• TAC: started day 3 at dose of 0.1 mg/kg twice/d (target trough 8 to 15 ng/mL)
Prophylaxis (both groups)
• Co-trimoxazole: for 3 months for all patients• Valganciclovir: 450 mg/d, adjusted for eGFR, for all patients for 3 months unless CMV negative to neg-
ative
Outcomes • Pharmacokinetics and pharmacodynamics of different doses• Side effects• DGF• Acute rejection• BKV• CMV• Death• GraB survival
Notes • Funding source: grant from Genzyme
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not reported but likely unblinded, possible bias for some outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Likely unblinded but low risk in view of hard outcomes
Incomplete outcome data
(attrition bias) 
Low risk All patient outcome data reported
Buchler 2013  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Two authors from Genzyme (manufacturer of ATG); however ATG dose same in
both groups
Buchler 2013  (Continued)
 
 
Methods • Study design: parallel RCT; 2:1 randomisation (alemtuzumab: standard)• Study duration: October 2001 to September 2003• Study follow-up: 6 months
Participants • Country: Asia• Setting: multicentre (3)• Inclusion criteria: adult LD or DD kidney transplant recipients; randomised only after graB was con-
firmed as functioning post-op; either by urine output > 50 mL/h or perfusion on Doppler• Number: treatment group (20); control group (10)• Median age, range (years): treatment group (37.6, 21.2 to 56.0); control group (41.1, 25.1 to 54.2)• Sex (M/F): treatment group (10/10); control group (5/5)• Ethnicity (Chinese/Filipino/Malay/Indian) (%): treatment group (30/45/15/10); control group
(50/50/0/0)• DD/LD: treatment group (10/10); control group (4/6)• Exclusion criteria: positive lymphocyte cytotoxicity cross-match against donor cells; PRA > 85%; previ-
ous transplant; multi-organ transplant; patients deemed to require MMF as primary immunosuppres-
sion; prior treatment with alemtuzumab; use of other investigational agents within 6 weeks; history
of anaphylaxis after exposure to humanized monoclonal antibodies, pregnant or nursing women, un-
willingness or inability to practice an acceptable form of birth control; presence of major systemic or
other illness likely to interfere with the patient’s compliance with the protocol or compromise patient
safety; active infection; HIV antibody positive; Hep B surface antigen or anti-Hep C antibody positive,
who had autoimmune haemolytic anaemia, or who were unable to undergo transplant biopsy, includ-
ing patients who would require anticoagulation
Interventions Treatment group
• Alemtuzumab: 2 x 20 mg doses IV over 2 h, with pre-med of 500 mg MP* 1st dose within 6 h post-op, 2nd dose 24 h after 1st• CSA: started 48 h after 2nd dose alemtuzumab* 5 mg/kg twice/d for 48 h, then 4 mg/kg. Dose reduced to 3 mg/kg twice/d if DGF (dialysis in week 1)* Adjusted to maintain low trough of 90 to 110 ng/mL.• MP: 500 mg at time of surgery• ± pre-med before alemtuzumab with chlorpheniramine, pethidine, or paracetamol• Maintenance PRED only allowed after treatment of steroid resistant rejection or recurrent acute re-
jection
Control group
• CSA: 6 to 8 mg/kg/d (dependent if DGF); adjusted to trough 180 to 225 ng/mL• AZA: 1 mg/kg/d (titrated to WCC > 4 and platelet > 100)• PRED: according to local practice
Outcomes • GraB loss• Death• GraB function
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• Acute rejection• Infection• NODAT• PTLD/malignancy
Notes • Only short-term follow-up reported for most outcomes; small numbers• Planned follow up for 3 years but only 6 month follow up reported so far• No PTLD or malignancy documented (but unlikely in 6 months)• Funding source: partly funded by the National Medical Research Council, Ministry of Health, Singapore
and partially funded by ILEX pharmaceuticals (Alemtuzumab manufacturer)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequence used in balanced blocks of 3
Allocation concealment
(selection bias)
Low risk Sealed envelopes placed with the principal investigator of each centre; the en-
velopes were opened in serial order within 5 hr post-transplant
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Outcome is not likely to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome is not likely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported (to 6 months)
Other bias Unclear risk Partially funded by ILEX pharmaceuticals (Alemtuzumab manufacturer)
CAMPASIA Study 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 1985 to January 1986• Study follow-up: 20 years
Participants • Country: France• Setting: single centre• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group (60); control group (63)• Mean age ± SD (years): treatment group (36 ± 9); control group (40 ± 10)• Sex (M/F): treatment group (41/19); control group (47/16)• Exclusion criteria: not reported
Interventions Treatment group
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• ALG: 300 mg/d for 14 days• AZA: added day 45 to 90 if CSA dose was below 4 mg/kg; given at lower dose of 1 mg/kg
Control group
• AZA: started post-op at dose of 1.5 mg/kg
Immunosuppression (both groups)
• CSA: 4 mg/kg IV started pre-op, then switched to oral and levels of 150 to 250 ng/mL targeted• PRED: 2 mg/kg intra-op, then tapered to 5 mg by day 90
Outcomes • Death• GraB survival• Acute rejection• Infection• Malignancy• GraB function
Notes • Outcomes to 20 years• Primary disease/sensitised patients/HLA mismatch/cold ischaemia time all similar. More DGF in group
1 but not significant (26/63 versus 17/60)• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Outcome assessors probably not blinded but unlikely to influence outcome
however, less than 50% of acute rejection was biopsy-proven. Therefore, pos-
sible source of bias in making ‘clinical’ diagnosis of acute rejection
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding source not reported
Cantarovich 2008  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported
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• Study follow-up: 6 months
Participants • Country: France/Belgium/Italy/Switzerland• Setting: multicentre (30)• Inclusion criteria: ≥ 18 years DD kidney transplant recipients; donor was 60 years or younger and the
patient was not older than 65 years and HIV-negative; no evidence of drug addiction; no previous or
current malignancy; no known hypersensitivity or incompatibility with TAC, CSA, macrolides, poly-
oxyethylene hydrogenated castor oil, steroids, or AZA• Number: treatment group 1 (185); treatment group 2 (186); treatment group 3 (184)• Mean age ± SD (years): treatment group 1 (44.5 ± 11.0); treatment group 2 (44.7 ± 12.4); treatment
group 3 (43.6 ± 10.9)• Sex (M/F): treatment group 1 (121/64); treatment group 2 (118/66); treatment group 3 (116/68)• Ethnicity (white/black/other) (%): treatment group 1 (91.9/2.7/5.4); treatment group 2 (90.9/3.8/5.4);
treatment group 3 (88.8/6.0/6.0)• Exclusion criteria: ABO incompatible graB, had received another solid organ transplant or required
multiple organ transplantation; positive T-cell crossmatch on their most recent serum specimen;
required immunosuppressive drug therapy for other reasons than transplantation; systemic infec-
tions requiring therapy at the time of transplantation; significant thrombocytopenia (50,000 throm-
bocytes/L); elevated liver enzymes (> than 3 times the upper limit of the normal range) at study entry
Interventions Treatment group 1
• TAC triple group (no induction)* TAC: day 0 (0.30 mg/kg/d in 2 divided doses) then adjusted according to trough levels (days 1 to 42:
10 to 42 ng/mL; days 43 to 180: 5 to 15 ng/mL)* MP: day 0 (500 mg IV); day 1 (125 mg IV)* PRED: days 2 to 14 (20 mg); days 15 to 28 (15 mg); days 29 to 90 (10 g); days 91 to 180 (≤ 10 mg)* AZA: day 0 (2 mg/kg IV); days 1 to 90 (1 to 2 mg/kg orally); then stopped
Treatment group 2
• ATG induction-TAC* ATG: 1.25 mg/kg with 12 hours of operation; subsequent doses form day 1 to 10 adjusted according
to clinical condition of patient. Stopped on day 11* TAC: 1st dose on day 9 and adjusted as per treatment group 1* MP, PRED and AZA as per treatment group 1
Treatment group 3
• ATG induction-CSA* ATG as for treatment group 2* CSA: 1st dose on day 9 (8 mg/kg/s in 2 divided doses); adjusted according to trough levels (days 9
to 42: 150 to 300 ng/mL; days 43 to 180: 100 to 200 ng/mL)* MP, PRED and AZA as per treatment group 1
Outcomes • Biopsy-proven acute rejection• Death• GraB loss• Leucopenia• Infection• Serum sickness• Tremor• Malignancy• NODAT• GraB function
Notes • TAC triple therapy versus ATG induction-TAC group were compared for the purpose of this review
Charpentier 2002  (Continued)
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• More redo transplants in ATG induction-CSA group (14.1% versus 8.1%/6.5%, P = 0.03)• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Appears free from other bias except that funding source not reported
Charpentier 2002  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: April 1972 to April 1975• Study follow-up: 18 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group (26); control group (24)• Age range: 19 to 56 years• Sex (M/F): not reported• Exclusion criteria: double-haplotype HLA-identical match
Interventions Treatment group
• hATG: 15 mg/kg IV for 14 days.• PRED and AZA as per control
Control group
• PRED: 2 mg/kg/d, tapered to 0.5 mg/kg by one month, then to maintenance of 15 to 17.5 mg/d• AZA: 5 mg/kg for 48 h, then maintenance of 2.5 mg/kg if WCC ok
Chatterjee 1976 
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Outcomes • Death• GraB survival• Malignancy
Notes • hATG, no CNI in either group• Funding source: Upjohn Company prepared and supplied hATG
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Patients assigned a number, however method not described
Allocation concealment
(selection bias)
Low risk "sealed envelope containing directions for randomization to the treated
(HAHTG) or nontreated (non-HAHTG) group."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Outcome is not likely to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome is not likely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Upjohn prepared and supplied hATG
Chatterjee 1976  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: November 2002 to September 2004• Study follow-up: 24 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult 1st DD kidney transplant recipients• Number: treatment group 1 (30); treatment group 2 (30); treatment group 3 (30)• Mean age ± SE (years): treatment group 1 (49.3 ± 2.5); treatment group 2 (50.2 ± 2.1); treatment group
3 (49.9 ± 2.4)• Sex (M/F): treatment group 1 (19/11); treatment group 2 (19/11); treatment group 3 (18/12)• Ethnicity (White/Hispanic/African-American/Other): treatment group 1 (15/7//7/1); treatment group 2
(10/7/12/1); treatment group 3 (14/3/12/0)• Exclusion criteria: not reported
Interventions Treatment group 1
Ciancio 2005 
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• ATG: 1mg/kg/day for 7 days• TAC: 0.1 mg/kg twice daily when SCr < 4 mg/dL; trough target was 8 to 10 ng/mL• MMF: 1 g twice daily as tolerated• MP: 500 mg for 3 days then weaned to 0.3 mg/kg at one month and 0.15 mg/kg at 3 months
Treatment group 2
• Alemtuzumab: 0.3 mg/kg on day 0 and day 4• MP preceded alemtuzumab (day 0: 500 mg; day 4: 250 mg)• TAC started when SCr < 4 mg/dL; trough target was 4 to 7 ng/mL at one month post-transplant, and
4 to 6 ng/mL at6 months post-transplant• MMF: 500 mg twice daily• Plan to avoid long-term steroids after 1st week
Treatment group 3
• Daclizumab: 1 mg/kg day 0 and 4 additional doses once every 2 weeks• TAC: 0.1 mg/kg twice daily when SCr < 4 mg/dL; trough target 8 to 10 ng/mL• MMF: 1 g twice daily as tolerated• MP: 500 mg for 3 days then weaned to 0.3 mg/kg at one month and 0.15 mg/kg at 3 months
Outcomes • Death• GraB survival• Acute rejection• GraB function• Infection
Notes • Only treatment groups 1 and 2 were included in this review as IL-2RA included in separate review• Funding source: this work was supported by the National Institutes of Health grant No. R01D-
K25243-24, Miami Veterans Affairs Medical Center research support, and Fujisawa Pharmaceuticals,
Tokyo, Japan
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Randomization was performed using a standard randomized block design
with block sizes of three or six patients (ordering of the block sizes was also
randomized), ensuring a balance of patients across treatment arms after each
block of patients was randomized"
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Outcome is not likely to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome is not likely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Ciancio 2005  (Continued)
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Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funded by National Institutes of Health grant No. R01DK25243-24, Miami Vet-
erans Affairs Medical Center research support, and Fujisawa Pharmaceuticals,
Tokyo, Japan
Ciancio 2005  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: September 2002 to October 2006• Study follow-up: 29/36 followed beyond 36 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: LD 1st kidney transplant recipients aged 16 to 66 years• Number: treatment group 1 (13); treatment group 2 (13); treatment group 3 (12)• Mean age ± SE (years): treatment group 1 (44.5 ± 3.1); treatment group 2 (40.0 ± 3.7); treatment group
3 (47.2 ± 2.8)• Sex (M/F):treatment group 1 (10/3); treatment group 2 (9/4); treatment group 3 (7/5)• Ethnicity (White/Hispanic/African-American/Other): treatment group 1 (7/4/2/0); treatment group 2
(5/3/4/1); treatment group 3 (5/4/2/1)• Exclusion criteria: "similar to other prospective randomized trials performed at our center"
Interventions Treatment group 1
• Thymoglobulin: 1 mg/kg/d for 7 days• TAC: 0.1 mg/kg twice daily when SCr < 4 mg/dL; trough target was 6 to 8 ng/mL• MMF: 1 g twice daily as tolerated• MP: 500 mg for 3 days then weaned to 0.3 mg/kg at one month and 0.15 mg/kg at 3 months
Treatment group 2
• Alemtuzumab: 0.3 mg/kg on day 0 and day 4• MP: preceded alemtuzumab (day 0: 500 mg; day 4: 250 mg)• TAC: 0.1 mg/kg twice daily when SCr < 4 mg/dL; trough target was 4 to 6 ng/mL• MMF: 500 mg twice daily as tolerated• Aim to totally avoid steroids after the 1st week
Treatment group 3
• Daclizumab: 1 mg/kg day 0 and 4 additional doses once every 2 weeks• TAC: 0.1 mg/kg twice daily when SCr < 4 mg/dL; trough target was 6 to 8 ng/mL• MMF: 1 g twice daily as tolerated• MP: 500 mg for 3 days then weaned to 0.3 mg/kg at one month and 0.15 mg/kg at 3 months
Outcomes • Death• Biopsy-proven acute rejection• DGF• CAN• Infection• NODAT• GraB function
Ciancio 2010 
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Notes • Only treatment groups 1 and 2 were included in this review as IL-2RA included in separate review• Funding source: "Salary support for the Principal Investigator(Dr. Burke), the biostatistician (Dr.
Gaynor), research coordinator(Ms. Hanson), and data coordinator (Ms. Tueros and Dr. Zarak)was pro-
vided by Roche Laboratories, Inc. via a Clinical Research Agreement to fund part of the costs of con-
ducting and evaluating the results of this clinical trial"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Open-label, unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Open-label, unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Investigators funded by Roche
Ciancio 2010  (Continued)
 
 
Methods • Study design: parallel RCT, stratified for the DM and for each centre• Study duration: not reported• Study follow-up: 1 year
Participants • Country: USA• Setting: multicentre (3)• Inclusion criteria: adult 1st DD kidney transplant recipients• Number: treatment group 1 (83); treatment group 2 (83)• Mean age, range (years): treatment group 1 (48.43, 22 to 72); treatment group 2 (47.31, 22 to 70)• Males: treatment group 1 (66%); treatment group 2 (60%)• Exclusion criteria: refused consent; positive skin test to rATG
Interventions Treatment group 1
• RATG: 0.15 mL/kg/d as continuous IV infusion within 12 h of transplant; adjusted to keep lymphocyte
count < 200/mL3; given for 10 to 14 days• CSA initiated at 2 mg/kg twice daily once kidney function was established (SCr < 250 µmol/L) but at
least 7 days after surgery; target trough of 100 to 300 ng/mL
Cole 1994 
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Treatment group 2
• OKT3: 5 mg given during operation prior to anastomosis, then 5 mg/d IV infusion* MP: 1 mg/kg IV plus 50 mg oral or IV Benadryl and 650 mg acetaminophen every 6 h were given 1
h before OKT3 administration for the 1st 2 or 3 doses* CD3 levels not routinely monitored
Immunosuppression (both groups)
• MP: 1 mg/kg IV within 1 h of transplant; 0.25 mg/kg every 6 h post-op for 48 h; converted to PRED (0.5
mg/kg/d) then tapered to 0.2 mg/kg/d by day 11, 0.15 mg/kg/d by week 6 and continued for 1 year• AZA: 1 mg/kg IV within 1 h of transplant and then continued at 1 mg/kg/d for 1 year unless WCC >
3000/mL3
Outcomes • Death• GraB loss• Acute rejection• Infection (not able to be included in review as reported as total number of infections rather than total
number of patients with infection)
Notes • Kidney function: SCr at 1, 3, 6 and 12 months 'similar' both groups (numbers not given)• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Clinically diagnosed acute rejection (no biopsy-proven acute rejection)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Expected outcomes reported, however infection data cannot be included in
our meta-analysis
Other bias Unclear risk Funding source not reported
Cole 1994  (Continued)
 
 
Methods • Study design: parallel RCT; stratified according to age, histocompatibility, transfusion history• Study duration: not reported
Condie 1985 
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• Study follow-up: 3 years
Participants • Country: USA• Setting: multicentre (4)• Inclusion criteria: adults 1st DD kidney transplant recipients• Number: treatment group (81); control group (79)• Mean age: treatment group (37.8); control group (35.5)• Sex (males): treatment group (75.3%); control group (74.7%)• Exclusion criteria: contraindication of positive skin test; presence of circulating antibodies to horse
products
Interventions Treatment group
• Minnesota equine ALG: 30 mg/kg/d IV for 14 days• PRED and AZA: dosing regimen not reported
Control group
• Human albumin 30 mg/kg/d IV for 14 days• PRED and AZA: dosing regimen not reported
Outcomes • Death• GraB loss• Acute rejection• Infection• Malignancy• Side effects
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double blind
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not blinded, may affect some but not all outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Expected outcomes reported, however acute rejection rates and SCr not fully
reported (short-term only)
Other bias Unclear risk Funding not reported
Condie 1985  (Continued)
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Methods • Study design: parallel RCT• Study duration: January 1973 to November 1975• Study follow-up: 12 to 24 months (graB loss: 12 months; death: 24 months)
Participants • Country: USA• Setting: multicentre• Inclusion criteria: adult and children LD and DD kidney transplant recipients; aged 10 to 60 years• Number: treatment group (183); control group (175)• Mean age: treatment group (36.3 years); control group (34.4 years)• Sex (M/F): treatment group (123/60); control group (149/60)• 1st transplant/repeat transplant: treatment group (162/21); control group (149/26)• DD/LD: treatment group (173/10); control group (165/10)• Exclusion criteria: history of cancer; reaction to ATG skin test
Interventions Treatment group
• hATG (ATGAM): 2 different protocols used* Protocol 119: 10 to 20 mg/kg/d ATG, starting at transplant day 0, continued for 14 days□ AZA: 3mg/kg from day 0 and continued for 16 weeks□ MP: 1.2 mg/kg, starting day 0, continued for 1 week, taper to 24 mg/d by week 17 (or oral PRED)* Protocol 122: 20 to 30 mg/kg/d ATG□ AZA: 2 to 3 mg/kg□ MP: 1.2 mg/kg, starting day 0, continued for 1 week, taper to 24 mg/d by week 17 (or oral PRED)
Control group
• AZA and MP or oral PRED (doses not reported)
Outcomes • Death• GraB loss• Time of onset of acute rejection• Serious infections
Notes • Funding source: Upjohn company and from General Research Support Grants RR-05486-12 and
HL1-18646-01
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table used
Allocation concealment
(selection bias)
Low risk Central allocation via Upjohn company – list kept by "Hypersensitivity Dis-
eases Research’s co-ordinating center for ATG studies"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Open-label; unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Most outcomes not likely to be affected but not all acute rejection was biop-
sy-proven acute rejection
Cosimi 1976 
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Side effects not reported for controls. Authors felt likely to be under-report-
ed in controls as not double blinded study, therefore data not given (likely to
be much higher rate of side effects in ATG group, even if double blinded, there-
fore, probably not acceptable reason for not reporting
Also, some hard outcomes such as WCC and platelets could be easily collected
for both groups
Other bias High risk Authors on Wechter paper are from Upjohn Co (suppliers of ATG).
Cosimi paper– supported in part by research grants from the Upjohn Co and
from General Research Support Grants RR-05486-12 and HL1-18646-01, both
from US Public health service
Cosimi 1976  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: not reported
Participants • Country: Belgium• Setting: single centre• Inclusion criteria: non-hyperimmunised patients receiving 1st DD kidney transplant• Number: treatment group (21); control group (21)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• OKT3: 5 mg/d from day 0 to day 14• CSA: started day 12 and adjusted to tough level between 100 to 150 ng/mL• AZA: tapered from 1 mg/kg to 2 mg/kg on day 15• PRED: gradually tapered from day 14
Control group
• CSA: 4 to 8 mg/kg/d from day 0, adjusted to tough level between 100 to 150 ng/mL• AZA: 1 mg/kg/d from day 0• PRED: gradually tapered from day 14
Outcomes • Acute rejection• DGF• GraB loss
Notes • No table 1; recipients ‘comparable’ for age, sex, PRA, blood transfusions, time on HD, cold ischaemia
time, HLA mismatch• GraB function reported as similar in both groups but no figures given• Infectious complications also reported as similar• Funding source: not reported
De Pauw 1990 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unclear if acute rejection episodes were biopsy-proven acute rejection
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Death not reported at all and only limited reporting of some other outcomes;
data for graB function and infectious complications not available to meta-
analyse
Other bias Unclear risk Insufficient information to permit judgement and funding source not specified
De Pauw 1990  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 4 years
Participants • Country: France• Setting: single centre (Paris)• Inclusion criteria: 1st DD kidney transplant recipients• Number: treatment group (18); control group 1 (18); control group 2 (19)• Mean age ± SD (years): treatment group (35.4 ± 1.9); control group 1 (36.8 ± 2.0); control group 2 (36.3
± 202)• Sex (M/F): treatment group (14/4); control group 1 (9/9); control group 2 (15/4)• Exclusion criteria: not reported
Interventions Treatment group
• OKT3: 5 mg/d For 14 days minimum, up to 30 days• AZA: 3 mg/kg/d as long as tolerated• PRED: taper from 1 mg/kg to 0.25 mg/kg/d
Control group 1
• AZA: 3 mg/kg/d as long as tolerated• PRED: taper from 1 mg/kg to 0.25 mg/kg/d
Debure 1987 
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Control group 2
• AZA: 3 mg/kg/d as long as tolerated• PRED: 5 mg/kg/d for 5 days then tapered over next 2 to 3 weeks
Outcomes • Death• GraB loss• Acute rejection• GraB function
Notes • Control group 1 used as had identical co-interventions to OKT3 group• Side effects also reported but only for OKT3 group. Cytokine release syndrome common with 1st 2
doses of OKT3• No PTLD or malignancy observed• Funding source: not reported; one author an employee if Ortho Pharmaceuticals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk '...the randomisation schedule was computer generated’
Allocation concealment
(selection bias)
High risk No comment in paper about whether treatment allocations were concealed
Imbalance in HLA mismatches (see above) favouring controls suggesting prob-
lems with randomisation, but would potentially bias results in favour of con-
trols
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Not blinded, unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not blinded, unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Funding source not declared, however 1 author was an employee of Ortho
Pharmaceuticals
Debure 1987  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 3 to 31 months
Participants • Country: USA
Diethelm 1979 
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• Setting: single centre• Inclusion criteria: DD kidney transplant recipients• Number: treatment group (26); control group (27)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• ATG: 10 to 15 mg/kg/d from day 0 for 28 days
Control group
• No ATG
Immunosuppression (both groups)
• AZA: 5 mg/kg for 2 days, tapered to 3 mg over 1 week, maintained at 75 to 200 mg (depending on WCC)• PRED: 5 mg/kg/d, tapered over 1 week, tapered to 15 to 20 mg by 1 year
Outcomes • Death• GraB survival• Infection
Notes • No table 1; age, sex, race were the ‘same’ in two groups• Death and graB loss reported but not at a consistent time point (some only followed for 3 months);
cannot be included in review analyses• Only irreversible acute rejection reported, therefore not included in review analyses. (reversible
episodes reported as similar but no figures given)• 2 kidneys taken from non-heart beating donors – never functioned due to ATN, these 2 patients were
excluded• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Unblinded; unlikely to influence most outcomes but may influence some
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not clear if acute rejection was biopsy-proven acute rejection
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing patients unlikely to affect results (2 with never functioned kidneys ex-
cluded)
Selective reporting (re-
porting bias)
High risk Acute rejection, death and graB loss reported but could not be included in
meta-analyses
Diethelm 1979  (Continued)
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Other bias Unclear risk Funding source not reported
Diethelm 1979  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 1 year
Participants • Country: Finland/Sweden/Norway/Germany• Setting: multicentre (10)• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group (131); control group (131)• Mean age, range (years): treatment group (48.0, 21 to 78); control group (45.1, 16 to 77)• Sex (M/F): treatment group (83/48); control group (89/42)• Exclusion criteria: history of malignancy; previous exposure to murine antibodies; active infection;
ongoing pregnancy
Interventions Treatment group
• Enlimomab: 160 mg IV 3 hours prior to transplant, then 40 mg/d for 5 days• CSA/AZA/PRED per local protocol
Placebo
• CSA/AZA/PRED per local protocol
17 patients across both groups got ATG for DGF
Outcomes • Death• GraB loss• Acute rejection - at 3 months and 1 year• DGF• Infections• Malignancy
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 'Performed in blocks of 6 to ensure balanced distribution of treatment per cen-
tre'
Allocation concealment
(selection bias)
Low risk Central allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blinded
Blinding of outcome as-
sessment (detection bias) 
Low risk Double-blinded; pathologist reviewing biopsies for suspected acute rejection
was also blinded
EARTS Study 1999 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Unclear risk All expected outcomes reported
Other bias Unclear risk Appears free from other bias but funding source not declared
EARTS Study 1999  (Continued)
 
 
Methods • Study design: pilot parallel RCT• Study duration: August 2008 to December 2011• Study follow-up: 12 months
Participants • Country: USA• Setting: multicentre (2)• Inclusion criteria: kidney transplant recipients aged 18 to 65 years old considered high immunologic
risk by at least one of the following criteria: (1) current cytotoxic PRA ≥ 20% or peak cytotoxic PRA ≥ 50,
(2) T or B cell positive crossmatch (by flow cytometry) with confirmed DSA on solid-phase assay, (3)
historical positive serologic or cytotoxic crossmatch or donor specific antibody to donor or (4) prior
allograft loss with a history of more than one acute rejection episode• Number: treatment group 1 (10); treatment group 2 (10); treatment group 3 (10); control group (10)• Mean age (years): treatment group 1 (52.8); treatment group 2 (50.6); treatment group 3 (50.1); control
group (49.9)• Sex (M/F): treatment group 1 (5/5); treatment group 2 (2/8); treatment group 3 (6/4); control group
(5/5)• Exclusion criteria: contraindications to bortezomib, rituximab or rATG; HLA identical living-related
kidney transplants; previously received or were receiving a transplant other than kidney; previous
allograft loss due to disease recurrence; history of allergic/anaphylactic reactions to humanized or
murine mAbs or polyclonal antibodies; ANC < 1000/mm3 or platelet count < 100,000/mm3 within 30
days; grade 2 peripheral neuropathy within 14 days; MI within 6 months; class III or IV heart failure;
uncontrolled angina; uncontrolled ventricular arrhythmias; electrocardiographic evidence of acute
ischaemia or active conduction system abnormalities; anti-HIV-positive, Hep B surface antigen-posi-
tive or anti-Hep C virus-positive within 1 year; malignancy within 3 years; systemic infections within
2 weeks; live vaccine within 4 weeks; investigational drugs within 30 days or five half-lives; severe liv-
er disease with abnormal liver profile within 30 days; pregnant or lactating women; women of child-
bearing potential must have negative serum pregnancy test within 48 h prior to receiving study med-
ication; EBV serologic mismatch; CMV serologic mismatch
Interventions Treatment group 1
• rATG: 1.5 mg/kg/dose, 5 doses on alternate days• Rituximab: 375 mg/m2, 1 dose on day 1
Treatment group 2
• rATG: 1.5 mg/kg/dose, 5 doses on alternate days• Bortezomib: 1.3 mg/m2/dose, 4 doses on days 0, 3, 7, 10
Treatment group 3
• rATG: 1.5 mg/kg/dose, 5 doses on alternate days• Rituximab: 200 mg/m2, 1 dose on day 1
Ejaz 2013 
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• Bortezomib: 1.3 mg/m2/dose, 4 doses on days 0, 3, 7, 10
Control group
• rATG: 1.5 mg/kg/dose, 6 doses on alternate days
Immunosuppression (all groups)
• TAC: started within 72 h of transplant, target of 8 to 15 ng/mL for 3 months, then target 5 to 12 ng/mL• MMF: 1000 mg twice daily, could increase to 1500 mg in African-American patients• PRED: rapid taper to 5 mg daily by 7 days and then continued for 1 year post transplant
Prophylaxis (all groups)
• Valganciclovir: 90 days if recipient CMV +ve, if CMV –ve to –ve then 30 days only• Nystatin: 90 days• Co-trimoxazole/pentamidine/dapsone: 1 year
Outcomes • Death• GraB loss• Acute rejection• GraB function• Malignancy• PTLD• Infection
Notes • Funding source: "Bortezomib (Velcade®) was provided by Millennium Pharmaceuticals, Inc. Research
grant support for this study was provided by Genzyme (now Sanofi)"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Central computerised block randomisation, generated by independent statis-
tician
Allocation concealment
(selection bias)
Low risk Sealed envelopes, sequential order as consented
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label, some outcomes (e.g. reporting of side effects) likely to be influ-
enced
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label, may affect assessment of toxicities
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Two authors received research funds from both Genzyme and Millennium
Ejaz 2013  (Continued)
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Research grant support from Genzyme, Bortezomib provided by Millennium
Pharm
Ejaz 2013  (Continued)
 
 
Methods • Study design: parallel RCT; divided into high or low immunologic risk and then randomised• Study duration: 1 February 2005 to 15 June 2006• Study follow-up: median 2 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult (> 18 years) kidney and pancreas transplant recipients• Number: treatment group (113); control group (109)• Mean age (years): treatment group (51 ± 12); control group (51 ± 13)• Sex (M/F): treatment group (67/46); control group (62/47)• Black/white: treatment group (34/74); control group (36/69)• Exclusion criteria: not reported
Interventions Treatment group
• Alemtuzumab: 30 mg single dose, started intra-operatively
Control group
• rATG: 1.5 mg/kg, via CVC, 1st dose started intra-operatively; subsequent infusions same dose, to 3 to
7 in total, on alternate days until 50% drop in SCr and CNI started
Immunosuppression (both groups)
• TAC or CSA: targets dependent on immunologic risk* High risk trough levels: TAC (10 to 12 ng/mL) or CSA (250 to 350 ng/mL) for 3 months, then TAC (8
to 10 ng/mL) or CSA (150 to 250 ng/mL)* Low: risk tough levels: TAC (8 to 10 ng/mL) or CSA (250 to 325 ng/mL) for 3 months, then TAC (6 to
8 ng/mL) or CSA (150 to 250 ng/mL)• MMF: 500 to 1000 mg twice daily (500 if > 60yrs and on TAC)• PRED: dose dependent on immunologic risk* High risk or DGF: rapid taper to 5 mg by 2 months* Low risk: 6 doses max
Prophylaxis (both groups)
• PCP: prophylaxis for 1 year• Valganciclovir: 3 months minimum• Nystatin: 1 month
Outcomes • Biopsy-proven acute rejection• GraB survival
Notes • Enrolment of kidney alone recipients discontinued in Sept 2007 due to higher incidence of biop-
sy-proven acute rejection in the rATG group (? due to steroid withdrawal)• Other outcomes reported for kidney and pancreas patients combined, therefore cannot be included
in this review• Funding source: self-funded by Wake Forest University Baptist Medical Center
Risk of bias
Farney 2008 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk '2 distinct randomly generated lists'
Allocation concealment
(selection bias)
Low risk Allocation done independently by research co-ordinator. Co-ordinator in-
formed transplant surgeon just before surgery which agent to use.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Unable to meta-analyse death, DGF, infection due to combined data
Other bias Low risk Appears free from other bias; study self-funded (by Wake Forest University
Baptist Medical Center)
Farney 2008  (Continued)
 
 
Methods • Study design: parallel RCT; patients stratified by age (18 to 49 versus ≥ 50 years), diabetes, previous
transplant, graB survival if previous transplant• Study duration: July 1987 to September 1990• Study follow-up: 2 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: kidney and kidney-pancreas DD transplant recipients• Number (kidney/kidney-pancreas): treatment group (67/17); control group (71/18)• Mean age ± SD (years): treatment group (41 ± 1.3); control group (42 ± 1.3)• Sex (M/F): treatment group (45/39); control group (51/38)• Ethnicity (white): treatment group (90%); control group (93%)• Exclusion criteria: Initially excluded kidney transplant patients who had rejected a previous transplant
in the 1st year; this was changed 1 year into the study toot include all kidney transplant recipients;
kidney-pancreas recipients excluded if > 50 years or were undergoing a retransplant of either a kidney
or pancreas
Interventions Treatment group
• OKT3: 5 mg/d for 7 days; given 1st dose in operating theatre after pre-med with steroids
Control group
• mALG: 20 mg/kg/d for 7 days; 1st dose 1 day post-op; ALG continued for up to 10 days with delayed
CSA start if oliguria
Immunosuppression (both groups)
Frey 1991 
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• PRED: 1 mg/kg/d, taper to 0.5 mg/kg by day 10• AZA: 5 mg/kg taper to 2.5 mg/kg• CSA: 4 mg/kg twice daily from day 5 post-op
Outcomes • Death up to 2 years• GraB survival up to 2 years• Acute rejection• Malignancy• CMV infection• GraB function up to 2 years
Notes • Results reported here only for kidney transplant recipients (pancreas and kidney recipients excluded)• All acute rejection were biopsy-proven acute rejection• Funding source: supported by NIH Research Grant 5P01-DK 13083
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Low risk Sealed envelopes used
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes, all acute rejection was biopsy-proven
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk Expected outcomes reported
Other bias Low risk Supported by NIH research grant
Frey 1991  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 1 year
Participants • Country: UK• Setting: single centre• Inclusion criteria: adult (> 16 years) DD kidney transplant recipients• Number: treatment group (26); control group (26)• Mean age, range (years): treatment group (45, 21 to 67); control group (40.4, 16 to 68)
Friend 1987 
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• Sex (M/F): treatment group (18/8); control group (18/8)• Exclusion criteria: Hep B carriers; multiorgan recipients; already entered study with previous trans-
plant; transplant biopsy not possible; could not be treated with standard immunosuppressive proto-
col; refused consent
Interventions Treatment group
• Alemtuzumab: 25 mg (IV), twice daily for 10 days• MP: 0.5 g• CSA: 4 mg/kg (IV) for 2 to 3 days, then 17 mg/kg (oral) to maintain trough levels 200 to 400 U
Control group
• No alemtuzumab
Immunosuppression (both groups)
• MP: 0.5 g• CSA: 4 mg/kg (IV) for 2 to 3 days, then 17 mg/kg (oral) to maintain trough levels 200 to 400 U
If steroid-resistant acute rejection (after 2 or more courses of steroids) switched to either:
• CSA + PRED + AZA on alternate days, or daily PRED + AZA
Outcomes • Acute rejection• Infections• Reactions• GraB survival• Patient survival• GraB function
Notes • Funding source: supported by the Medical Research Council, The British Technology Group, the Ben
Hardwick Memorial Fund, the Addenbrooke's Children's Liver Transplant Fund, and the East Anglian
Regional Heath Authority
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Permuted block randomisation
Allocation concealment
(selection bias)
Low risk Sealed envelopes used
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Mainly low risk but not all acute rejection was biopsy-proven acute rejection.
Some was diagnosed and treated even when no evidence on biopsy but high
clinical suspicion
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Friend 1987  (Continued)
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Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Low risk Appears free from other bias
Friend 1987  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 1985 to May 1986• Study follow-up: 1 year
Participants • Country: France• Setting: single centre• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group (29); control group (27)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• ALG: for 15 days (dose not reported)• CSA: 8 mg/kg/d• PRED: 2mg/kg/d, taper to 10 to 15 mg/day at 1 month• AZA: added for maintenance if CSA reduced to 4mg/kg/d for nephrotoxicity
Control group
• Triple therapy: low dose combination of AZA, CSA and PRED (doses not reported)
Outcomes • Death• GraB loss• Acute rejection• CMV infection
Notes • No information, other than 3 re-transplant patients, others all 1st transplant. All DD transplant recip-
ients.• Abstract only• Cannot use any results for reporting; 29 versus 27 patients were randomised to treatment groups.
However, 51 patients were given ALG altogether (therefore, 22 of these were not randomised). Results
are given including the 51 patients for the ALG group, therefore including the non-randomised pa-
tients. Cannot use for review outcomes• funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement, abstract only
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement, abstract only
Fries 1988a 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement, abstract only
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement, abstract only
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement, abstract only
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement, abstract only
Other bias Unclear risk Insufficient information to permit judgement, abstract only
Fries 1988a  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: October 1987 to December 1989• Study follow-up: 1 year
Participants • Country: France• Setting: single centre• Inclusion criteria: for 2 years all patients having DD transplant were recruited then only 'high
risk' (highly sensitised with PRA > 75 or re-transplant) were included; 36 'high risk' included from 1st
period but these were really a subgroup of all the randomised patients; 46 truly randomised patients
from second period (when only 'high risk' patients were eligible for randomisation)• Number (randomised/analysed): treatment group 1 (45/44); treatment group 2 (37/37)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• OKT3: 5 mg/d for 10 days• PRED, AZA and CSA (doses not reported)
Treatment group 2
• ATG: 3775 mg/d (Thymoglobulin, Merieux) for 10 days• PRED, AZA and CSA (doses not reported)
Outcomes • Death• GraB loss• Acute rejection• DGF• Infection• GraB function
Notes • Protocol changed half way through study
Fukuuchi 1996 
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• Results reported include combination of high risk subgroup from 1st protocol and randomised high
risk patients from 2nd protocol. Therefore, not included in review analyses• Recipient age and PRA were not evenly distributed, 5 recipients over 50 years in OKT3 versus 13 recip-
ients in ATG• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Change in eligibility for randomisation part way through
Selective reporting (re-
porting bias)
High risk Change in eligibility for randomisation part way through
Other bias Unclear risk Funding source not reported
Fukuuchi 1996  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 1983 to February 1986• Study follow-up: 2 years
Participants • Country: Belgium• Setting: single centre• Inclusion criteria: 1st and 2nd DD kidney transplant recipients• Number: treatment group (66); control group (58)• Mean age ± SD (years): treatment group (33.3 ± 35.1); control group (33.1 ± 35.4)• Sex ratio (M/F): treatment group (3/1); control group (2.8/1)• Exclusion criteria: causative nephropathy was diabetes or oxalosis; positive T cell crossmatch with
donor lymphocytes
Interventions Treatment group
• CSA: 3 mg/kg IV infusion for 24 hours, then oral 14 mg/kg for 1 week (subsequently reduced to 1 to 3
days only), then 12 mg/kg/d, then adjusted by levels; target < 100 ng/mL• MP: 1g IV on day of transplant• PRED: 0.4mg/kg/d, tapered to 0.1 mg/kg/d by 9 months
Gianello 1987 
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Control group
• ALG: started pre-op, given 50 mg/kg/d for 3 days, then 25 mg/kg/d for 11 days• AZA: 1.5 to 2.5 mg/kg/d IV for 1st day then oral, adjusted for WCC• MP: IV, total dose 4.5 g over 6 days• PRED: at 0.7 mg/kg/d tapered to 0.1 mg/kg/d by 1 year
Outcomes • Death• GraB loss• Acute rejection• DGF• GraB function at 2 years
Notes • Age, 1st/2nd graB, gender, dialysis vintage, previous blood transfusion, HLA match, total ischaemic
time, cause of ESRD all similar in both groups• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not reported but likely not blinded; low risk of bias for hard outcomes but bias
possible for some outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Likely not blinded; some acute rejection was biopsy-proven acute rejection
but some was clinical
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Seems results are combined here for 2 separate studies; one study of 1st DD
transplant recipients, another study of 2nd DD transplant recipients. ‘we have
concurrently conducted a similar studyin secondary cadaver gra/s…we analyse
in this report the outcome of both…..’.
Gianello 1987  (Continued)
 
 
Methods • Study design: open-label, parallel, pilot RCT• Study duration: November 2010 to April 2013• Study follow-up: 12 months
Participants • Country: USA
Grafals 2014 
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• Setting: single centre• Inclusion criteria: > 18 years LD or DD kidney transplant recipients• Number: treatment group 1 (23); treatment group 2 (20)• Mean age ± SD (years): treatment group 1 (52.9 ± 12.1); treatment group 2 (56.6 ± 11.6)• Sex (M/F): treatment group 1 (16/7); treatment group 2 (16/4)• White/Hispanic/African American/other: treatment group 1 (13/6/2/2); treatment group 2 (16/2/2/0)• DD/LD: treatment group 1 (14/9); treatment group 2 (12/8)• Exclusion criteria: multiorgan transplant; current or historic panel reactive antibody > 20%; presence
of donor specific anti-HLA antibodies; contraindication to ATG use
Interventions Treatment group 1
• Standard dose ATG: 3.75 mg/kg total dose; 1.25 mg/kg, 3 doses on days 0, 1, 2
Treatment group 2
• Low dose ATG: 2.25 mg/kg total dose; 0.75 mg/kg, 3 doses on days 0, 1, 2
Immunosuppression (both groups)
• TAC 2 mg twice a day, target level 8 to 10 ng/mL for 1st 6 months• MMF: 1000 mg twice a day• 7 day steroid taper: 3 days MP, 4 days PRED• Co-trimoxazole prophylaxis: 480 mg once/day for 6 months (pentamidine if allergic)• Valganciclovir: 450 mg once/d, adjusted for eGFR for 6 months for high risk patients for CMV (donor
positive to negative recipient), or for 3 months for all other patients
Outcomes • Death• GraB loss• Biopsy-proven acute rejection• DGF• GraB function• Adverse outcomes
Notes • Funding source: "Robert Weiss Grant (MG) and American Heart Association (LVR). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manu-
script."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated protocols used for randomisation
Allocation concealment
(selection bias)
Low risk Randomisation performed by research coordinator, sealed envelopes used
(see clinical trials website)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Open label but low risk in view of outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Open label but low risk in view of outcomes
Grafals 2014  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk all expected outcomes reported
Other bias Low risk Appears free of other biases
Grafals 2014  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 1986 to January 1988• Study follow-up: 15 years
Participants • Country: Spain• Setting: single centre• Inclusion criteria: adult 1st DD kidney transplant recipients• Number: treatment group (50); control group (50)• Mean age ± SD (years): treatment group (40 ± 11); control group (37 ± 13)• Sex (M/F): treatment group (37/13); control group (32/18)• Exclusion criteria: diabetic and highly sensitized patients (PRA > 70%)
Interventions Treatment group
• ALG (horse, Merieux): 10 mg/kg IV, 1 day post-op, then alternate days, maximum 6 doses• MP: 1 g, then PRED 0.25 mg/kg, taper to 0.1 mg/kg by 6 months• CSA: 3 mg/kg IV pre transplant, then 1 mg/kg twice daily until able to take oral, then 8 mg/kg/d, trough
target 300 to 600 ng/mL
Control group
• CSA: 5 mg/kg pre-op IV, then 2.5 mg/kg twice daily, then oral 15 mg/kg; trough target of 300 to 800
ng/mL• MP or PRED: 0.5 mg/kg ‘during surgery’, taper to 0.1 mg/kg/d by 6 months
Immunosuppression (both groups)
• Oral PD: 7.5 to 15 mg/d• CSA: 3 to 8 mg/kg/d
Outcomes • Death at 15 years• GraB loss at 15 years• Acute rejection
Notes • Control group had higher dose CSA• Death censored graB survival excluded as only reported as percentages• Denominator not clear• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Grino 1990 
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Random sequence genera-
tion (selection bias)
High risk 'the allocation to treatment groups was done alternately'
Allocation concealment
(selection bias)
High risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Acute rejection episodes diagnosed clinically (no biopsy)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Unclear risk Some expected outcomes not reported such as infection and other adverse
outcomes
Other bias Unclear risk Funding source not reported
Grino 1990  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: March 1988 to December 1990• Study follow-up: 2 years
Participants • Country: Spain• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients• Number: treatment group 1 (68); treatment group 2 (72)• Mean age ± SD (years): treatment group 1 (42.6 ± 13); treatment group 2 (39 ± 11)• Sex (M): treatment group 1 (59%); treatment group 2 (57%)• Exclusion criteria: not reported
Interventions Treatment group 1
• Horse ALG: 15 mg/kg pre-transplant, 12 mg/kg day 1, then 10 mg/kg alternate days for 4 doses* Dose adjusted to maintain CD3 counts 10% to 20%
Treatment group 2
• OKT3: 5mg IV at induction, continued daily for 5 doses total
Immunosuppression (both groups)
• MP: 1 mg/kg in operating theatre, then 0.25 mg/kg, then taper to 0.1 mg/kg• CSA: 3 mg/kg IV pre-op, then 3 mg/kg in 2 doses post-op, then oral 8 mg/kg in 2 doses
Outcomes • Death• GraB loss• DGF
Grino 1991 
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• Acute rejection• Serious infection
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Low risk "randomly allocated by a closed-envelope technique"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding source not reported
Grino 1991  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: May 1981 to July 1983• Study follow-up: 1 year
Participants • Country: Germany• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients• Number: treatment group (47); control group (47)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• ALG (Merieux): 0.5 mL/kg/d (max 30 mL) for 1st 3 weeks post transplant
Control group
• No ALG
Immunosuppression (both groups)
Grundmann 1984 
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• PRED: 250 mg day 1, reduced by 25 mg/day to 100 mg, then by 5 mg every other day to 10 mg• AZA: max 3 mg/kg/day but dose adjusted for WCC/platelets/side effects
Outcomes • Death• GraB loss• DGF• Infection• Acute rejection
Notes • No table 1 but states 2 groups were similar in terms of age, time on dialysis, HLA mismatch and cold
ischaemia time• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Outcomes not likely to be influenced
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk May affect some outcomes and not reported if blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to assess whether an important risk of bias exists;
funding source not reported
Grundmann 1984  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: September 1983 to November 1985• Study follow-up: all followed to November 1986
Participants • Country: Germany• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients• Number: treatment group 1 (50); treatment group 2 (50)• Mean age ± SD (years): treatment group 1 (38.5 ± 10.8); treatment group 2 (38.7 ± 12.0)• Sex ratio (M/F): treatment group 1 (1.9/1); treatment group 2 (1.6/1)
Grundmann 1987 
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• Exclusion criteria: not reported
Interventions Treatment group 1
• ALG: 14 days; dose 5 mL/kg/d to max of 30 mL/d via CVC continuous IV infusion• PRED: 250 mg day 1, taper by 25 mg/d till 100 mg, then taper by 5 mg/d to 5 to 10 mg/d achieved• AZA: max 3 mg/kg/d, depending on WCC platelet count• AZA and ALG switched to CSA at day 14 or earlier if unable to tolerate complete ALG course• CSA: 8 mg/kg (2 doses), aim for trough levels of 300 ng/mL
Treatment group 2
• ALG, AZA and steroids: given for 7 days post-op; thereafter ALG and AZA switched to CSA
Outcomes • Death• GraB loss• DGF• Acute rejection• Infection• Tolerability of treatment
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not specified if diagnosis of acute rejection was biopsy proven or clinical
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Unclear risk Unsure why acute rejection not reported beyond 3 weeks if there were any in-
cidences of any other side effects such as malignancy/PTLD
Other bias Unclear risk Funding source not reported
Grundmann 1987  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported
Guttmann 1997 
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• Study follow-up: 3 months
Participants • Country: European• Setting: multicentre• Inclusion criteria: DD kidney transplant recipients• Number: treatment group (147); control group (154)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• Anti-LFA-1: 15 to 30 mg/day for 10 days• AZA and PRED• CSA: from day 9
Control group
• CSA-based ‘triple therapy’ from day 0
Outcomes • Patient survival• GraB survival• Incidence of acute rejection• Infection• Adverse events
Notes • Abstract-only publication• 2 groups were ‘demographically comparable’• No figures reported for results• States patient survival, graB survival, incidence of acute rejection, infection and adverse events all
similar at 3 months• Reports trend towards decreased DGF in Anti-LFA-1 group• No extractable data for review analyses
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement; abstract only
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement; abstract only
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement; abstract only
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement; abstract only
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement; abstract only
Guttmann 1997  (Continued)
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Selective reporting (re-
porting bias)
High risk No actual figures reported for any outcomes
Other bias High risk Abstract only publication, no full-text publication identified
Guttmann 1997  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: all patients have been followed for at least 1 month (ALG: mean 5.7 months; CSA:
mean 7.4 months)
Participants • Country: Canada• Setting: multicentre (2)• Inclusion criteria: DD kidney transplant recipients• Number: treatment group (19); control group (26)• Median age (years): treatment group (37); control group (37.5)• Sex (M): treatment group (68%); control group (62%)• Exclusion criteria: LD; acute or progressive liver disease; received any drug that caused hepatic or
myelotoxicity ≤ 3 months prior to transplant; history of neoplasia; received cytotoxic drugs ≤ 3 months
prior to transplant; positive Terasaki T-cell crossmatch; previously entered this study; received < 2
units of whole blood or packed RBC 2 weeks or more before transplant; unable to ensure adequate
follow-up; < 12 years
Interventions Treatment group
• mALG: pre-op 10 mg/kg then 20 mg/kg/d via CVC over 8 to 24 hours* Usually 14 to 21 doses over 14 to 28 days (could be alternate day after day 14)* Adjusted as per WCC, platelet and lymphocyte counts.• AZA: 1 mg/kg during ALG, then increased as per WCC• PRED: dose not reported
Control group
• CSA: 20 mg/kg pre-op, then 20 mg/kg in 2 divided doses to maintain level of 100 to 400 ng/mL• PRED: alternate days from day 14 (dose not reported)
Outcomes • Death• GraB loss• CMV infection• Acute rejection
Notes • 2 centres used mALG for all ‘control’ (non CSA) patients. Results of these 2 centres combined in this
report• Acute rejection reported as number of episodes per patient. Not included in review as analyses• Part of the Canadian Multicentre Cyclosporine Trial
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Balance, restricted randomisation according to treatment centre; randomised
block of varying size was generated
Halloran 1982 
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Allocation concealment
(selection bias)
Low risk Opaque envelopes held by the research pharmacist at each participating cen-
tre
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 3 patients switched groups from control to mALG, not clear how analysed
Selective reporting (re-
porting bias)
High risk Unable to include acute rejection results in the meta-analysis
Other bias Low risk Appears free of other bias. Funded by grant from Medical Research council of
Canada. Also grant from Conacher foundation
Halloran 1982  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: May 2005 to February 2006• Study follow-up: 3 years
Participants • Country: USA• Setting: multicentre (30)• Inclusion criteria: ≥ 18 years; LD or DD recipient, high risk subgroup• Number: treatment group 1 (70); treatment group 2 (69)• Mean age ± SD (years): treatment group 1 (44.7 ± 12.8); treatment group 2 (48.5 ± 11.0)• Sex (M/F): treatment group 1 (37/33); treatment group 2 (39/30)• Ethnicity (White/black/other (%)): treatment group 1 (26/71/3); treatment group 2 (29/68/3)• LD/DD: treatment group 1 (28/42); treatment group 2 (26/43)• Exclusion criteria: expanded criteria donors; kidneys from donors without a heartbeat; kidneys with is-
chaemic times exceeding 36 hours; positive cytotoxic or flow-cytometric cross-matches; kidneys from
HLA-identical live donors
Interventions Treatment group 1
• Alemtuzumab: 30 mg single IV infusion
Treatment group 2
• rATG: 1.5 mg/kg given for 4 doses daily from day 0
Maintenance immunosuppression (both groups)
• MMF: 1g twice a day• TAC: within 48 hours (or later if DGF), dose 0.1 to 0.2 mg/kg/d, 2 divided doses; trough target 7 to 14
ng/mL for 90 days, then 4 to 12 ng/mL• PRED: 1 g or less over 5 days
Hanaway 2011 
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Outcomes • Biopsy-proven acute rejection• Death• GraB loss• Infection• Adverse events• Cancer
Notes • GraB function - reported as SCr similar at 1 year but actual figures not given• Funding source: sponsored by Astellas Pharma Global Development. "The study was conceived and
designed by two academic and two industry authors. The manuscript was written by five academic
and two industry authors, and all these authors made the decision to submit the manuscript for pub-
lication. The sponsor held the data, to which all authors had free access. Three academic and two in-
dustry authors analyzed the data"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk 'Automated system' used but not really clear.
Allocation concealment
(selection bias)
Unclear risk Randomisation stated but no information on method used is available. Even
after reading supplementary appendix, info is still vague. 
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported however SCr similar at 1 year but actual fig-
ures not given and cannot be meta-analysed
Other bias Low risk Study appears free form other bias. Funding by Astellas Pharma Global Devel-
opment
Hanaway 2011  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: May 1987 to December 1989• Study follow-up: 3 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult 1st DD kidney transplant recipients• Number: treatment group 1 (59); treatment group 2 (58)• Mean age ± SD (years): treatment group 1 (43 ± 11); treatment group 2 (44 ± 11)
Hanto 1991 
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• Sex (M/F): treatment group 1 (31/28); treatment group 2 (40/18)• Ethnicity (white/black/other): treatment group 1 (40/19/0); treatment group 2 (31/26/1)• Exclusion criteria: not reported
Interventions Treatment group 1
• ALG (Minnesota): 20 mg/kg/d for 7 days, ALG given 6 to 12 hours post-op (risk of low platelets and
bleeding)
Treatment group 2
• OKT3: 5 mg/d for 7 days (given intra-op)
Maintenance immunosuppression (both groups)
• AZA: 2.5 mg/kg pre-op then 2 to 2.5 mg/kg/d to maintain WCC > 3000/mm3• MP: 7 mg/kg pre-op, then PRED 1 mg/kg, tapered to 0.3 mg/kg by 3 months, and 0.15 mg/kg by 12
months• CSA: 8 mg/kg/d from day 5 post-op, trough level 175 to 200 ng/mL trough, tapered to 5 mg/kg by 9
months
Outcomes • Death• GraB loss• Acute rejection• CMV disease• GraB function
Notes • Infections reported but only as total number and number per patient (not reported as number of pa-
tients with infection)• Monitoring of CD3, 4 and 8 cells in both groups• Funding source; not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported; unable to meta-analyse infection data
Hanto 1991  (Continued)
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Other bias Unclear risk Funding source not reported
Hanto 1991  (Continued)
 
 
Methods • Study design: parallel quasi-RCT• Study duration: December 1995 to March 1997• Study follow-up: minimum 24 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: LD and DD kidney transplant recipients; only patients with good post-op diuresis
included (DGF excluded) ‘to avoid disadvantaging patients if in control group and getting immediate
CSA with early dysfunction’• Number: treatment group (55); control group (49)• Mean age, range (years): treatment group (49, 16 to 76); control group (45, 16 to 74)• Sex (M/F): treatment group (40/15); control group (30/9)• Ethnicity (white/black): treatment group (43/12); control group (37/12)• LD/DD: treatment group (18/37); control group (10/39)• Exclusion criteria: DGF; not surviving past 3 months
Interventions Treatment group
• OKT3: given for 5 to 7 days (dose not reported), until SCr 2.5 to 3 mg/dL• CSA: started with 1 day overlap with OKT3, trough target 250 mg/mL
Control group
• CSA: started within 12 hours post-op, trough target 250 mg/mL
Immunosuppression (both groups)
• PRED: 2 mg/kg, weaned to 0.15 mg/kg by 3 months• MMF: 1 g twice daily
Outcomes • Death• GraB loss (death-censored)• Acute rejection• CMV disease
Notes • GraB function reported but no SD or SE given, therefore cannot be included in analysis of this review• Funding source: supported by a grant from Orthi-BioTech
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Randomised according to whether patient record number ended in odd or
even number
Allocation concealment
(selection bias)
Unclear risk Randomised according to whether patient record number ended in odd or
even number.
Blinding of participants
and personnel (perfor-
mance bias) 
Low risk Unlikely to influence outcomes
Henry 2001 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unlikely to influence outcomes although uncertain if acute rejection episodes
were biopsy proven or clinically diagnosed
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported however unable to included graB function in
the meta-analyses as no SD or SE reported
Other bias High risk Potential bias due to funding from OKT3 (Grant from Ortho Bio-Tech – OKT3
manufacturer)
Henry 2001  (Continued)
 
 
Methods • Study design: parallel RCT; initial randomisation took place of the day of transplantation; a 2nd ran-
domisation took place in the 3rd month post-transplant• Study duration: not reported• Study follow-up: 3 to 24 months
Participants • Country: France• Setting: single centre• Inclusion criteria: LD or DD kidney transplant recipients; 1st or 2nd transplant• Number: treatment group 1 (32); treatment group 2 (21); control group (35)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• High dose CSA (Cys group II): 15 mg/kg/d• PRED: 1mg/kg/d
Control group
• ATG (standard group): for 3 weeks (dose and manufacturer not reported)• PRED: 1 mg/kg• AZA: 2 to 3 mg/kg/d
2nd randomisation at 3 months of the control group only to continue with standard treatment or
switch to low dose CSA monotherapy (6 mg/kg/d) (treatment group 2 - Cys group I)
Outcomes • Death• GraB loss• Acute rejection• GraB function• Infection
Notes • Decision made not to use results in review analyses given double intervention of both induction and
maintenance• Funding source: not reported
Hourmant 1985a 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Some outcomes reported with insufficient detail to fully assess e.g. infection
Selective reporting (re-
porting bias)
High risk Some outcomes reported with insufficient detail to fully assess
Other bias Unclear risk Insufficient information to permit judgement
Hourmant 1985a  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 1 year
Participants • Country: France• Setting: multicentre (5)• Inclusion criteria: adults 1st DD kidney transplant recipients; cold ischaemia time < 48 hours• Number: treatment group 1 (52); treatment group 2 (49)• Mean age ± SD (years): treatment group 1 (46 ± 11); treatment group 2 (45 ± 11)• Sex (M/F): treatment group 1 (34/18); treatment group 2 (39/10)• Exclusion criteria: hyperimmunized patients (> 75% PRA), patients transplanted across a positive his-
torical cross-match, focal glomerulosclerosis as the initial kidney disease, documented hepatopathy
or a past history of malignancy
Interventions Treatment group 1
• Anti-LFA-1: 30 mg via peripheral vein, over 30 min, 2 hours pre-op; further daily dose of 15 mg days 2
to 10; circulating trough levels of anti-LFA-1 mAb measured
 Treatment group 2
• rATG: 1.25 mg/kg/d over 4 hours via CVC/AVF; dose adjusted as per local protocols
Maintenance immunosuppression (both groups)
• AZA: 2 mg/kg
Hourmant 1996 
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• MP: 5 mg/kg day before operation, then 1mg/kg PRED, taper by 10 mg/week• CSA: 8 mg/kg/d, from morning of 9th day; adjusted as per levels, as per each centre• Ongoing maintenance as per centre (either AZA/PRED or AZA/CSA or triple). ‘Distribution balanced
between the 2 groups'
Outcomes • Death• GraB loss• Acute rejection• DGF• Tolerability• CMV disease• Infection
Notes • GraB function at 3 months given but graB survival at 3 months not reported. Therefore, cannot be
used in review analyses• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes; all acute rejection was biopsy-proven
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk GraB survival at 3 months not reported
Other bias Unclear risk Funding source not reported
Hourmant 1996  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: February 1978 to September 1979• Study follow-up: 2 years
Participants • Country: Norway, Sweden• Setting: multicentre (2)• Inclusion criteria: adult 1st DD kidney transplant recipients
Jakobsen 1981 
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• Number: treatment group (30); control group (30)• Mean age, range (years): treatment group (52, 19 to 68); control group (47, 19 to 70)• Sex (M/F): treatment group (16/14); control group (20/10)• Exclusion criteria: not reported
Interventions Treatment group
• ALG: 30 mg/kg/d for 21 days, starting day of transplant; given IV in 200 to 300 mL saline
Control group
• No ALG
Immunosuppression (both groups)
• AZA: 2 to 3 mg/kg, adjust as per WCC• PRED: 120 mg/d, taper to 40 mg/d by 1 month, taper to 15 mg/d by 1 year
Outcomes • Death• GraB loss• Acute rejection
Notes • Patients over 60 years: treatment group (10); control group (5)• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk ‘patients allotted by drawing cards marked yes or no’; Half patients in each
group in each centre
Allocation concealment
(selection bias)
High risk Drawing cards
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unclear if acute rejection was biopsy-proven acute rejection or clinical diagno-
sis
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding source not reported
Jakobsen 1981  (Continued)
 
 
Methods • Study design: parallel RCTKasiske 1997 
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• Study duration: October 1994 to January 1996• Study follow-up: 3 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult DD or LD with one haplotype mismatch kidney transplant recipients• Number: treatment group (50); control group (50)• Mean age ± SD (years): treatment group (47.5 ± 13.1); control group (44.7 ± 14.5)• Sex (M): treatment group (66%); control group (52%)• DD/LD: treatment group (25/25) control group (33/17)• Exclusion criteria: allergy to diltiazem, ATG, or CSA; medical contraindication to diltiazem, such as sick
sinus syndrome or second- or third degree atrioventricular block without a functioning ventricular
pacemaker
Interventions Treatment group
• hATG (ATGAM): 20 mg/kg IV daily for 7 to 14 days; withheld if platelet count < 70,000/mm3* ATG stopped after 4th dose CSA or dose 14 of ATG• CSA: 8 mg/kg/d (2 divided doses) once CrCl reached 30 mL/min; trough level 150 to 200 ng/mL until
8 weeks, then 75 to 100 ng/mL
Control group
• CSA: 8 mg/kg at induction, then 8 mg/kg/d (2 divided doses)• Diltiazem: 0.28 mg/kg IV, then 0.002 mg/kg/min for 24 hours, then 60 mg oral sustained release twice/d
Immunosuppression (both groups)
• MP: 1 g IV day 0; 500 mg IV day 1; /250 mg IV day 2; 125 mg IV day 3, then PRED 0.75 mg/kg tapered
to 0.2 mg/kg by day 120• AZA: 5 mg/kg, decrease to 2 mg/kg day 3
Outcomes • Death• GraB loss• Acute rejection• DGF• CMV disease
Notes • GraB function up to 90 days reported as similar but actual values not given• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Kasiske 1997  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes; all acute rejection was biopsy proven
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Expected outcomes reported; unable to meta-analyse graB function
Other bias Unclear risk Funding source not reported
Kasiske 1997  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: 2004 to 2006• Study follow-up: 1 month
Participants • Country: Iran• Setting: single centre• Inclusion criteria: > 14 years, LD kidney transplant recipients; PRA < 30%• Number: treatment group (31); control group (37)• Mean age ± SD (years): treatment group (36.4 ± 13.6); control group (36.0 ± 10.9)• Sex (M/F): treatment group (12/19); control group (20/17)• Exclusion criteria: simultaneous treatment with IL-2RA; significant intraoperative or postoperative
complications of transplantation
Interventions Treatment group
• ATG: single dose (4 to 5 mg/kg given roughly 12 hours pre-op)
Control group
• No ATG
Immunosuppression (both groups)
• CSA: 5 to 8 mg/kg• AZA (100 mg) or MMF (2 g)• MP: 1 g for 3 days, then 1 mg/kg, then tapered dose
Outcomes • Acute rejection in 1st month• GraB loss
Notes • SCr reported as similar at 1 month but actual values not given• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Khosroshahi 2008 
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Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Acute rejection was both biopsy-proven acute rejection and clinical
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Limited outcomes reported and only very short-term follow-up
Other bias High risk Exclusion criteria included intra-op and post-op problems; patients would al-
ready have been entered prior to this. Therefore, were patients withdrawn af-
ter randomisation? No real details about this. Funding source not reported
Khosroshahi 2008  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 2 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: DD kidney transplant recipients• Number: treatment group (34); control group (32)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• ATG (Upjohn Company): 750 mg IV daily for 14 days, then 7 doses on alternate days (1 month therapy
total)• AZA: 150 mg/d• PRED: 120 mg/d, taper to 30 mg over 1 month
Control group
• AZA: 150 mg/d• PRED: 120 mg/d, taper to 30 mg over 1 month
Outcomes • Death• GraB loss• Acute Rejection
Notes • Limited data given about other side effects
Kountz 1977 
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• Funding source: Upjohn Company
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Limited info about how acute rejection was diagnosed
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk Results seem to be a mixture of 2 studies. Initial study had 4 groups, including
2 x low dose ATG (1 x IV, 1 x IM). These 2 groups excluded after 15 patients in
each group. Results combined with this study. Upjohn company funded study
and provided the ATG; result in favour of ATG
Kountz 1977  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: March 1977 to August 1978• Study follow-up: 2 years
Participants • Country: France• Setting: single centre• Inclusion criteria: DD kidney transplant recipients• Number: treatment group (24); control group (25)• Mean age ± SD (years): treatment group (34.7 ± 1.7); control group (30.9 ± 1.5)• Sex (M/F): treatment group (18/6); control group (16/9)• Exclusion criteria: positive ATG skin test
Interventions Treatment group
• hATG: 500 to 1250 mg (weight adjusted) daily for 2 weeks then alternate days for 2 weeks* Dose adjust according to level of rosette forming cells aiming to maintain at 10% of baseline• MP: 40 mg IV, immediately prior to each ATG (this was subtracted from total daily PRED dose)• PRED: 3 mg/kg/d, tapered over 10 weeks to 0.25 mg/kg
Control group
Kreis 1980 
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• PRED: 3 mg/kg/d, tapered over 10 weeks to 0.25 mg/kg
Outcomes • Death• GraB loss• Bacterial infections
Notes • 'Reversible kidney failure episodes' but not specifically acute rejection reported, therefore not includ-
ed in results of this review
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random-number table used
Allocation concealment
(selection bias)
Low risk 'Physicians in charge of the patients were not aware of the list kept at the Up-
john Company'
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not clear for 'reversible renal failure episodes' or acute rejection
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Expected outcomes reported, however unsure if reversible kidney failure
episodes is acute rejection and therefore results were not used
Other bias High risk ATG provided by Upjohn co and computer analysis also done by them
Kreis 1980  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 1 year
Participants • Country: France• Setting: single centre• Inclusion criteria: not reported• Number: treatment group (19); control group (18)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• OKT3: 5 mg/d IV for 15 days minimum, continued to 30 days if no antibodies (if T3 marker remained
≤ 30%)
Kreis 1986 
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Control group
• No OKT3
Immunosuppression (both groups)
• AZA: dose not reported• Low dose PRED: dose not reported
Outcomes • Death• GraB loss• Acute rejection
Notes • 60 patients into 3 groups, 4 patients excluded early for technical reasons (immediately after randomi-
sation)• Low dose PRED group to be used for comparisons in this review as maintenance identical to OKT3
group• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement if acute rejection episodes were
biopsy proven or not
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement and funding source not declared
Kreis 1986  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: March 1996 to March 1997• Study follow-up: 1 year
Participants • Country: USA• Setting: single centre• Inclusion criteria: DD kidney transplant recipients
Kumar 1998a 
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• Number: treatment group 1 (26); treatment group 2 (24)• Mean age ± SD (years): treatment group 1 (42.21 ± 18.82); treatment group 2 (44.22 ± 16.56)• Sex (M/F): treatment group 1 (14/10); treatment group 2 (15/11)• Exclusion criteria: not reported
Interventions Treatment group 1
• hATG (ATGAM): daily dose adjusted to maintain peripheral CD3 count between 50 to 100/µL
Treatment group 2
• OKT3: daily dose adjusted to maintain peripheral CD3 count between 50 to 100/µL
Immunosuppression (both groups)
• CNI (CSA or TAC): started 5 to 7 days post-transplant, troughs CSA: 250 to 300 ng/mL, TAC: 10 to 15
ng/mL• PRED: does not reported• MMF or AZA: dose not reported
Outcomes • Death• GraB loss• Acute rejection• Infection
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Funding source not specified
Kumar 1998a  (Continued)
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Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 2 years
Participants • Country: France• Setting: single centre• Inclusion criteria: DD kidney transplant recipients; ABO compatibility and negative lymphocytotoxic
cross-match• Number: treatment group (21); control group (15)• Mean age ± SD (years):not reported• Sex (M/F): not reported• 2nd transplant: treatment group (2); control group (1)• Exclusion criteria: not reported
Interventions Treatment group
• ALG (horse, Merieux, Lyon): 10 mg/kg/d IV for 14 days, then 252 mg IM every other day for 14 days,
then twice/week until end of 4th month
Control group
• No ALG
Immunosuppression (both groups)
• AZA: 5 mg/kg day 1, then 1 to 2 mg/kg, adjusted for WCC• PRED: 1 mg/kg/d, reduced by 5 mg every 5 days to 30 mg by 1 month, then 25 mg by 6 months
Outcomes • Death• GraB loss• Acute rejection
Notes • Limited information on additional outcomes• Funding source: supported in part by a grant from the University of Rennes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Launois 1977 
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Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Low risk Supported by a grant from University of Rennes
Launois 1977  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: February 1991 to August 1991• Study follow-up: 4 to 10 months
Participants • Country: Canada• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients aged 18 to 65 years• Number: treatment group (10); control group (10)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: participation in another study using an investigational immunosuppressive new
drug within 8 wk before entry into or during participation in the study; significant liver or cardiac im-
pairment or total lymphocyte count < 1000 cells/mm3 active infection; current positive T cell cross-
match against the donor; multiple organ transplant (heart/kidney, liver/kidney); history of malignan-
cy: HIV or Hep B positive serologies; pregnancy
Interventions Treatment group
• CD7 human-mouse chimeric mAb (SDZCHH380): 30 mg IV, 6 doses, days 0 (1 to 6 h pre-op), days 2, 6,
11, 17 and 24• CSA: 3 mg/kg IV infusion in recovery, switch to oral 8 mg/kg when able, aim for target trough of 250
to 450 ng/mL
Control group
• OKT3: 10 doses, 5 mg dose, day 0 (in theatre), then once/d• CSA: 2 mg/kg IV, then 6 mg/kg oral, target level 150 to 350 ng/mL, then target 250 to 450 ng/mL once
OKT3 complete• AZA: 25 mg pre-op and while on OKT3 to try to prevent anti-mouse antibodies
Immunosuppression (both groups)
• MP-PRED: 250 mg 1 hour before 1st dose of SDZCHH380, then 1 mg/kg, decreased by 5 mg/d until 20
mg, then decreased until 15 mg on alternate days
Outcomes • Death• GraB loss• Acute rejection• Infection
Notes • Small numbers only• Clinical tolerance better in CD7 group but not reported in these results as not pre-specified outcome• Acute rejection diagnosis was clinical and/or biopsy (FNA or core)• Funding source: supported in part by a grant from the Kidney Foundation of Canada and by Sandoz
Canada Inc
Risk of bias
Lazarovits 1993 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded and therefore high risk for certain outcomes, e.g. tolerance of anti-
body therapy
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No blinding and acute rejection could be diagnosed clinically
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funded by grants from Kidney Foundation of Canada and Sandoz Canada Inc
(CD7 manufacturer)
Lazarovits 1993  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: October 2007 to December 2009• Study follow-up: median follow-up 338 days
Participants • Country: China• Setting: single centre• Inclusion criteria: DD kidney transplant recipients; high immunological risk PRA ≥ 10%• Number: treatment group 1 (11); treatment group 2 (11)• Mean age ± SD (years): treatment group 1 (38.9 ± 4.2); treatment group 2 (40.8 ± 4.4)• Sex (M/F): treatment group 1 (5/6); treatment group 2 (4/7)• 1st/2nd/3rd transplant: treatment group 1 (6/5/0); treatment group 2 (5/5/1)• Exclusion criteria: not reported
Interventions Treatment group 1
• Alemtuzumab: 15 mg before reperfusion and 15 mg 24 hours post op• MP: 500 mg bolus prior to completion of anastomoses and 8 mg/kg/d for 3 days post-op
Treatment group 2
• rATG: 9 mg/kg single bolus given 2 hours pre-op• MP: 500 mg bolus prior to completion of anastomoses and 8 mg/kg/d for 3 days post-op
Maintenance immunosuppression (both groups)
• MMF: 1 g twice daily started 1 day pre-op, then 0.5 to 1 g twice daily
Lu 2011 
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• TAC: started 2 days post-op, 0.1 mg/kg/d aiming for trough of 10 to 13 ng/mL for month 1, 8 to 10ng/
mL to month 3, 6 to 8 ng/mL to month 6, 4 to 6 ng/mL to month 12
Outcomes • Death• GraB loss• Acute rejection• Infection• Malignancy• Cumulative graB survival
Notes • GraB function and WCC count reported but not able to be used for review analysis as no figures given• Reported as SCr and urea similar both groups• WCC counts significantly reduced in alemtuzumab group at most time points up to 6 months• Funding source: Supported by grant from Fujian Key Laboratory of Transplant Biology (No. 2008J1006)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Open label but probably low risk given hard outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk As above; all acute rejection was biopsy-proven acute rejection
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported; graB function, WCC count could not be in-
cluded in our meta-analyses
Other bias Low risk None apparent. Supported by grant from Fujian Key Laboratory of Transplant
Biology (No. 2008J1006)
Lu 2011  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 12 months
Participants • Country: Italy• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients• Number: not reported
Maiorca 1984 
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• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• ALG: 20 mg/kg for 1st 14 days* 20 mg/kg for 10 days if any acute rejection episode
Control group
• No ALG
Immunosuppression (both groups)
• AZA: 5 mg/kg• MP: 200 mg IV on induction then 6 hourly for 3 further doses• AZA: after MP 1.5 mg/kg and PRED 20 mg; AZA increased to 3 mg/kg when CrCl > 20 mL/min• PRED: taper to 10 mg after 6 months
Outcomes • Death• GraB loss
Notes • Abstract-only publication• Acute rejection reported in study as number of rejection episodes/patient. Total number of patients
with acute rejection not reported, therefore this outcome is not included in the review• Reported as higher percent of bacterial infections in ALG group but not statistically significant. Viral
infections same. Types of infection and figures not disclosed• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
High risk Acute rejection, infection could not be used in our meta-analyses
Other bias Unclear risk Insufficient information to permit judgement, funding not reported
Maiorca 1984  (Continued)
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Methods • Study design: parallel RCT• Study duration: January 2004 to June 2005• Study follow-up: 1 year
Participants • Country: Germany, Austria• Setting: multicentre (4)• Inclusion criteria: 1st DD kidney transplant recipients aged 18 to 65• Number: treatment group (65); control group (66)• Mean age ± SD (years): treatment group (50 ± 13.1); control group (45 ± 14.9)• Sex (M/F): treatment group (37/28); control group (34/32)• Exclusion criteria: positive cross match against donor cells; PRA > 25%; previous kidney transplant;
multiorgan recipients previous treatment with alemtuzumab; the use of other investigational agents
within 6 weeks; active systemic infection; HIV-positive patients or donors, autoimmune haemolytic
anaemia; history of anaphylaxis following exposure to humanized monoclonal antibodies; pregnant
or breast-feeding women; LD recipients
Interventions Treatment group
• MP: 250 mg immediately post-op and on day 1• Alemtuzumab: 20 mg 1 hour later, over 3 to 6 hours and the same on day 1• TAC: on day 3, 0.05 mg/kg twice daily, trough target levels 8 to 12 ng/mL for 6 months then 5 to 8 ng/
mL, aimed for above 10 ng/mL in 1st 3 months
Control group
• TAC: pre-op or immediately post theatre same dose, same targets as treatment group• MMF: 1 to 1.5 g/d (adjusted if evidence of clinical toxicity)• Steroids as per local regimen* 3 centres: 500 mg on day 2, tapered to 25 mg by day 10, tapered to 5 mg at 1 year* 4th centre: 200 mg PRED day of transplant, reduced to 20 mg by day 10 and 5 mg by 1 year
Outcomes • Biopsy-proven acute rejection (6 and 12 months)• Patient survival at 12 months• GraB survival at 12 months• Adverse event
Notes • GraB function for both groups similar at 12 months. Figures not able to be used as no SD given in study• All clinical suspected acute rejection had to have biopsy, all later confirmed by 1 x histopathologist• Funding source: supported by Astellas Pharma GmbH, Munich
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Margreiter 2008 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes but not clear if the biopsy reviewer was blinded
to the treatment group
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Outcomes reported as per protocol (as per Clinicaltrials.gov); however unable
to meta-analyse the graB function results (no SD)
Other bias High risk Supported by Astellas Pharma GmbH, Munich (Tacrolimus supplier)
Margreiter 2008  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 24 months
Participants • Country: Portugal• Setting: single centre• Inclusion criteria:• Number: treatment group (22); control group (23)• Mean age, range: 39, 19 to 67 years• Sex (F): 63%• Exclusion criteria: not reported
Interventions Treatment group
• ATG: single bolus 9 mg/kg prior to surgery
Control group
• No ATG
Immunosuppression (both groups) 
• AZA, CSA, PRED (dosage not reported)
Outcomes • GraB survival• Patient survival• Acute rejection• Steroid-resistant acute rejection
Notes • Abstract-only publication; stated ‘groups were comparable’• Divided into high immunological risk (PRA > 50%, 2nd or more allograft, cold ischaemia time 24 hours)
or normal risk• High risk bolus (10): high risk standard (5); normal risk bolus (22); normal risk standard (23). Only 'nor-
mal risk' patient groups will be compared in this review• SCr reported as similar in all 4 groups, values not given.• ‘ATG did not increase infection rate’, figures not given• Funding source: not reported - one author and employee of Fresenius
Risk of bias
Martins 2004 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unlikely to influence outcomes but unclear if acute rejection was clinical diag-
nosis or biopsy-proven acute rejection
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement; 2 patients excluded from analy-
ses due to death with a functioning graB; probably should have been included
Selective reporting (re-
porting bias)
High risk SCr and infection could not be included in our meta-analyses
Other bias High risk Funding not reported, but one of the co-authors is from Fresenius Biotech
Martins 2004  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: December 1985 to March 1988• Study follow-up: 1 year
Participants • Country: USA• Setting: single centre• Inclusion criteria: DD kidney transplant recipients with DGF at 24 hours post-op (urine output < 700
mL over 1st 24 hours and no fall in SCr)• Number (randomised/analysed): treatment group (21/19); control group (30/26)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Initial treatment (both groups)
• CSA: 12 mg/kg/d (oral) or 4 mg/kg/d (IV) for 24 hours
Treatment group
• ALG: 20 mg/kg/d with dose adjustment based on WCC and platelet counts• Upon resolution of DGF CSA reinstated at 10 mg/kg/d and adjusted to levels of 100 to 150 ng/mL
Control group
• CSA: dose lowered to 10 mg/kg/d adjusted to keep levels of 100 to 150 ng/mL
Reassessment after 2 weeks
Michael 1989 
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Outcomes • Duration of DGF• Mean length of hospital stay• SCr at 1, 3, 6 and 12 months (SCr figures given but no SD or SE therefore, not able to be included in
review analyses)• GraB survival (shown as graph only but no figures given)
Notes • No extractable data available for review outcomes• Patients whose graBs never functioned were excluded form analyses• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation via computerised random number generation
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unclear whether all acute rejection was biopsy proven (likely yes while patient
had DGF but unclear if diagnosed after graB started functioning)
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Patients whose graBs never functioned were excluded from the analyses
Selective reporting (re-
porting bias)
High risk No extractable data available for review outcomes, SD and SE not reported;
several results only presented as figures
Other bias Unclear risk Funding not reported
Michael 1989  (Continued)
 
 
Methods • Study design: parallel RCT; stratified for age (18 to 40; 41 to 55), diabetes, donor source, 1st or 2nd
transplant• Study duration: September 1980 to December 1983• Study follow-up: 2.5 to 6 years (mean 46 months)
Participants • Country: USA• Setting: single centre• Inclusion criteria: 1st or 2nd LD or DD kidney transplant recipients from HLA mismatched donors; aged
18 and 55 years; no previous history of malignancy or liver disease; in the retransplant group, the 1st
graB must have functioned for at least 1 year• Number: treatment group (109); control group (121)• Mean age ± SD (years): treatment group (34.9 ± 8.7); control group (35.0 ± 8.6)• Sex (M/F): treatment group (69/40); control group (76/45)• LD/DD: treatment group (40/69); control group (48/73)
Minnesota Study 1982 
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• Exclusion criteria: not reported
Interventions Treatment group
• mALG: 30 mg/kg/d as IV infusion for 14 doses• AZA: 5 mg/kg/d for 3 days, tapered by 0.5 mg/kg/d to 2.5 mg/kg/d, dose adjusted further to maintain
a WCC ≥ 4000/mm3• PRED: 2 mg/kg/d for 3 days, then tapered to 0.5 mg/kg/d by 3 months
Control group
• CSA: 14 mg/kg /day for 1 week post-op, then 12 mg/kg/d, trough level of 100 to 200 ng/mL and SCr
< 2 mg/dL• PRED: 2 mg/kg/d for 3 days, decreased until 0.5 mg/kg/d by 1 month, then gradual taper to 0.2 mg/
kg/d by 1 year
Outcomes • Death• GraB loss• DGF• Acute rejection• GraB function• Bacterial, viral, fungal infections• CMV• PTLD• Leucopenia• NODAT
Notes • Multiple different reports of the same study, patient numbers in each group seems to vary in the dif-
ferent reports• Funding source: supported in part by a grant from NIH
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stratified but method not specified
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported, however patient numbers vary in the differ-
ent reports of this study
Minnesota Study 1982  (Continued)
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Other bias Unclear risk Funding not fully disclosed. Supported in part by a grant from NIH
Minnesota Study 1982  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 2 years
Participants • Country: Spain• Setting: multicentre (14)• Inclusion criteria: 1st DD kidney transplant recipients, aged > 50 years• Number: treatment group (41); control group (44)• Mean age ± SD (years): treatment group (59 ± 4); control group (58 ± 6)• Sex (M/F): treatment group (23/18); control group (29/15)• Exclusion criteria: hyperimmunised patients (HLA > 50%); chronic hepatopathy; Hep B-antigen posi-
tive; diabetes, haemolytic uraemic syndrome
Interventions Treatment group
• OKT3: 5 mg/d for 4 days• CSA: 10 mg/kg/d, tapered slowly to maintain trough of 150 to 250 ng/mL
Control group
• CSA: 10 mg/kg/d, tapered slowly to maintain trough of 150 to 250 ng/mL• PRED: 0.3 mg/kg/d, lower by 2.5 mg every 15 days until 10 mg/d
Outcomes • Death• GraB loss• Acute rejection• DGF
Notes • GraB function also reported but no SD or SE included, therefore cannot be used in review analyses• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement if acute rejection episodes were
biopsy-proven acute rejection
Morales 1994a 
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
High risk SD and SE not reported for graB function; complications such as infection or
malignancy not well reported
Other bias Unclear risk Funding source not reported
Morales 1994a  (Continued)
 
 
Methods • Study design: parallel RCT; stratified by centre• Study duration: November 1995 to July 1997• Study follow-up: 12 months
Participants • Country: France, Belgium• Setting: multicentre (15)• Inclusion criteria: 1st or 2nd DD kidney transplant recipients• Number (randomised/analysed): treatment group (153/151); control group (159/158)• Mean age, range (years): treatment group (43.2, 18 to 66); control group (42.8, 19 to 60)• Sex (M/5): treatment group (97/54); control group (113/48)• White/black/oriental/other: treatment group (136/9/3/3); control group (141/7/3/7)• Exclusion criteria: positive T-cell cross-match on the most recent serum specimen; intolerant to
steroids, macrolides, HCO-60, or ATG; symptoms or had, during the last 5 years, any history of neoplas-
tic disease of any type; systemic infections requiring therapy; a significant liver disease, active colla-
gen-vascular disease; pregnant or breast feeding; participation in another clinical study in the past
28 days; HIV positive; history of substance abuse; psychiatric disorder; condition of noncompliance;
receiving another organ transplant, other than a kidney
Interventions Treatment group
• ATG: 1.25 mg/kg/d for 10 days.• TAC: started on day 9 at a dose of 0.2 mg/kg/d
Control group
• TAC: started within 24 hours of completion of anastomosis at an initial dose of 0.2 mg/kg/d
Immunosuppression (both groups)
• TAC: initial dose 0.2 mg/kg/d, target trough of 10 to 15 ng/mL for 1st 6 weeks; target trough 5 to 10
ng/mL to 3 months, then target < 10 ng/mL• MP: 500 mg day 0, 125 mg day 1, then 20 mg PRED for 2 weeks tapered to 10 mg from 1 to 3 months,
then 5 mg/day• AZA: 1 to 2 mg/kg from day 0
Outcomes • Death• GraB loss• Biopsy-proven acute rejection• Adverse events
Notes • 24 and 17 withdrawals in each group respectively. Results given as ITT. Main reason for withdrawal
was early graB failure (e.g. primary non-function, thrombosis, refractory acute rejection), then adverse
events (neurologic events (2), worsening diabetes (2), acute respiratory distress syndrome (1) – all in
ATG group)
Mourad 1998 
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• GraB function similar at 12 months, not included as no SD given• Funding source: Fujisawa GmbH
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation list generated centrally. Patients randomised 1:1 and stratified
by centre
Allocation concealment
(selection bias)
Low risk Sealed envelopes opened post-op
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes (all acute rejection was biopsy-proven acute
rejection)
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Relatively large drop out numbers in each group; ITT results reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Funded by Fujisawa GmbH (TAC manufacturers)
Mourad 1998  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: September 1987 to May 1988• Study follow-up: not reported
Participants • Country: France• Setting: single centre• Inclusion criteria: children, 1st DD kidney transplant recipients• Number: treatment group 1 (14); treatment group 2 (14)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• OKT3 (Cilag): 1 mL/10 kg up to 40 kg, 5 mL if over 40 kg, given for 21 days* Given via peripheral vein over 2 min, 1st dose prior to reperfusion
Treatment group 2
• ALG (Merieux) 1mL/kg via AVF or CVC via IV infusion over 12 h; given for 21 days
Immunosuppression (both groups)
Niaudet 1990 
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• AZA: 0.75 to 1.5 mg/kg/d• PRED: 60 mg/m2/d, tapered to 30 mg/m2 by day 30• CSA: 150 mg/m2 from day 18, adjusted to maintain level 100 to 200 ng/mL
Outcomes • Patient survival• GraB survival• Acute rejection• Infection• Other side effects
Notes • No table 1, states similar for age, sex, previous blood transfusions, HLA, PRA, cold ischaemia time• There was also a 2nd part to paper about high dose versus low dose OKT3. There was limited info but
low and high dose groups did not appear to be randomised. This data therefore not included• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding source not reported
Niaudet 1990  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: July 1986 to August 1987• Study follow-up: 4 to 16 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult DD kidney transplant recipients• Number (randomised/analysed): 80/72; treatment group (34); control group (38)• Mean age ± SD (years): not reported
Norman 1988 
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• Sex (M/F): 42/38• Exclusion criteria: no exclusions based on age or underlying cause of kidney failure
Interventions Treatment group
• OKT3: 5mg/d for 14 days• MP: 500 mg• AZA: 2 mg/kg/d for 2 weeks; tapered to 1 mg/kg/d by 9 months• PRED: 0.5 mg/kg/d for 2 weeks, tapered to 0.1 mg/kg/d by 5 months• CSA: from day 11 at 5 mg/kg/d from day 14
Control group
• AZA: 2 mg/kg/d for 2 weeks, tapered to 1 mg/kg/d by 9 months• PRED: 1 mg/kg/d for 2 weeks, 0.5 mg/kg/d for 2 weeks, tapered to 0.1 by 5 months• CSA: 5 mg/kg/d for 2 weeks, 4 mg/kg 4 to 12 months, 3 mg/kg after 12 months
Outcomes • Death• GraB loss• DGF• Acute rejection• GraB function
Notes • Acute rejection episodes treated differently* OKT3 group: treated with increased oral PRED* control group: treated with either OKT3 or oral PRED• Funding source: supported by Ortho Pharmaceutical Corporation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 8 patients excluded from analyses; 6 excluded as received graBs form donor
under age 5 years (historically poor outcomes); 2 excluded in OKT3 group as
only received 1 or 2 doses of OKT3 (reasons not reported)
Selective reporting (re-
porting bias)
High risk Some expected outcomes not reported
Other bias Unclear risk 'Supported by Ortho Pharmaceutical' (OKT3 manufacturers)
Norman 1988  (Continued)
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Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 5 years
Participants • Country: USA• Setting: multicentre (5 centres)• Inclusion criteria: adults and children DD kidney transplant recipients• Number: treatment group (105); control group (102)• Median age, range (years): treatment group (43, 12 to 73); control group (40, 10 to 66)• Sex (M/F): treatment group (67/38); control group (64/38)• Transplant (1st/2nd/more than 1): treatment group (94/9/2); control group (85/16/1)• Ethnicity (white/non-white): treatment group (77/28); control group (73/29)• Diabetic: treatment group (23); control group (30)• Exclusion criteria: donor < 2 years; evidence of fluid overload; evidence of congestive heart failure;
previous exposure to OKT3; lactating or pregnant women
Interventions Treatment group
• OKT3: 5 mg/d from day 0 for 10 to 14 doses• MP: 0.5 to 2 g prior to 1st dose OKT3• AZA: 2.5 mg/kg/d, taper after day 11 as per centre protocol• PRED: 0.25 to 0.5 mg/kg day 0 to 10, taper to maintenance dose as per centre protocol• CSA: 6 to 12 mg/kg/d, from day 11 onwards
Control group
• AZA: 2.5 mg/kg/d, taper as per centre protocol• PRED-MP: 0.5 to 2 g MP prior to transplant; 1 mg/kg/d, then taper to maintenance dose as per centre
protocol• CSA: 6 to 12 mg/kg/d
Outcomes • Death (5 years)• GraB loss (5 years)• Acute rejection (1 year)• Infection (6 months)• DGF• Malignancy (2 years)• GraB function (12 months)
Notes • Possibly continuation of study from Norman 1988 (however, intervention protocols documented are
different)• Funding source: R.W. Johnson Pharmaceutical Research Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation stated but insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Norman 1993 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Safety analyses 111 versus 104 included (215 total)
Efficacy analyses 105 versus 102 included (207 total)
224 patients entered into the study
9 patients excluded after randomisation as 'not treated' (whether this means
not transplanted or not treated as per protocol is not reported)
Additional 8 patients excluded from efficacy analyses and therefore included
only in safety analyses (6 paediatric patients and 2 patients who did not follow
randomisation schedule)
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Funded by RW Johnson pharmaceutical research institute; corresponding au-
thor is an employee of RW Johnson
Norman 1993  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: July 1990 to August 1991• Study follow-up: 12 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: 18 to 50 years; 1st DD kidney transplant recipients• Number: treatment group 1 (13); treatment group 2 (13)• Mean age (years): treatment group 1 (39); treatment group 2 (37)• Sex (M/F): treatment group (5/8); treatment group 2 (11/2)• Diabetic: treatment group 1 (4); treatment group 2 (1)• Exclusion criteria: "entrance criteria were chosen to minimize both recipient and donor factors that
could lead to graB dysfunction or loss not due to immunologic causes"
Interventions Treatment group 1
• High dose OKT3: 5 mg/day for 12 days, starting in operating theatre
Treatment group 2
• Low dose OKT3: 1 mg/d for 2 days, then 2 mg/d for 10 days
Immunosuppression (both groups)
• AZA: 5 mg/kg (IV), then 2 mg/kg (oral)• MP-PRED: MP 500 mg in operating theatre then 125 mg twice/d day 1, then PRED 1 mg/kg day 2 tapered
to 0.4 mg/kg by end of 1 month, tapered to 0.1 mg/kg by end of 5 months
Norman 1993a 
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• CSA: 7 mg/kg/d at day 5
Outcomes • Death• GraB loss• Acute rejection• DGF• Infection• Side effects
Notes • More women and diabetics in high dose group (but only small numbers)• GraB function at 12 months reported in study but not SD or SE given, results therefore not included
in this review• All patients in both groups had features of Cytokine Release Syndrome• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk limited info. ‘The patients were randomised in blocks of four patients’. 
Allocation concealment
(selection bias)
Low risk Randomisation schedule kept by pharmacy
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Patients, nurses and doctors all blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk SD/SE not reported for graB function and cannot be meta-analysed
Other bias Unclear risk Funding source not reported
Norman 1993a  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 6 months
Participants • Country: Sweden• Setting: single centre• Inclusion criteria: adults with ‘indication for ATG induction therapy within 48 hours of surgery’ (higher
risk group)• Number: treatment group 1 (45); treatment group 2 (45)
Norrby 1997 
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• Mean age (years): treatment group 1 (49.1); treatment group 2 (47.8)• Sex (M/F): treatment group 1 (28/17); treatment group 2 (29/16)• LD/DD: treatment group 1 (4/41); treatment group 2 (1/44)• Exclusion criteria: not reported
Interventions Treatment group 1
• ATG (Fresenius): 5 mg/kg/d for 4 to 7 days
Treatment group 2
• ATG (Merieux): 2.5 mg/kg/d for 4 to 7 days
Immunosuppression (both groups)
• Not reported
Outcomes • Acute rejection• CMV infection
Notes • Outcomes of death, patient survival and graB function all reported as 'no significant difference'. No
numbers given, therefore not able to be included as outcomes in this review.• Acute rejection rates are high in both groups in this study. Likely explained as patients are probably
a high risk group immunologically• Funding source: Gothenburg University, Riksforbundet Njursjuka, Njursjukas forening i Vast Sverige,
and Gelins Minnesfond
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Denominators sometimes unclear
Selective reporting (re-
porting bias)
High risk Outcomes reported but actual numbers not given, therefore difficult to verify
data
Other bias Unclear risk Unclear due to limited information. Funding from 4 different groups: Gothen-
burg University, Riksforbundet Njursjuka, Njursjukas forening i Vast Sverige,
and Gelins Minnesfond.
Norrby 1997  (Continued)
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Methods • Study design: parallel RCT• Study duration: October 1978 to October 1980• Study follow-up: to 42 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients with no history of allergic reactions or prior ex-
posure to horse serum protein• Number: treatment group (31); control group (36)• Mean age ± SD (years): not reported• Sex (M/F): treatment group (26/5); control group (30/6)• Ethnicity (Caucasian/other): treatment group (28/3); control group (29/7)• Exclusion criteria: not reported
Interventions Treatment group
• ALG: 30 mg/kg/d for 14 days
Control group
• Placebo: 30 mg/kg/d of human albumin solution for 14 days
Immunosuppression (both groups)
• AZA: 3 to 5 mg/kg pre-op, then 1.5 to 2 mg daily• MP-PRED: 1 g in operating theatre, then 2 mg/kg/d PRED post-op, rapid taper over 2 months to 0.6
mg/kg/d, then slow decrease to 0.25 mg/kg/d
Outcomes • Death• GraB loss• Acute rejection• Adverse events
Notes • ALG group: 4 excluded as received < 50% ALG dose• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Previously numbered drug vials’ but not clear how sequence generated
Allocation concealment
(selection bias)
Low risk Randomised via a central office at the University of Minnesota
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Novick 1983 
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Patients only receiving 50% of ALG total dose or less were excluded from re-
sults (4/35; 10% of group (2 withdrew, 2 unable to tolerate due to side effects)
Not certain if these patients would have altered outcomes if included
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Low risk University of Minnesota ALG lab provided the ALG
Novick 1983  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 20 months
Participants • Country: Spain• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients; PRA < 25%• Number: treatment group 1 (26); treatment group 2 (24)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• ATG: 10 mg/kg/d until Cr < 3 mg/dL
Treatment group 2
• OKT3: 2.5 mg/d until serum Cr <3mg/dL
Immunosuppression (both groups)
• CSA, PRED. AZA: dosage not reported
Outcomes • Death• GraB loss• DGF• Acute rejection
Notes • Abstract-only publication• Reported no difference in demographic data of recipients or donors, in HLA mismatch or cold is-
chaemia time• Acute rejection reported as number of episodes/patient (not total number of patients with acute re-
jection), therefore not included in review analyses• Nephrotoxicity, infections and other medical and surgical complications reported as similar in both
groups• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Perez-Tamajon 1996 
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
142
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported however unable to use acute rejection data
Other bias Unclear risk Insufficient information to permit judgement and funding source not clear
Perez-Tamajon 1996  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 1 year
Participants • Country: Spain• Setting: single centre• Inclusion criteria: not reported• Number: 31 (group assignment not reported)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• ATG monitored by CD3: 1 mg/kg/d day 0 and day 1, then only if CD3+ count was above 10 mm3 until
day 10
Treatment group 2
• Fixed dose ATG: 1 mg/kg/d from day 0 to day 4
Outcomes • Acute rejection• Infection• Lymphocyte subsets
Notes • Abstract-only publication• No extractable data for our review• "The incidence of opportunistic infections or acute rejections were not significantly different between
the two groups"
Pernin 2012 
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• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Limited reporting of outcomes
Selective reporting (re-
porting bias)
High risk Has not been published as full paper
Other bias High risk Abstract only
Pernin 2012  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: October 1987 to December 1989• Study follow-up: 24 months
Participants • Country: France• Setting: single centre• Inclusion criteria: DD kidney transplant recipients• Number: treatment group 1 (70); treatment group 2 (73)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Retransplantation: treatment group 1 (20%); treatment group 2 (16%)• Exclusion criteria: not reported
Interventions Treatment group 1
• OKT3: 5 mg/kg for 10 days
Treatment group 2
• ATG (Merieux): 25 mg/20 kg/d for 10 days
Immunosuppression (both groups)
• MP-PRED: MP 15 mg/kg pre-op, then PRED 1 mg/kg tapered to 20 mg by 1 month
Ra>aele 1991 
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
144
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• AZA: 2 to 3 mg/kg• CSA: 1 mg/kg IV for 2 days, then oral 4 mg/kg/d, adjust as per trough
Outcomes • CMV infection• CMV disease (symptomatic)• Acute rejection
Notes • Specifically looking at CMV infection• Not specified if given CMV prophylaxis• PRA > 80% significantly higher in OKT3 group (14 versus 4)• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to be influenced
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not specified whether acute rejection episodes were biopsy-proven acute re-
jection
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Expected outcomes reported given only short-term follow-up. However, graB
loss and death not reported. (may be none but would expect these outcomes
to be reported)
Other bias Unclear risk Insufficient information to permit judgement to assess and funding source not
declared
Ra>aele 1991  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 1 month
Participants • Country: France• Setting: single centre• Inclusion criteria: adult DD kidney transplant recipients; PRA > 30%• Number: treatment group 1 (8); treatment group 2 (8)• Mean age ± SD (years): not reported• Sex (M/F): not reported
Rostaing 2010 
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• Exclusion criteria: not reported
Interventions Treatment group 1
• rATG (Genzyme): 6.2 mg/kg ± 2.9 over 7 days
Treatment group 2
• hATG (Fresenius) 22.6 mg/kg ± 7.9 over 7 days
Immunosuppression (both groups)
• MMF: 2.5 g/d• TAC: troughs of 8 to 12 ng/mL• PRED: 1 mg/kg/d for 7 days, then tapered to 0.25 mg/kg/d by 1 month
Prophylaxis (both groups)
• PCP prophylaxis• CMV prophylaxis
Outcomes • Acute rejection• DGF• Infection
Notes • Designed to look at haematologic effects of the 2 different ATG preparations at 1 month• Fall in platelet count more pronounced in hATG group at days 2, 3 and 5 post-op• Mild leucopenia in 1 rATG patient only.• Hb levels similar in both groups (roughly 10 g/dL up to day 10)• More EPO given in hATG group compared to rATG group• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported given short follow-up only
Rostaing 2010  (Continued)
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Other bias Unclear risk Funding not declared
Rostaing 2010  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 1990 to September 1990• Study follow-up: 1 year
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group 1 (46); treatment group 2 (37)• Mean age ± SD (years): treatment group (43 ± 13); treatment group 2 (42 ± 12)• Sex (M/F): treatment group (31/15); treatment group 2 (21/26)• Exclusion criteria: not reported
Interventions Treatment group 1
• Minnesota ALG: 10 mg/kg; duration not reported
Treatment group 2
• Minnesota ALG: 20 mg/kg; duration not reported
Immunosuppression (both groups)
• PRED: dose and dosage not reported• AZA: dose and dosage not reported• CSA: started when good graB function (good urine output and Cr decrease to < 50% pre transplant);
dose and dosage not reported
Outcomes • GraB loss• Acute rejection• Severe infection• Leucopenia
Notes • Death not reported• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgment
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Unlikely to influence outcomes
Sakhrani 1992 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated how acute rejection was determined
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Kidneys did not function in 4 patients (2 in each group) and 1 patient from
each group moved out of the country
Selective reporting (re-
porting bias)
High risk Death not reported; results reported as percentages and could not be meta-
analysed
Other bias Unclear risk Funding not reported
Sakhrani 1992  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: November 1997 to April 1999• Study follow-up: 5 years
Participants • Country: Poland• Setting: multicentre (2 centres)• Inclusion criteria: 1st DD kidney transplant recipients• Number: treatment group (40); control group (39)• Mean age ± SD (years): treatment group (43 ± 10); control group (40 ± 12)• Sex (M/F): treatment group (23/17); control group (25/14)• Exclusion criteria: active bacterial, viral or fungal infections; thrombocytopenia; leukopenia; patients
known to be sensitized to rabbit immunoglobulins; patients with chronic liver disease
Interventions Treatment group
• hATG (Fresenius): 9 mg/kg given pre-op as single bolus, via CVC, prior to completion of anastomosis
Control group
• No ATG
Immunosuppression (both groups)
• MMF: 1g twice daily, converted to AZA 2mg/kg after 4th month• CSA: 8 mg/kg• MP-PRED: 500 mg MP pre-op, then 250 mg post-op, switch to PRED 0.5 mg/kg/d on 4th day
Prophylaxis (both groups)
• Antibiotic prophylaxis: piperacillin sodium and tazobactam for 3 days
Outcomes • Patient survival• GraB survival• Acute rejection• GraB function• Complications
Notes • Funding source: not reported
Risk of bias
Samsel 1999 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not all acute rejection was biopsy-proven
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported; 1 patient excluded in control group as im-
munosuppression was withdrawn however was included in the safety analysis
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding source unclear; ATG supplied by Fresenius Pharma Support
Samsel 1999  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: February 1972 to October 1974• Study follow-up: at least 4 months
Participants • Country: UK• Setting: single centre• Inclusion criteria: adult DD kidney transplant recipients• Number: treatment group (43); control group (42)• Mean age ± SD (years): treatment group (36.3 ± 11.1); control group (36.0 ± 12)• Sex ratio (M:F): treatment group (1.8:1); control group (2.0:1)• Exclusion criteria: not reported
Interventions Treatment group
• ALG: 2 different types used and an intradermal test used to decide which variety to be given (anti-hu-
man thymocyte ALG; anti-cultured lymphoblast rabbit ALG)* 1 g in 500 mL isotonic saline IV over 4 h for 10 days□ Only used for 1st 11 patients as 1 patient died due to anaphylaxis after 4th dose* Route changed to SC and dose decreased to 500 mg for 10 days. 32 subsequent patients received
this
Control group
• No ALG
Immunosuppression (both groups)
• Hydrocortisone: 200 mg pre-op
Sansom 1976 
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
149
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• AZA: 5 mg/kg IV pre-op• PRED (post-op): 75 mg for 10 days, tapered to 12.5 to 15 mg by 4 to 6 months• AZA (post-op): maximum daily dose to keep WCC > 3000/mm3
Outcomes • Death• GraB loss• Acute rejection
Notes • 100 patients randomised, only 1st transplant recipients were analysed (not stratified) therefore only
85 patients analysed• Acute rejection reported as total number of episodes but not clear if some patients had multiple
episodes, therefore total number of patients with acute rejection unknown and not used in review
analysis• Funding source: GD Searle and Queen Elizabeth Hospital Renal Research Fund
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk 'randomised numbers consecutively...' insufficient to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Unlikely to influence reported outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unclear if acute rejection was biopsy-proven
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Higher immunological risk patients excluded (2nd transplant patients) after
randomisation; no results given for these 15 patients
Selective reporting (re-
porting bias)
High risk As above; acute rejection results could not be included in the meta-analysis
Other bias Unclear risk Funding source unclear "giB of rabbit ALG and financial assistance" provided
by GD Searle; Queen Elizabeth Hospital Renal Research Fund provided some
funding
Sansom 1976  (Continued)
 
 
Methods • Study design: parallel RC; possibly 3:1 however not well described• Study duration: not reported• Study follow-up: 1 year
Participants • Country: Egypt• Setting: single centre• Inclusion criteria: LD kidney transplant recipients• Number: treatment group (63); control group (20)
Sharaf El Din 2006 
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• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• Alemtuzumab: 20 mg, 2 doses day 0 and day 1• MP: 250 mg prior to each treatment• CSA: 4 mg/kg/d from day 1• MMF: 500 mg twice daily from day 1
Control group
• MP: 250 mg in operating theatre at induction and at declamping• PRED: with gradual decrease to 10 mg/d by 3 months• CSA: 8 mg/kg/d from day 2• MMF: 1 g twice daily from day 2
Outcomes • Patient survival• GraB survival• Acute rejection• SCr
Notes • Abstract-only publication• Not clear if randomised but states that it was• Attempted to contact author to clarify methods but no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not clear if acute rejection was biopsy-proven
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Sharaf El Din 2006  (Continued)
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Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 5 years
Participants • Country: Egypt• Setting: single centre• Inclusion criteria: LD kidney transplant recipients• Number: treatment group (40); control group (40)• Mean age ± SD (years): treatment group (30.3 ± 13.1); control group (31.7 ± 10.45)• Sex (M/F): treatment group (33/7); control group (33/7)• Exclusion criteria: not reported
Interventions Treatment group
• rATG (Fresenius): 9 mg/kg given in operating theatre prior to revascularization
Control group
• No ATG
Immunosuppression (both groups)
• Steroids: dose regimen not reported• CNI: dose regimen not reported• Anti-proliferative agents: dose regimen not reported
Outcomes • Patient survival• GraB survival• Biopsy-proven acute rejection• Side effects
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Low risk Sequentially numbered, opaque, sealed envelopes
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcomes reported
Sheashaa 2008 
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Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk No obvious source but funding source not declared
Sheashaa 2008  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: June 1986 to January 1991• Study follow-up: 3 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: DD kidney transplant recipients• Number: treatment group (99); control group (31)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: possessed anti-mouse Ab; refused the drug
Interventions Treatment group
• OKT3: 5 mg IV bolus given in operating theatre after induction and intubation; no further information
provided
Control
• No OKT3
Immunosuppression (both groups)
• MP: dose not reported• AZA: dose not reported• No patient received CSA within 36 h of the transplant
Outcomes • Death• GraB loss• DGF
Notes • Records of all kidney transplant recipients analysed: 31 patients LD (no OKT3); all DD transplant re-
cipients received OKT3 intra-op unless they were ‘randomised’ to non-OKT3 arm (may not be truly
randomised)• Authors made decision to include with sensitivity analysis• DD only used for our comparisons• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Limited information but no reason for severe imbalance in LD vs DD patients
and unequal numbers in intervention and treatment groups. Likely selection
bias; possibly post-hoc report of unpublished RCT
Shield 1993 
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Allocation concealment
(selection bias)
High risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Percentages given but no actual numbers for survival and no causes of patient
or graB loss
Selective reporting (re-
porting bias)
High risk Acute rejection not reported
Other bias Unclear risk Insufficient information to permit judgement and funding not declared
Shield 1993  (Continued)
 
 
Methods • Study design: parallel RCT; stratified for age (> or < 50 years), diabetes• Study duration: January 1988 to September 1990• Study follow-up: to 4.5 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: adult 1st DD kidney transplant recipients with immediate graB function• Number: treatment group (61); control group (60)• Mean age ± SD (years): treatment group (47.4 ± 13.9); control group (47.3 ± 14.2)• Sex (M/F): treatment group (36/25); control group (33/27)• ethnicity (Caucasian/Black/other): treatment group (42/15/4); control group (43/15/2)• Exclusion criteria: not reported
Interventions Treatment group
• ALG (Minnesota): 5 mg/kg on day 1, 10 mg/kg day 2, 20 mg/kg days 3 to 7• CSA: 10 mg/kg, commenced on day 6• AZA: 2.5 mg/kg, adjusted as per WCC (aim > 4000 cells/mm3).• PRED: 1 mg/kg/d, decrease to 0.5 mg/kg/d by 2 weeks, tapered to 0.15 mg/kg by 6 months
Control group
• CSA: 10 mg/kg/d (oral) within 24 h• AZA: 5 mg/kg/d, tapered to 2.5 mg/kg/d by day 8• PRED: as for treatment group
Outcomes • Death• GraB loss• Acute rejection• GraB function
Slakey 1993 
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• Infection
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcomes reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding not declared
Slakey 1993  (Continued)
 
 
Methods • Study design: parallel RCT; stratified by PRA and history of previous transplant• Study duration: December 2007 to June 2012• Study follow-up: to 6 months
Participants • Country: Netherlands• Setting: single centre• Inclusion criteria: LD or DD kidney transplant recipients; 18 years• Number: treatment group (138); control group (142)• Mean age ± SD (years): treatment group (50.8 ± 13.2); control group (49.8 ±12.3)• Sex (M): treatment group (69.6%); control group (63.4%)• LD/DD: treatment group (58.7/41.3); control group (57.0/43.0)• Ethnicity (white): treatment group (94.9%); control group (96.5%)• Exclusion criteria: HLA identical living donor; haemolytic uraemic syndrome as original kidney dis-
ease; focal segmental glomerulosclerosis that had recurred in a previous graB; 3 or more previously
failed graBs; a current or historic PRA > 85%; total WCC < 3.0 x 109/L; platelet count < 75 x 109/L; active
infection with Hep B, Hep C or HIV; a history of tuberculosis; previous treatment with rituximab
Interventions Treatment group
• Rituximab: single dose 375 mg/m2 IV (500 mL bag) at the time of transplantation
Smeekens 2013 
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Control group
• Placebo: identical 500 mL bag
Pre-med, immunosuppression and prophylaxis (both groups)
• PRED: 100 mg at start of operation; 100 mg/d for 3 days; 15-5 mg/d and tapered to 0.1 mg/kg/d• Clemastin: 2 mg at start of operation• Standard antibiotic prophylaxis at start of operation• TAC: 0.1 mg/kg twice daily, target trough 15 to 20 ng/mL for 2 weeks, then 10 to 15 ng/mL for 4 weeks,
thereafter 5 to 10 ng/mL• MMF: 1000 mg twice daily for 2 weeks, then 1500 mg/d thereafter (or 2000 mg if weight > 90 kg),• Co-trimoxazole: 480 mg daily for 3 months, then 3 times/week until 12 months• Valganciclovir: for 3 months if CMV D+/R-
Outcomes • Biopsy-proven acute rejection• Patient survival• GraB survival• GraB function (CrCl)• CAN• Infection• Malignancy• Cost
Notes • Funding source: "Funding for the clinical trial was provided by Hoffmann–La Roche and Astellas Phar-
ma. Rituximab (MabThera, Hoffman-La Roche) was donated."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated list of random numbers, prepared by independent inves-
tigator
Allocation concealment
(selection bias)
Low risk Study numbers only available to authorised nurses who signed confidentiality
statements. Medication prepared by authorised nurses
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Medication in identical bags for rituximab and placebo
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Low risk None apparent. 'Both companies were informed of the results and had no role in
study design, data collection, analysis, interpretation or writing of the report.'
Smeekens 2013  (Continued)
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Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 1 year
Participants • Country: Germany• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients; 18 to 60 years; cold ischaemia time < 48 h• Number: not reported• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: history of malignancy; hyperimmunised patients; positive historical crossmatch
Interventions Treatment group
• Odulimomab: 30 mg, 2 h pre-op. 15 mg/d for further 9 days.• CSA: started day 9 at 8 mg/kg/d, then adjusted as per trough level
Control group
• CSA: 3 mg/kg/d pre-op, then 8 mg/kg/d, as per trough level
Immunosuppression (both groups)
• AZA: 1.5 to 2 mg/kg/d• PRED: 500 mg in operating theatre, then 30 mg/d, reduced by 5 mg every week to maintenance of 10
mg/d
Outcomes • Acute rejection• Patient survival• GraB survival• DGF• Infections• GraB function
Notes • Acute rejection episodes recorded as 5 versus 12 episodes. Number of patients with acute rejection in
each group not specified (some patients may have had multiple episodes of acute rejection). Unable
to meta-analyse• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
Low risk Unlikely to influence outcomes
Spillner 1998 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk Unable to meta-analyse acute rejection results
Other bias Unclear risk Funding not reported
Spillner 1998  (Continued)
 
 
Methods • Study design: parallel RCT; stratified by 1st and 2nd graB• Study duration: April 1995 to February 1996• Study follow-up: 6 months
Participants • Country: Belgium• Setting: single centre• Inclusion criteria: DD kidney transplant recipients; ≥ 18 years• Number: treatment group (20); control group (20)• Mean age ± SD (years): treatment group (39.90 ± 11.38); control group (37.40 ± 11.70)• Sex (M/F): treatment group (10/10); control group (10/10)• 1st/2nd transplant: treatment group (16/4); control group (16/4)• Exclusion criteria: not reported
Interventions Treatment group
• Humanised anti-CD2 rat MAb: BTI-322 5 mg/d IV for 10 days. 1st dose given in operating theatre prior
to vascular anastomosis• MP: 250 mg at unclamping and repeat 6 h later• CSA, AZA, PRED as per control
Control group
• CSA: 3 to 8 mg/kg/d, adjust for trough 200 to 400 ng/mL• AZA:' 1 mg/kg/d• PRED: 0.5 mg/kg/d tapered to 0.1 mg/kg/d by 9 months
Outcomes • Patient survival• GraB survival• Biopsy-proven acute rejection• Infection• DGF• Malignancy
Notes • Funding source: supported by a grant from BioTransplant Inc
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Squi>let 1997 
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Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Supported by the manufacturers of BTI-322
Squi>let 1997  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 6 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: DD kidney transplant recipients; oliguria in first 24 to 36 hours; increase in SCr in 1st
12 to 36 h post transplant• Number: treatment group 1 (26); treatment group 2 (25)• Mean age ± SD (years): treatment group 1 (43.2 ± 12.55); treatment group 2 (42.5 ± 10.9)• Sex (M/F): treatment group 1 (13/13); treatment group 2 (17/8)• Exclusion criteria: not reported
Interventions Treatment group 1
• ALG (Minnesota): 10 to 20 mg/kg/d IV via CVC, dose adjusted CD2 and CD3 counts (aim to maintain at
20 to 40 cells/mm or below), stopped after 2 or 3 day overlap with CSA
Treatment group 2
• OKT3: initial dose 5 mg, dose adjust between 5 to 10 mg, depending on CD3 suppression (aim for 10
to 20 cells/mm), stopped after 2 or 3 day overlap with CSA
Immunosuppression (both groups)
• CSA: started when SCr decreasing and urine output established, adjusted for trough of 150 to 300 ng/
mL for month 1, then 100 to 200 ng/mL thereafter• AZA: 1 to 1.5 mg/kg, adjusted as per WCC• PRED: 30 mg/d, tapered after 1 month
Outcomes • Death• GraB loss
Steinmuller 1991 
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• Acute rejection• Infection• Side effects
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Some outcomes reported in an unclear way (e.g. graB losses seems to include
some deaths but not all deaths)
Selective reporting (re-
porting bias)
High risk Most expected outcomes reported but some not clear.
Some patients had early acute rejection but were treated by course of anti-
body therapy (therefore, rates of acute rejection may be lower than expected)
Not clear if all patients were biopsied or only those whose SCr continued to
rise post antibody treatment or SCr fell then rose again
GraB function: documented at 6 months but not included in meta-analysis as
no SD or SE given
Other bias Unclear risk Funding not reported
Steinmuller 1991  (Continued)
 
 
Methods • Study design: parallel RCT; stratified into 6 groups: white versus non-white, DD versus LD; listed for
pancreas after kidney versus not listed• Study duration: April 2004 to December 2007• Study follow-up: 6 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: 18 to 64 years; LD or DD kidney transplant recipients; 1st or repeat transplant• Number (analysed/randomised): treatment group 1 (70/79); treatment group 2 (72/81)• Mean age ± SD (years): treatment group 1 (45.5 ± 12.4); treatment group 2 (49.3 ± 10.5)• Sex (M/F): treatment group 1 (46/24); treatment group 2 (45/27)• White-Asian/other: treatment group 1 (62/8); treatment group 2 (61/11)
Stevens 2008 
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• LD/DD: treatment group 1 (30/40); treatment group 2 (31/41)• Exclusion criteria: > 65 years; PRA > 75%; HLA-identical recipients; required chronic steroids
Interventions Treatment group 1
• Single high dose rATG: 6 mg Infused over 24 h in 1 L of normal saline, started in operating theatre,
prior to re-perfusion
Treatment group 2 
• Split dose rATG: 4 x 1.5 mg doses over 7 days (day 0, 2, 4, 6)* 1st dose 1.5 mg/kg over 24 h, started before reperfusion* Subsequent doses in 250 mL over 6 to 12 h every 2nd day
Pre-meds, immunosuppression, prophylaxis (both groups)
• Pre-med: MP, paracetamol, antihistamine* MP: 3 mg/kg every 6 h for 24 h• Immunosuppression* TAC: 1 to 3 mg twice daily when Cr < 3g/dL (trough target 4 to 6 ng/mL, 2 to 4 ng/mL after 3/12)* Sirolimus: 5 mg 4 times/d when SCr < 3 mg/dL, (trough 8 to 10 ng/mL to 3 months, 4 to 8 ng/mL
after 3 months)□ MMF: used if BMI > 32, 500 to 1000 mg twice/d• Prophylaxis* Valaciclovir for 3 months* Clotrimazole for 3 months* Co-trimoxazole (or dapsone or aerosolized pentamidine if allergy) for PCP for 3 months
Outcomes • Kidney function (eGFR)• CAN by protocol biopsy at 6 months• Biopsy-proven acute rejection• Patient survival• GraB survival• Safety profile• NODAT
Notes • Switch in maintenance immunosuppression at 6 months. Either CNI withdrawal and switch to MMF or
continued on TAC. 50% of each group. These results not reported, therefore outcomes only to 6/12• Funding source: "supported by the Ann Goldstein-Cheryl Cooper New Frontiers in Transplant Medi-
cine Fund, a Research Support Fund grant from the Nebraska Medical Center and the University of
Nebraska Medical Center and an unrestricted research grant from Genzyme, Inc"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk ‘Randomly generated treatment group assignments’ after stratification into 6
different groups
Allocation concealment
(selection bias)
Low risk ‘Sequentially numbered sealed envelopes’. 
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Stevens 2008  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All patient outcome data reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing outcome data balanced in numbers across intervention groups, with
similar reasons for missing data across groups
Selective reporting (re-
porting bias)
High risk Primary outcomes not well reported (graphs only, no figures reported for kid-
ney function)
Other bias Unclear risk Partly funded by Genzyme with unrestricted grant. (but ATG in both arms)
Stevens 2008  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 12 months
RCT
Multicentre - 12 centres across Canada
12 month follow up
Participants • Country: Canada• Setting: multicentre (12)• Inclusion criteria: DD kidney transplant recipients• Number: treatment group (87); control group (92)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: ABO incompatibility; positive direct crossmatch; previous ALG therapy; positive skin
test for sensitivity to horse serum protein; previous transplant
Interventions Treatment group
• Horse ALG: 20 mg/kg IV over 8 h once/d for 10 days, starting post-op (some via CVC, some via AVF)
Control group
• No ALG
Immunosuppression (both groups)
• As per treating physician, could include:* AZA* PRED/hydrocortisone* Actinomycin D* GraB radiation• 'Dose adjusted according to progress'
Outcomes • Death• GraB loss• Acute rejection• Other complications
Taylor 1976 
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Notes • Funding source: Medical Research Council, Canada
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Table of random numbers used
Allocation concealment
(selection bias)
Low risk sealed envelopes with patient allocations, only opened during operation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgement, in particular, not clear how
acute rejection episodes were diagnosed and what made them a minor versus
a major acute rejection episode
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported; graB function reported at 60 days but not
able to be used in analyses of this review as no SD or SE given
Other bias Low risk Appears free of other bias; funding by Medical Research Council, Canada
Taylor 1976  (Continued)
 
 
Methods • Study design: parallel RCT; stratified by PRA into 5 groups• Study duration: 1991 to 1995• Study follow-up: median 25 months
Participants • Country: France• Setting: single centre• Inclusion criteria: adult LD or DD sensitised kidney transplant recipients; 1st or 2nd graB• Number: treatment group (47); control group (42)• Mean age ± SD (years): treatment group (47 ± 12); control group (46 ± 13)• Sex (M/F): treatment group (28/19); control group (30/12)• LD/DD: treatment group (0/47); control group (/42)• 1st/2nd transplant: treatment group (34/13); control group (26/16)• Exclusion criteria: 3rd graBs; graBs performed against a positive historical T-cell crossmatch
Interventions Treatment group
• rATG (Pasteur-Merieux): 1.25 mg/kg/d, given once/d for 10 days, dose adjusted by CD2 and CD3 counts,
done 3 times/week• AZA: only introduced when ATG stopped• CSA and PRED: as per control
Control group
Thibaudin 1998 
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• CSA: started pre-op at oral equivalent of 14 mg/kg/d, tapered every 2nd day to 8 mg/kg/day by end
of week 1, adjusted per trough of 100 to 300 µg/L• PRED: 30 mg/d• AZA: 2 mg/kg/d
Outcomes • Death• GraB survival• Acute rejection• Side effects• GraB function
Notes • Time frame for some outcomes not entirely clear as not all patients followed to same time point• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unlikely to influence outcomes
Not all acute rejection was biopsy proven (72% in ATG group and 90% in con-
trol)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding source not reported
Thibaudin 1998  (Continued)
 
 
Methods • Study design: quasi-RCT• Study duration: January 1974 to May 1976• Study follow-up: 1 to 3 years
Participants • Country: USA• Setting: single centre• Inclusion criteria: DD kidney transplant recipients aged 14 to 55 years• Number: treatment group (34); control group (37)• Mean age (years): treatment group (38.79); control group (37.65)
Thomas 1977 
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• Sex (F): treatment group (35%); control group (19%)• 1st transplant: treatment group (82%); control group (78%)• Exclusion criteria: abnormal lower urinary tract
Interventions Treatment group
• High potency ALG: 1.5 mg/kg/d IM for 5 days
Control group
• Low potency (group A) ALG: 1.5 mg/kg/d IM for 5 days
Immunosuppression (both groups)
• AZA: 2 to 3 mg/kg• PRED: 1 mg/kg/d reduced to a mean 0 to 0.5 mg/kg/d by 1 month
Outcomes • Acute rejection• Death• GraB loss
Notes • Funding source: supported in part BY NIH grants IRO AI12822-O1 and R01 AI12586-01
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk 'randomisation usually on an alternate basis but not necessarily so'.
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Reported as double blind "neither medical nor nursing staI aware of which
letter group was high potency (H.P.-A.L.G.) and which was moderate potency
(M.P.-A.L.G.)" Labelled group A and group B – low risk given hard outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Five patients excluded due to inadvertent major deviations from standard pro-
tocol
Selective reporting (re-
porting bias)
High risk Deaths not fully reported. Infection not fully reported
Other bias Low risk None apparent. Funded in part by 2 x NIH grants
Thomas 1977  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 2005 to May 2006• Study follow-up: 12 months
Thomas 2007 
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Participants • Country: USA• Setting: single centre• Inclusion criteria: "high risk" DD kidney transplant recipients (either PRA > 20% or previous failed
transplant)• Number: treatment group 1 (11); treatment group 2 (8)• Mean age ± SEM (years): treatment group 1 (43.5 ± 4.1); treatment group 2 (47.1 ± 4.2)• Sex (M/F): treatment group 1 (6/5); treatment group 2 (2/6)• Caucasian/African-American/Hispanic/Asian): treatment group 1 (5/2/4/0); treatment group 2
(1/2/4/1)• Exclusion criteria: not reported
Interventions Treatment group 1
• Alemtuzumab: 30 mg single dose, before reperfusion• TAC: from day 1 post-op, trough target of 10 ng/mL
Treatment group 2
• ATG: 1.5 mg/kg ATG pre-op; 1.5 mg/kg/d for 4 days• PRED: 250 mg MP with 2nd dose of ATG; Oral PRED day 3, 50 mg twice daily, tapered to 10 mg over
5 days• MMF: started pre-op (dose not specified)• TAC: started when Cr < 3.0 g/dL or day 3 post-op (whichever earlier); trough target 10 ng/mL
Outcomes • Death• GraB loss• Acute rejection
Notes • 2 patients withdrew after randomisation and were excluded• Infection reported but not able to be included in review analyses as reported as total numbers only
(number of patients with infections not reported). Results as follows:* Alemtuzumab: UTI (9), wound (2), infected seroma (1), skin pustules (1)* ATG: UTI (4), wound (1), colitis (1), west Nile virus meningitis (1)• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
Low risk All patient outcome data reported
Thomas 2007  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
High risk Unable to analyse infection data
Other bias Unclear risk Funding source not reported
Thomas 2007  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 1 year
Participants • Country: USA• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients• Number: treatment group 1 (25); treatment group 2 (25)• Mean age (years): treatment group 1 (47); treatment group 2 (42)• Sex (M/F): treatment group 1 (18/7); treatment group 2 (16/9)• Black/white: treatment group 1 (11/14); treatment group 2 (5/20)• Exclusion criteria: not reported
Interventions Treatment group 1
• Horse or goat ALG: 20 mg/kg/d, starting 1 day post-op, for 14 days; adjust as per WCC and platelets
(dose 5 to 20 mg/kg/d)* Dose adjusted if platelets fell to 50 to 100 x 103/mm3, or WCC 3000 to 5000/mm3* Stopped if platelets < 50,000/mm3 or WCC < 3000/mm3
Treatment group 2
• hATG: up to 15 mg/kg/d, started 1 day post-op, continued for 14 days at dose 5 to 15 mg/kg/d* Dose adjusted if platelets fell to 50 to 100 x 103/mm3, or WCC 3000 to 5000/mm3* Stopped if platelets < 50,000/mm3 or WCC < 3000/mm3
Immunosuppression (both groups)
• AZA 5mg/kg/d on 1st day post-op, then 1 to 2.5 mg/kg/d as per WCC• PRED: 1 mg/kg/d, reduced to 20 to 25 mg/d by 3rd or 4th week
Outcomes • Death• GraB loss• Acute rejection• Side effects
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Toledo-Pereyra 1985 
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Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias Unclear risk Funding source not reported
Toledo-Pereyra 1985  (Continued)
 
 
Methods • Study design: parallel RCT; 2:1 randomisation• Study duration: October 2003 to December 2004• Study follow-up: 1 year
Participants • Country: USA• Setting: multicentre (17)• Inclusion criteria: LD kidney transplant recipients > 18 years; PRA < 20%• Number: treatment group (103); control group (48)• Mean age ± SD (years): treatment group (45.7 ± 13.65); control group (45.8 ± 13.04)• Sex (M/F): treatment group (61/42); control group (27/21)• Caucasian/African American/Hispanic/Asian or other: treatment group (65/13/19/6/1); control group
(31/9/3/5/0)• Prior transplant: treatment group (1); control group (0)• Exclusion criteria: HLA identical matched living-donor transplant recipient; > 2 previous kidney trans-
plants; loss of first kidney transplant within one year; current PRA > 20%; history of a positive cross-
match with the donor; donor or recipient serology positive for either HIV, HBV. HCV; chronic corticos-
teroids use except for inhaled corticosteroids to treat asthma; use of any investigational products
during the 90 d prior to screening; requirement for multiple organ transplant; subject without a func-
tioning urinary bladder; known contraindication to administration of rATG; currently abusing drugs
or alcohol, or patients at high risk for poor compliance or with significant medical or psychosocial
problems or unstable disease states that would warrant exclusion from the study in the opinion of
individual investigators
Interventions Treatment group
• ATG: 5 to 6 mg/kg total dose, given in 4 equal divided doses over 4 days (spread over 7 days maximum
if any delayed doses)• PRED-MP: MP 500 mg day 0, then 1 mg/kg PRED tapered to 0.25 mg/kg by day 6, then stopped
Control group
• PRED-MP: 500 mg MP, then PRED 1 mg/kg, tapered as per local protocol to minimum of 5 mg/d
TRIMS Study 2010 
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Immunosuppression (both groups)
• TAC: 0.1 mg/kg/d, started within 24 h of operation, trough as per local protocol• MMF: 1000 mg day 0, then 1g twice daily till day 4, then as per local protocol
Prophylaxis (both groups)
• CMV: valganciclovir or ganciclovir if donor CMV +ve for 6 months. If recipient +ve but donor –ve, or
both –ve received acyclovir for 3 months• PCP: as per local protocol
Outcomes • Biopsy-proven acute rejection (6 and 12 months)• GraB loss (6 and 12 months)• Death (6 and 12 months)• DGF• GraB function• Adverse events• NODAT
Notes • Funding source: sponsored by Genzyme
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Sponsored by Genzyme (rATG manufacturers)
NB: enrolment stopped early at 151 patients (planned to enrol 200) by study
sponsor – due to ‘budget reasons’
TRIMS Study 2010  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported
Tsai 2012 
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• Study follow-up: 6 months
Participants • Country: Taiwan• Setting: single centre• Inclusion criteria: non-sensitised (PRA < 20%), HLA-mismatched DD kidney transplant recipients• Number: treatment group 1 (15); treatment group 2 (15); control group (16)• Mean age (range): 42.5 years (16 to 65)• Sex (M/F): 23/23• Exclusion criteria: not reported
Interventions Treatment group 1
• Rituximab: single dose of 375 mg/m2 during surgery• TAC: dose/trough level not reported• Steroids: dose not reported
Treatment group 2
• Rituximab: single dose of 375 mg/m2 during surgery• Steroids: dose not reported• MMF: dose between 1000 and 2000 mg/d to keep WCC between 4000 and 6000/mm3• TAC: dose/trough level not reported
Control group
• No induction• Steroids: dose not reported• MMF: dose between 1000 and 2000 mg/d to keep WCC between 4000 and 6000/mm3• TAC: dose/trough level not reported
Outcomes • Acute rejection• Infection• GraB function
Notes • Abstract-only publication• Treatment group 2 and control group compared• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Tsai 2012  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
High risk Full study not reported
Other bias High risk Abstract only. Funding source unknown
Tsai 2012  (Continued)
 
 
Methods • Study design: parallel RCT, stratified by LD or DD• Study duration: March 1964 to November 1972• Study follow-up: 18 months
Participants • Country: USA• Setting: single centre• Inclusion criteria: LD (all intra-familial) or DD kidney transplant recipients• Number: treatment group (36); control group (35)• Mean age ± SD (years): not reported• Sex (M/F): not reported• LD/DD: treatment group (17/19); control group (18/17)• Exclusion criteria: not reported
Interventions Treatment group
• hATG: once/day via IM, starting 3 days pre-op for LD or immediately pre-transplant for DD, 3.5 mg/kg/
d prior and for 7 days post-op, 1.8 mg/kg days 8 to 21, 0.9 mg/kg days 22 to 35• AZA: 3 mg/kg immediately post-op adjust as per WCC• PRED: 0.6 mg/kg/d for LD and 1.2 mg/kg/d for DD, by week 8 0.5 mg/kg for LD and 0.75 mg/kg for DD
Control group
• AZA: 3 mg/kg immediately post-op adjust as per WCC• PRED: double dose of treatment group, more rapid taper over 8 weeks, by week 8 0.5 mg/kg for LD
and 0.75 mg/kg for DD
Outcomes • Patient survival• GraB survival• GraB function• Complications• Acute rejection
Notes • Acute rejection: reported in study but not included in the review analyses as reported as total number
of acute rejection episodes (rather than total number of patients with acute rejection)• Infection: reported as total episodes rather than number of patients• Adverse reactions to ATG: all had high fevers; urticarial (9), anaphylaxis (‘mild’) (2), serum sickness (1)• Stopped early days 32 and 33 (2)• Funding source: hATG provided by Upjohn Co; Maud T. Lane Fund and research grant from Public
Health Service
Risk of bias
Turcotte 1973 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Separate sets of random cards for DD and LD recipients
Allocation concealment
(selection bias)
Low risk Cards in sealed envelopes, not opened until the time of surgery
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported, however unable to use acute rejection or in-
fection data
Other bias Unclear risk Unclear: hATG provided by Upjohn Co (therefore partially funded by them)
Also funded by Maud T. Lane Fund and research grant from Public Health Ser-
vice
Turcotte 1973  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: November 2005 to May 2007• Study follow-up: 3 years
Participants • Country: Sweden• Setting: multicentre (4)• Inclusion criteria: ≥18 years, recipient of 1st or 2nd transplant from LD or DD; single organ only• Number: treatment group (68); control group (68)• Mean age ± SD (years): treatment group (51.3 ± 12.0); control group (47.0 ± 13.4)• Sex (M/F): treatment group (46/23); control group (44/24)• DD/LD: treatment group (49/19); control group (43/25)• 1st/2nd transplant: treatment group (68/0); control group (62/6)• Exclusion criteria: HLA-identical siblings; receiving immunosuppressive therapy within the preceding
28 days; PRA > 50% within 6 months before enrolment; history of malignancy; active infection; preg-
nant or lactating females; women of child bearing potential not willing to use reliable form of contra-
ception
Interventions Treatment group
• Rituximab: 375 mg/m2 BSA, within 24 hr, given mixed in 500 mL 5% dextrose
Control group
• Placebo: 500 mL 5% dextrose
Tyden 2009 
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Immunosuppression (both groups)
• TAC: 0.1 mg/kg twice daily, trough 10 ng/mL 1st month, 5 to 10 ng/mL 2nd month, 5 ng/mL thereafter• MMF: 1 g twice daily, adjusted per AUC, target 90 to 180 µmol/L h• PRED: 100 mg, reduce by 10 mg/d to 20 mg, continued for 1 month then tapered to 5 mg by 4 months
Prophylaxis (both groups)
• CMV: either valganciclovir or valaciclovir• PCP: co-trimoxazole for 6 months
Outcomes • Acute rejection (6 months)• Death (6 months)• GraB failure (6 months)• GraB function• Infection• Adverse events• Malignancy
Notes • All acute rejection was biopsy proven• 3 year follow-up: poor follow-up of initial patient groups* Rituximab: 53/68 (15 declined); of the 53, graB failed (1), deaths (8)* Placebo: 48/68 (20 declined): of the 48, graB failed (1), death (0)• Funding source: grants from Roche, Sweden and Astellas Pharma 'Had advisory input into study de-
sign, collected data via electronic reporting and monitored study conduct'
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement ("...in randomization blocks of
four")
Allocation concealment
(selection bias)
Low risk Randomisation performed at hospital pharmacy department
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Infusion bags marked ‘Mantra study medication’ with content blinded to both
the patient and the investigator
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Most expected outcomes reported but no mention of malignancy in the study;
poor follow-up at 3 years
Selective reporting (re-
porting bias)
Low risk All expected outcomes were reported
Other bias High risk Grants from Roche, Sweden and Astellas Pharma
'Had advisory input into study design, collected data via electronic reporting
and monitored study conduct'
Tyden 2009  (Continued)
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Methods • Study design: parallel RCT; stratified for age (< 50 or ≥ 50) and warm ischaemia time (< 30 min or ≥
30 min)• Study duration: January 2008 to June 2010• Study follow-up: 3months
Participants • Country: Netherlands• Setting: multicentre (4)• Inclusion criteria: adult 1st DD kidney transplant recipients• Number: treatment group (28); control group (24)• Mean age, range (years): treatment group (54, 21 to 70); control group (56, 24 to 68)• Sex (M/F): treatment group (18/10); control group (17/7)• Exclusion criteria: previous transplant or proposed transplant with multiple organs; blood group in-
compatibility; current pregnancy or history of more than 3 pregnancies; lack of consistent data on a
PRA; known presence of antibodies against rabbit immunoglobulin or previous treatment with rabbit
immunoglobulin; known intolerance to any component of basal immunosuppression; HIV-positivity;
leukocytes < 3.0 × 109/L and/or platelets < 50 × 109/L before transplant; (cured) malignancy (with the
exception of basocellular or spinocellular skin cancer); pulmonary oedema or other signs of overhy-
dration
Interventions Treatment group
• ATG (Fresenius): 9 mg/kg in 500 mL normal saline, single dose intra-op, given over 4 h• MP: 250 mg IV prior to ATG
Control group
• MP: 250 mg intra-operatively
Immunosuppression (both groups)
• TAC: 0.2 mg/kg/d, adjusted to level of 15 to 20 mg/L for 2 weeks, then 10 to 15 mg/L for 4 weeks,
thereafter 5 to 10 mg/L• PRED: 100 mg IV for 3 days then as per local policies• MMF: 2000 mg/d for 2 weeks then 1500 mg/d unless weight >90 kg
Prophylaxis (both groups)
• PCP: co-trimoxazole 480 mg/d• CMV: valganciclovir if D+/R-
Outcomes • DGF• Death• GraB loss• Acute rejection• Adverse events (infection, malignancy, other serious adverse events)
Notes • Terminated early due to ‘lower than anticipated inclusion rate’. 180 planned (only 54 recruited)• Funding source: "This study was financially supported by Fresenius Biotech GmbH, Gräfelfing, Ger-
many. The company had no input in study design, data collection, data analysis, and writing or editing
of the manuscript"
Risk of bias
Bias Authors' judgement Support for judgement
van den Hoogen 2013 
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Random sequence genera-
tion (selection bias)
Low risk Computer derived algorithm at coordinating centre
Allocation concealment
(selection bias)
Low risk Printed on paper and put into sealed, numbered envelopes. patients assigned
a consecutive number in the order in which they entered the study
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk DGF was primary outcome and decision regarding need for dialysis post-op
may be quite subjective; unlikely to influence other outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Terminated early due to poor recruitment
'This study was financially supported by Fresenius Biotech GmbH, Gräfelfing,
Germany. The company had no input in study design, data collection, data
analysis, and writing or editing of the manuscript'.
van den Hoogen 2013  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: January 1989 to January 1993• Study follow-up: 12 months
Participants • Country: France• Setting: single centre• Inclusion criteria: adult 1st, 2nd or 3rd kidney transplant recipients; PRA > 50%• Number: treatment group 1 (23); treatment group 2 (15)• Mean age ± SD (years): treatment group 1 (48 ± 2); treatment group 2 (42 ± 3)• Sex (M/F): treatment group 1 (11/12); treatment group 2 (5/10)• Exclusion criteria: not reported
Interventions Treatment group 1
• ALG (Merieux): 3-4 ‘vials’/d• CSA: 10 mg/kg/d, started when SCr < 200 µmol/L* ALG stopped when CSA trough reached 150 to 200 ng/mL
Treatment group 2
• OKT3: 5 mg/day, stopped on day 10• CSA: 10 mg/kg/d, started day 8
Immunosuppression (both groups)
• AZA: 150 mg/d
Vela 1994 
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• PRED: 20 mg/d
Outcomes • Patient survival• GraB survival• Acute rejection• Viral infections• Other side effects• GraB function
Notes • 3 patients assigned to OKT3 were switched to ALG group due to fluid overload.• All side effects higher in the OKT3 group compared to ALG, except for rash• Numbers with cytokine release syndrome not given but 100% in OKT3 group had fever, compared to
13% in ALG group• GraB function given as bar graph but no actual figures given therefore not able to be included in meta-
analyses• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported however unable to use graB function data
Other bias Unclear risk Funding source not reported
Vela 1994  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 3 months
Participants • Country: France• Setting: single centre• Inclusion criteria: 1st DD kidney transplant recipients
Vigeral 1986 
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• Number: treatment group (6); control group (7)• Mean age ± SD (years): treatment group (34.3 ± 9.2); control group (35.7 ± 11.2)• Sex (M/F): treatment group (3/3); control group (4/3)• Exclusion criteria: not reported
Interventions Treatment group
• OKT3: 5 mg/d, IV for 14 days starting 1 day pre-transplant (pre-treatment skin test prior) then stopped• AZA: 3 mg/kg/d from day 14
Control group
• AZA: 3 mg/kg/d, given from 1 day pre-op• PRED: 5 mg/kg/d for 5 days, then tapered to 0.25 mg/kg/d over 11 weeks
Outcomes • Death• GraB loss• Acute Rejection• Bacterial infection• CMV disease• Tolerance of OKT3
Notes • If episode of acute rejection, OKT3 was stopped and patient was switched to PRED and AZA• Very early study possibly 1st using OKT3 as prophylaxis• Pre CNI maintenance• All patients in OKT3 group had side effects with fever, chills, anxiety and diarrhoea for 1st infusion and
then not after (? vs none in control group although not actually reported)• All developed antibodies to OKT3• Not effective as single agent (worse outcomes compared to controls)• Funding source: not reported, however 1 author an employee of Ortho Pharmaceuticals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Most cases of acute rejection were biopsy-proven acute rejection but not all.
Clinical decision for acute rejection without biopsy could be prone to bias
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported given short term follow-up only
Vigeral 1986  (Continued)
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Other bias High risk Funding source not declared; one of the authors is from Ortho Pharmaceutical
Corporation (OKT3 manufacturer)
Vigeral 1986  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: November 1971 to June 1972• Study follow-up: 2 years
Participants • Country: USA• Setting: multicentre (3)• Inclusion criteria: DD kidney transplant recipients• Number: treatment group (20); control group (20)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• ATG: 7 mg/kg IV once/d for 4 days, 3.5 mg/kg once/d for 26 days, 7 mg/kg twice weekly for 8 weeks,
then 7 mg/kg once weekly for 4 weeks; given in 250 mL saline over at least 3 hours• AZA: dosage not reported• PRED-MP: dosage not reported
Control:
• AZA: dosage not reported• PRED-MP: dosage not reported
Outcomes • Death• GraB loss• Acute rejection (within 28 days)• NODAT
Notes • Other side effects only reported for ATG• Funding source: not reported, contact author employee of Upjohn company (manufacturer of ATG)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
High risk Acute rejection episodes mainly diagnosed clinically; lack of blinding may
have influenced reporting of adverse outcomes.
Wechter 1979 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Side effects not well reported for control group
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Other bias High risk Contact author an employee of Upjohn company
Wechter 1979  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Study follow-up: 2 years
Participants • Country: Israel• Setting: single centre• Inclusion criteria: low and high risk 1st or retransplant kidney transplant recipients• Number: treatment group (19); control group (19)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• rATG (Fresenius): single dose of 9 mg/kg given as IV infusion in 500 mL saline prior to revascularistion• MP: 500 mg
Control group
• No ATG
Immunosuppression (both groups)
• PRED: as per protocol, started post-op; dosage not reported• AZA: as per protocol, started post-op; dosage not reported• CSA: as per protocol, started post-op; dosage not reported
Outcomes • Death• GraB loss• Acute rejection• DGF• Infection
Notes • GraB function reported but timing not specified and no SD or SE given, cannot be meta-analysis• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Yussim 2000 
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Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Unlikely to influence outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unlikely to influence outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patient outcome data reported
Selective reporting (re-
porting bias)
High risk All expected outcomes reported however SD/SE not reported for graB function
Other bias Unclear risk Insufficient information to permit judgement
Yussim 2000  (Continued)
ALG - antilymphocyte globulin; ANC - absolute neutrophil count; ATG - antithymocyte globulin; ATGAM - horse ATG; ATN - acute tubular
necrosis; AZA - azathioprine; BKV - BK virus; CAN - chronic allograft nephropathy; CMV - cytomegalovirus; CNI - calcineurin inhibitor; CSA
- cyclosporin A; DD - deceased donor; DGF - delayed graB function; DEX - dexamethasone; EBV - Epstein–Barr virus; eGFR - estimated
glomerular filtration rate; ESKD - end-stage kidney disease; GI - gastrointestinal; hATG - horse ATG; Hep - hepatitis; HIV - human immun-
odeficiency virus; HLA - human leukocyte antigen; IL-2RA - interleukin 2 receptor antagonist; IV - intravenous; LD - living donor; mALG -
Minnesota ALG; M/F - male/female; MMF - mycophenolate mofetil; MP - methylprednisolone; NODAT - new-onset diabetes after transplan-
tation; post-op - post-operative; PRA - panel reactive antibodies; PRED - prednisone; PTLD - post-transplant lymphoproliferative disease;
rATG - rabbit ATG; RBC - red blood cell; RCT- randomised controlled trial; SCr - serum creatinine; SD - standard deviation; SE - standard
error; SEM - standard error of the mean; WCC - white cell count
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Alloway 1993 Study includes kidney-pancreas recipients, results not reported separately for kidney only recipi-
ents
Kirsch 2006 No outcomes relevant to this review (critical circulating DC subsets, i.e. myeloid (DC1) versus lym-
phoid (DC2) DC)
Kumar 2002b "Due to financial constraints randomization was based on affordability to bear the cost of ATG.
Those who could afford the cost were included in the study group and those who couldn't became
the control"
NCT00000936 Study terminated; no data available
NCT01312064 Study terminated; no data available
ATG - antilymphocyte globulin
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Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised, open-label, parallel assignment (phase 2)
Participants 150 participants, ≥18 years, LD kidney transplant recipients
Interventions rATG with rapid discontinuation of steroids versus steroids per hospital standards for at least 1st 90
days after transplant
Outcomes Primary: kidney transplant rejection, organ loss and death at 6 months
Secondary: kidney function after transplantation and overall safety of rATG
Notes This study has been completed but no study results have been posted on Clinicaltrials.gov
NCT00089947 
 
 
Methods Randomised, open-label, parallel assignment (phase 4)
Participants 40 participants, ≥18 years, recipients of kidney transplants of high immunological risk
Interventions ATG (Fresenius) versus thymoglobulin
Outcomes Primary: adverse events
Secondary: rejection, graB function, patient survival, graB survival
Notes This study has been completed but no study results have been posted on Clinicaltrials.gov
NCT00861536 
 
 
Methods Randomised, open-label, parallel assignment (phase 4)
Participants 38 participants, age > 14 years, 1st LD kidney transplant recipients
Interventions ATG versus alemtuzumab versus daclizumab
Outcomes Primary: effectiveness and toxicity at 3 years, patient and graB survival at 1 and 3 years
Secondary: incidence of adverse reactions at 1 and 3 years
Notes This study has been completed but no study results have been posted on Clinicaltrials.gov
NCT01046955 
 
 
Methods Randomised, open-label, parallel assignment (Phase 4)
Participants 300 participants, ≥ 18 years, low risk kidney transplant recipients
Interventions Single dose ATG and everolimus versus basiliximab and everolimus versus basiliximab and MMF
NCT01354301 
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Outcomes Primary: incidence of CMV infection or disease at 1 year
Secondary: incidence of treatment failure at 1 year (composite of biopsy-confirmed acute rejec-
tion, graB loss, death, loss to follow-up)
Notes This study has been completed but no study results have been posted on Clinicaltrials.gov
NCT01354301  (Continued)
 
 
Methods Double-blind, double-dummy RCT
Participants 18 to 65 years DD or LD kidney transplant recipients
Interventions Single dose rATG versus divided dose rATG
Outcomes Primary: composite endpoint of fever, hypotension, hypoxia, cardiac events, DGF
Secondary: patient survival; graB survival acute rejection; incomplete ATG infusion; eGFR
Notes Results yet to be incorporated
Stevens 2016 
CMV - cytomegalovirus; DGF - delayed graB function; LD - living donor; MMF - mycophenolate mofetil; rATG - rabbit antilymphocyte globulin
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Anti-T-lymphocyte globulin (ATG) in renal transplantation of kidneys with a non-heart-beating
(NHB) donor
Methods Randomised, open-label, parallel assignment (Phase 3)
Participants 180 participants, recipients of DD kidney transplants
Interventions rATG versus no intervention
Outcomes Primary: incidence of initial DGF (defined as need for dialysis) within 3 months
Secondary: duration of initial DGF, incidence of primary never-functioning graBs, incidence of biop-
sy-proven acute rejection within 3 months, kidney function (MDRD) at 1,2 and 3 months, protein-
uria at 1, 2 and 3 months, % of patients with arterial hypertension at 3 months, % of patients with
antihypertensive drugs at 3 months, % of hyperlipidaemic patients at 3 months, % of post-trans-
plant DM at 3 months, incidence of CMV infection at 3 months, incidence of tumours/PTLD at 3
months, patient and graB survival at 3 months, incidence of other infections at 3 months, microal-
buminuria at 1, 2 and 3 months
Starting date January 2008
Contact information Radboud University (Prof. Dr Andries Hoitsma, UMC St Radboud Hospital)
Notes Estimated study completion date was June 2010; recruitment status unknown; study details last
verified in August 2008
NCT00733733 
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Trial name or title Evaluating safety and efficacy of TOL101 induction versus anti-thymocyte globulin to prevent kid-
ney transplant rejection
Methods Randomised, open-label, parallel assignment (Phase 1 and Phase 2)
Participants 85 participants, age 18-60, first kidney transplant recipients
Interventions ATG versus TOL101 dose A versus TOL101 dose B
Outcomes Primary: safety and tolerability of ascending doses of TOL101 and effectiveness of TOL101 to target
and down regulate T cells at 6 months
Secondary: effects of ascending doses of TOL101 on CD3+ T lymphocyte numbers and other im-
mune cell subsets at 14 days and 6 months, pharmacokinetic profile of TOL101 and exposure-re-
sponse relationship over time at 14 days, biopsy-proven acute organ rejection at 6 months, graB
survival at 6 months, patient survival at 6 months, kidney function by measured GFR at 6 months
and urine protein to creatinine ration at 3 and 6 months, DGF at 7 days, immunogenicity of TOL101
by measurement of anti-TOL101 antibodies at 14 and 28 days, presence of DSA at 3 months and 6
months
Starting date July 2010
Contact information Tolera Therapeutics Inc (Stuart Flechner MD, The Cleveland Clinic)
Notes Estimated study completion date was June 2013; recruitment status was active; not recruiting;
study details last verified in June 2013
NCT01154387 
 
 
Trial name or title RituxiMab INDuction in renal transplantation (ReMIND)
Methods Randomised, open-label, parallel assignment (phase 4)
Participants 612 participants, ≥18 years, recipients of LD kidney transplants
Interventions Rituximab and 1 week prednisolone versus continued prednisolone
Outcomes Primary: eGFR at 1 year
Secondary: biopsy proven acute rejection at 1, 2, 3, 4 and 5 years, allograft survival at 1, 2, 3, 4 and
5 years, patient survival at 1, 2, 3, 4 and 5 years, infection rate at 1 year, changes in B and T cell
repertoire
Starting date November 2010
Contact information Guy's and St Thomas' NHS Foundation Trust (Nizam Mamode, MD, FRCS(Gen)
Notes Estimated study completion date is October 2023; active, recruiting participants; study details last
verified August 2016
ReMIND Study 2013 
ATG - antilymphocyte globulin; CMV - cytomegalovirus; DD - deceased donor; DGF - delayed graB function; DM- diabetes mellitus; GFR
- glomerular filtration rate; LD - living donor: MDRD - Modification of Diet in Renal Disease; PTLD - post-transplant lymphoproliferative
disease; rATG - rabbit ATG
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D A T A   A N D   A N A L Y S E S
 
Comparison 1.   ATG versus placebo/no treatment
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death 16   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 At 3 to 6 months (+ CNI) 3 523 Risk Ratio (M-H, Random, 95%
CI)
0.41 [0.13, 1.22]
1.2 At 1 to 2 years (+ CNI) 5 632 Risk Ratio (M-H, Random, 95%
CI)
0.75 [0.27, 2.06]
1.3 At 1 to 2 years (no CNI) 6 621 Risk Ratio (M-H, Random, 95%
CI)
1.03 [0.86, 1.22]
1.4 At 5 years (+ CNI) 2 159 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.11, 7.81]
2 GraB loss (all cause) 13   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 At 3 to 6 months (+ CNI) 4 638 Risk Ratio (M-H, Random, 95%
CI)
0.60 [0.34, 1.05]
2.2 At 1 to 2 years (+ CNI) 3 549 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.36, 1.19]
2.3 At 1 to 2 years (no CNI) 4 500 Risk Ratio (M-H, Random, 95%
CI)
0.70 [0.49, 1.01]
2.4 At 5 years (+ CNI) 2 159 Risk Ratio (M-H, Random, 95%
CI)
1.13 [0.62, 2.05]
2.5 At 1 to 2 years (all studies) 7 1049 Risk Ratio (M-H, Random, 95%
CI)
0.71 [0.53, 0.95]
3 GraB loss (death censored) 10   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
3.1 At 1 to 2 years (+ CNI) 2 82 Risk Ratio (M-H, Random, 95%
CI)
0.57 [0.19, 1.75]
3.2 At 1 to 2 years (no CNI) 6 299 Risk Ratio (M-H, Random, 95%
CI)
0.55 [0.38, 0.78]
3.3 at 5 years (+ CNI) 2 148 Risk Ratio (M-H, Random, 95%
CI)
1.64 [0.20, 13.18]
3.4 At 1 to 2 years (all studies) 8 381 Risk Ratio (M-H, Random, 95%
CI)
0.55 [0.39, 0.77]
4 Acute rejection 17 2044 Risk Ratio (M-H, Random, 95%
CI)
0.63 [0.51, 0.78]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.1 At 1 to 2 years (+ CNI) 12 1491 Risk Ratio (M-H, Random, 95%
CI)
0.61 [0.49, 0.76]
4.2 At 1 to 2 years (no CNI) 5 553 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.43, 0.98]
5 Delayed graB function 9 1304 Risk Ratio (M-H, Random, 95%
CI)
0.93 [0.78, 1.10]
6 Infection 13   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
6.1 Any infection 7 824 Risk Ratio (M-H, Random, 95%
CI)
1.05 [0.88, 1.26]
6.2 CMV infection 6 1072 Risk Ratio (M-H, Random, 95%
CI)
1.55 [1.24, 1.95]
6.3 Other viral infection (not CMV) 4 664 Risk Ratio (M-H, Random, 95%
CI)
1.11 [0.43, 2.87]
6.4 Viral infection (all cause) 3 197 Risk Ratio (M-H, Random, 95%
CI)
1.38 [0.56, 3.39]
6.5 Bacterial infection 5 775 Risk Ratio (M-H, Random, 95%
CI)
1.15 [0.96, 1.37]
7 Leucopenia 4 920 Risk Ratio (M-H, Random, 95%
CI)
3.86 [2.79, 5.34]
8 Thrombocytopenia 4 848 Risk Ratio (M-H, Random, 95%
CI)
2.41 [1.61, 3.61]
9 Malignancy or PTLD 7   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
9.1 Malignancy at 1 to 2 years (+ CNI) 3 611 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.22, 3.94]
9.2 Malignancy at 5 years (+ CNI) 2 159 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.14, 6.23]
9.3 Malignancy at 1 to 2 years (no CNI) 2 121 Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
9.4 PTLD at 1 to 2 years (+ CNI) 1 151 Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
10 Other adverse outcomes 6   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
10.1 NODAT 6 935 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.56, 1.84]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
10.2 Serum sickness 1 371 Risk Ratio (M-H, Random, 95%
CI)
60.67 [3.74, 984.93]
10.3 Tremor 1 371 Risk Ratio (M-H, Random, 95%
CI)
0.93 [0.46, 1.87]
11 Serum creatinine 5   Mean Difference (IV, Random,
95% CI)
Subtotals only
11.1 At 6 months (+ CNI) 2 503 Mean Difference (IV, Random,
95% CI)
-5.34 [-13.44, 2.75]
11.2 At 1 year (+ CNI) 2 222 Mean Difference (IV, Random,
95% CI)
-10.56 [-21.81, 0.69]
11.3 At 1 year: LD recipients (no CNI) 1 30 Mean Difference (IV, Random,
95% CI)
-9.70 [-67.32, 47.92]
11.4 At 1 year: DD recipients (no CNI) 1 19 Mean Difference (IV, Random,
95% CI)
-23.0 [-62.70, 16.70]
11.5 At 5 years (+ CNI) 1 55 Mean Difference (IV, Random,
95% CI)
-32.70 [-68.98, 3.58]
 
 
Analysis 1.1.   Comparison 1 ATG versus placebo/no treatment, Outcome 1 Death.
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 At 3 to 6 months (+ CNI)  
Charpentier 2002 3/186 5/185 60.53% 0.6[0.14,2.46]
Kasiske 1997 1/50 5/50 27.27% 0.2[0.02,1.65]
van den Hoogen 2013 0/28 1/24 12.2% 0.29[0.01,6.74]
Subtotal (95% CI) 264 259 100% 0.41[0.13,1.22]
Total events: 4 (ATG), 11 (Control)  
Heterogeneity: Tau2=0; Chi2=0.77, df=2(P=0.68); I2=0%  
Test for overall effect: Z=1.61(P=0.11)  
   
1.1.2 At 1 to 2 years (+ CNI)  
Martins 2004 1/22 0/23 10.21% 3.13[0.13,72.99]
Mourad 1998 4/151 4/158 54.12% 1.05[0.27,4.11]
Thibaudin 1998 0/47 3/42 11.76% 0.13[0.01,2.41]
TRIMS Study 2010 0/103 1/48 10% 0.16[0.01,3.79]
Yussim 2000 1/19 1/19 13.91% 1[0.07,14.85]
Subtotal (95% CI) 342 290 100% 0.75[0.27,2.06]
Total events: 6 (ATG), 9 (Control)  
Heterogeneity: Tau2=0; Chi2=3.44, df=4(P=0.49); I2=0%  
Test for overall effect: Z=0.56(P=0.58)  
   
1.1.3 At 1 to 2 years (no CNI)  
Less with ATG 2000.005 100.1 1 Less with control
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Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chatterjee 1976 9/26 5/24 3.39% 1.66[0.65,4.26]
Cosimi 1976 104/183 93/175 85.29% 1.07[0.89,1.29]
Diethelm 1979 3/26 5/27 1.71% 0.62[0.17,2.35]
Kreis 1980 2/24 4/25 1.17% 0.52[0.1,2.59]
Turcotte 1973 9/36 13/35 5.95% 0.67[0.33,1.37]
Wechter 1979 4/20 6/20 2.48% 0.67[0.22,2.01]
Subtotal (95% CI) 315 306 100% 1.03[0.86,1.22]
Total events: 131 (ATG), 126 (Control)  
Heterogeneity: Tau2=0; Chi2=4.44, df=5(P=0.49); I2=0%  
Test for overall effect: Z=0.28(P=0.78)  
   
1.1.4 At 5 years (+ CNI)  
Samsel 1999 6/40 3/39 67.73% 1.95[0.52,7.25]
Sheashaa 2008 0/40 2/40 32.27% 0.2[0.01,4.04]
Subtotal (95% CI) 80 79 100% 0.94[0.11,7.81]
Total events: 6 (ATG), 5 (Control)  
Heterogeneity: Tau2=1.28; Chi2=1.91, df=1(P=0.17); I2=47.77%  
Test for overall effect: Z=0.06(P=0.95)  
Test for subgroup differences: Chi2=2.97, df=1 (P=0.4), I2=0%  
Less with ATG 2000.005 100.1 1 Less with control
 
 
Analysis 1.2.   Comparison 1 ATG versus placebo/no treatment, Outcome 2 GraB loss (all cause).
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 At 3 to 6 months (+ CNI)  
Banhegyi 1991 4/55 6/60 21.37% 0.73[0.22,2.44]
Charpentier 2002 7/186 12/185 37.88% 0.58[0.23,1.44]
Kasiske 1997 5/50 8/50 28.63% 0.63[0.22,1.78]
van den Hoogen 2013 2/28 4/24 12.13% 0.43[0.09,2.14]
Subtotal (95% CI) 319 319 100% 0.6[0.34,1.05]
Total events: 18 (ATG), 30 (Control)  
Heterogeneity: Tau2=0; Chi2=0.28, df=3(P=0.96); I2=0%  
Test for overall effect: Z=1.79(P=0.07)  
   
1.2.2 At 1 to 2 years (+ CNI)  
Mourad 1998 12/151 14/158 57.69% 0.9[0.43,1.88]
Thibaudin 1998 5/47 12/42 36.07% 0.37[0.14,0.97]
TRIMS Study 2010 2/103 1/48 6.24% 0.93[0.09,10.03]
Subtotal (95% CI) 301 248 100% 0.65[0.36,1.19]
Total events: 19 (ATG), 27 (Control)  
Heterogeneity: Tau2=0.02; Chi2=2.12, df=2(P=0.35); I2=5.65%  
Test for overall effect: Z=1.39(P=0.16)  
   
1.2.3 At 1 to 2 years (no CNI)  
Cosimi 1976 108/183 111/175 46.02% 0.93[0.79,1.1]
Diethelm 1979 9/26 16/27 20.81% 0.58[0.32,1.08]
Kreis 1980 5/24 12/25 12.82% 0.43[0.18,1.05]
Wechter 1979 8/20 13/20 20.35% 0.62[0.33,1.15]
Less with ATG 1000.01 100.1 1 Less with control
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Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 253 247 100% 0.7[0.49,1.01]
Total events: 130 (ATG), 152 (Control)  
Heterogeneity: Tau2=0.07; Chi2=6.05, df=3(P=0.11); I2=50.43%  
Test for overall effect: Z=1.89(P=0.06)  
   
1.2.4 At 5 years (+ CNI)  
Samsel 1999 12/40 12/39 79.5% 0.98[0.5,1.9]
Sheashaa 2008 6/40 3/40 20.5% 2[0.54,7.45]
Subtotal (95% CI) 80 79 100% 1.13[0.62,2.05]
Total events: 18 (ATG), 15 (Control)  
Heterogeneity: Tau2=0; Chi2=0.93, df=1(P=0.33); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
1.2.5 At 1 to 2 years (all studies)  
Cosimi 1976 108/183 111/175 39.72% 0.93[0.79,1.1]
Diethelm 1979 9/26 16/27 15.28% 0.58[0.32,1.08]
Kreis 1980 5/24 12/25 8.99% 0.43[0.18,1.05]
Mourad 1998 12/151 14/158 11.79% 0.9[0.43,1.88]
Thibaudin 1998 5/47 12/42 7.85% 0.37[0.14,0.97]
TRIMS Study 2010 2/103 1/48 1.49% 0.93[0.09,10.03]
Wechter 1979 8/20 13/20 14.89% 0.62[0.33,1.15]
Subtotal (95% CI) 554 495 100% 0.71[0.53,0.95]
Total events: 149 (ATG), 179 (Control)  
Heterogeneity: Tau2=0.05; Chi2=9.21, df=6(P=0.16); I2=34.87%  
Test for overall effect: Z=2.32(P=0.02)  
Test for subgroup differences: Chi2=2.74, df=1 (P=0.6), I2=0%  
Less with ATG 1000.01 100.1 1 Less with control
 
 
Analysis 1.3.   Comparison 1 ATG versus placebo/no treatment, Outcome 3 GraB loss (death censored).
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 At 1 to 2 years (+ CNI)  
Martins 2004 1/21 1/23 17.14% 1.1[0.07,16.43]
Yussim 2000 3/19 6/19 82.86% 0.5[0.15,1.71]
Subtotal (95% CI) 40 42 100% 0.57[0.19,1.75]
Total events: 4 (ATG), 7 (Control)  
Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%  
Test for overall effect: Z=0.98(P=0.33)  
   
1.3.2 At 1 to 2 years (no CNI)  
Chatterjee 1976 7/26 9/24 18.5% 0.72[0.32,1.63]
Khosroshahi 2008 0/31 1/37 1.23% 0.4[0.02,9.38]
Kountz 1977 11/28 20/26 48.2% 0.51[0.31,0.85]
Kreis 1980 5/22 12/21 16.91% 0.4[0.17,0.94]
Turcotte 1973 4/29 1/25 2.74% 3.45[0.41,28.87]
Wechter 1979 4/16 7/14 12.42% 0.5[0.18,1.36]
Subtotal (95% CI) 152 147 100% 0.55[0.38,0.78]
Total events: 31 (ATG), 50 (Control)  
Less with ATG 1000.01 100.1 1 Less with control
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Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=4.08, df=5(P=0.54); I2=0%  
Test for overall effect: Z=3.37(P=0)  
   
1.3.3 at 5 years (+ CNI)  
Samsel 1999 6/34 9/36 59.55% 0.71[0.28,1.77]
Sheashaa 2008 6/40 1/38 40.45% 5.7[0.72,45.17]
Subtotal (95% CI) 74 74 100% 1.64[0.2,13.18]
Total events: 12 (ATG), 10 (Control)  
Heterogeneity: Tau2=1.67; Chi2=3.51, df=1(P=0.06); I2=71.48%  
Test for overall effect: Z=0.47(P=0.64)  
   
1.3.4 At 1 to 2 years (all studies)  
Chatterjee 1976 7/26 9/24 16.85% 0.72[0.32,1.63]
Khosroshahi 2008 0/31 1/37 1.12% 0.4[0.02,9.38]
Kountz 1977 11/28 20/26 43.88% 0.51[0.31,0.85]
Kreis 1980 5/22 12/21 15.39% 0.4[0.17,0.94]
Martins 2004 1/21 1/23 1.53% 1.1[0.07,16.43]
Turcotte 1973 4/29 1/25 2.49% 3.45[0.41,28.87]
Wechter 1979 4/16 7/14 11.31% 0.5[0.18,1.36]
Yussim 2000 3/19 6/19 7.42% 0.5[0.15,1.71]
Subtotal (95% CI) 192 189 100% 0.55[0.39,0.77]
Total events: 35 (ATG), 57 (Control)  
Heterogeneity: Tau2=0; Chi2=4.35, df=7(P=0.74); I2=0%  
Test for overall effect: Z=3.51(P=0)  
Test for subgroup differences: Chi2=1.06, df=1 (P=0.79), I2=0%  
Less with ATG 1000.01 100.1 1 Less with control
 
 
Analysis 1.4.   Comparison 1 ATG versus placebo/no treatment, Outcome 4 Acute rejection.
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 At 1 to 2 years (+ CNI)  
Banhegyi 1991 20/55 42/60 8.05% 0.52[0.35,0.76]
Charpentier 2002 28/186 47/185 7.68% 0.59[0.39,0.9]
Kasiske 1997 21/49 14/45 6.44% 1.38[0.8,2.37]
Khosroshahi 2008 4/31 12/37 3.14% 0.4[0.14,1.11]
Martins 2004 7/22 6/23 3.64% 1.22[0.49,3.06]
Mourad 1998 23/151 48/158 7.43% 0.5[0.32,0.78]
Samsel 1999 9/40 14/39 4.97% 0.63[0.31,1.28]
Sheashaa 2008 9/40 26/40 5.73% 0.35[0.19,0.64]
Thibaudin 1998 18/47 27/42 7.62% 0.6[0.39,0.91]
TRIMS Study 2010 14/103 9/48 4.59% 0.72[0.34,1.56]
van den Hoogen 2013 6/28 7/24 3.52% 0.73[0.29,1.89]
Yussim 2000 5/19 11/19 4.07% 0.45[0.2,1.06]
Subtotal (95% CI) 771 720 66.88% 0.61[0.49,0.76]
Total events: 164 (ATG), 263 (Control)  
Heterogeneity: Tau2=0.05; Chi2=16.99, df=11(P=0.11); I2=35.26%  
Test for overall effect: Z=4.51(P<0.0001)  
   
Less with ATG 100.1 50.2 20.5 1 Less with control
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Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.2 At 1 to 2 years (no CNI)  
Cosimi 1976 120/176 120/169 10.4% 0.96[0.84,1.1]
Diethelm 1979 8/26 9/27 4.44% 0.92[0.42,2.02]
Kountz 1977 11/34 22/32 6.47% 0.47[0.27,0.81]
Kreis 1980 7/24 16/25 5.14% 0.46[0.23,0.91]
Wechter 1979 9/20 17/20 6.67% 0.53[0.32,0.89]
Subtotal (95% CI) 280 273 33.12% 0.65[0.43,0.98]
Total events: 155 (ATG), 184 (Control)  
Heterogeneity: Tau2=0.14; Chi2=14.7, df=4(P=0.01); I2=72.78%  
Test for overall effect: Z=2.06(P=0.04)  
   
Total (95% CI) 1051 993 100% 0.63[0.51,0.78]
Total events: 319 (ATG), 447 (Control)  
Heterogeneity: Tau2=0.11; Chi2=46.28, df=16(P<0.0001); I2=65.43%  
Test for overall effect: Z=4.24(P<0.0001)  
Test for subgroup differences: Chi2=0.07, df=1 (P=0.79), I2=0%  
Less with ATG 100.1 50.2 20.5 1 Less with control
 
 
Analysis 1.5.   Comparison 1 ATG versus placebo/no treatment, Outcome 5 Delayed graB function.
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Banhegyi 1991 24/55 26/60 16.28% 1.01[0.66,1.53]
Charpentier 2002 37/186 48/185 19.88% 0.77[0.53,1.12]
Kasiske 1997 14/50 17/50 8.17% 0.82[0.46,1.48]
Mourad 1998 27/151 38/158 14.62% 0.74[0.48,1.15]
Samsel 1999 18/40 20/39 13.42% 0.88[0.55,1.39]
Thibaudin 1998 13/47 14/42 7.14% 0.83[0.44,1.56]
TRIMS Study 2010 2/103 1/48 0.5% 0.93[0.09,10.03]
van den Hoogen 2013 22/28 13/24 16.38% 1.45[0.96,2.2]
Yussim 2000 7/19 6/19 3.61% 1.17[0.48,2.83]
   
Total (95% CI) 679 625 100% 0.93[0.78,1.1]
Total events: 164 (ATG), 183 (Control)  
Heterogeneity: Tau2=0; Chi2=7.45, df=8(P=0.49); I2=0%  
Test for overall effect: Z=0.88(P=0.38)  
Less with ATG 200.05 50.2 1 Less with control
 
 
Analysis 1.6.   Comparison 1 ATG versus placebo/no treatment, Outcome 6 Infection.
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 Any infection  
Charpentier 2002 126/186 108/185 40.73% 1.16[0.99,1.36]
Diethelm 1979 5/26 7/27 2.89% 0.74[0.27,2.04]
Samsel 1999 26/40 26/39 20.39% 0.98[0.71,1.34]
Sheashaa 2008 10/40 16/40 6.44% 0.63[0.32,1.21]
Less with ATG 100.1 50.2 20.5 1 Less with control
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Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
TRIMS Study 2010 41/103 22/48 15.37% 0.87[0.59,1.28]
van den Hoogen 2013 17/28 9/24 7.65% 1.62[0.89,2.94]
Yussim 2000 11/19 8/19 6.54% 1.38[0.72,2.64]
Subtotal (95% CI) 442 382 100% 1.05[0.88,1.26]
Total events: 236 (ATG), 196 (Control)  
Heterogeneity: Tau2=0.01; Chi2=7.97, df=6(P=0.24); I2=24.73%  
Test for overall effect: Z=0.58(P=0.56)  
   
1.6.2 CMV infection  
Charpentier 2002 45/186 29/185 29.33% 1.54[1.01,2.35]
Kasiske 1997 11/50 7/50 6.95% 1.57[0.66,3.72]
Mourad 1998 49/151 30/158 33.02% 1.71[1.15,2.54]
Thibaudin 1998 28/47 17/42 27.24% 1.47[0.95,2.28]
TRIMS Study 2010 3/103 2/48 1.68% 0.7[0.12,4.05]
van den Hoogen 2013 3/28 2/24 1.78% 1.29[0.23,7.07]
Subtotal (95% CI) 565 507 100% 1.55[1.24,1.95]
Total events: 139 (ATG), 87 (Control)  
Heterogeneity: Tau2=0; Chi2=1.13, df=5(P=0.95); I2=0%  
Test for overall effect: Z=3.79(P=0)  
   
1.6.3 Other viral infection (not CMV)  
Banhegyi 1991 11/55 12/60 30.41% 1[0.48,2.08]
Mourad 1998 27/151 9/158 30.58% 3.14[1.53,6.45]
Thibaudin 1998 2/47 2/42 14.78% 0.89[0.13,6.07]
TRIMS Study 2010 5/103 6/48 24.23% 0.39[0.12,1.21]
Subtotal (95% CI) 356 308 100% 1.11[0.43,2.87]
Total events: 45 (ATG), 29 (Control)  
Heterogeneity: Tau2=0.63; Chi2=10.8, df=3(P=0.01); I2=72.23%  
Test for overall effect: Z=0.21(P=0.83)  
   
1.6.4 Viral infection (all cause)  
Samsel 1999 12/40 5/39 40.28% 2.34[0.91,6.02]
Sheashaa 2008 5/40 8/40 37.25% 0.63[0.22,1.75]
Yussim 2000 4/19 2/19 22.48% 2[0.41,9.65]
Subtotal (95% CI) 99 98 100% 1.38[0.56,3.39]
Total events: 21 (ATG), 15 (Control)  
Heterogeneity: Tau2=0.29; Chi2=3.69, df=2(P=0.16); I2=45.85%  
Test for overall effect: Z=0.71(P=0.48)  
   
1.6.5 Bacterial infection  
Banhegyi 1991 23/55 19/60 13.05% 1.32[0.81,2.15]
Cantarovich 2008 76/186 70/185 47.99% 1.08[0.84,1.39]
Kreis 1980 19/24 17/25 26.84% 1.16[0.83,1.63]
Thibaudin 1998 6/47 5/42 2.49% 1.07[0.35,3.26]
TRIMS Study 2010 33/103 12/48 9.62% 1.28[0.73,2.25]
Subtotal (95% CI) 415 360 100% 1.15[0.96,1.37]
Total events: 157 (ATG), 123 (Control)  
Heterogeneity: Tau2=0; Chi2=0.71, df=4(P=0.95); I2=0%  
Test for overall effect: Z=1.56(P=0.12)  
Test for subgroup differences: Chi2=7.32, df=1 (P=0.12), I2=45.36%  
Less with ATG 100.1 50.2 20.5 1 Less with control
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Analysis 1.7.   Comparison 1 ATG versus placebo/no treatment, Outcome 7 Leucopenia.
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Charpentier 2002 72/186 16/185 41.75% 4.48[2.71,7.39]
Mourad 1998 57/151 15/158 38.44% 3.98[2.36,6.71]
Thibaudin 1998 20/47 7/42 18.54% 2.55[1.2,5.42]
TRIMS Study 2010 5/103 0/48 1.27% 5.18[0.29,91.87]
   
Total (95% CI) 487 433 100% 3.86[2.79,5.34]
Total events: 154 (ATG), 38 (Control)  
Heterogeneity: Tau2=0; Chi2=1.55, df=3(P=0.67); I2=0%  
Test for overall effect: Z=8.16(P<0.0001)  
Less with ATG 1000.01 100.1 1 Less with control
 
 
Analysis 1.8.   Comparison 1 ATG versus placebo/no treatment, Outcome 8 Thrombocytopenia.
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Charpentier 2002 22/186 6/185 21.14% 3.65[1.51,8.79]
Mourad 1998 17/151 5/158 17.31% 3.56[1.35,9.4]
Samsel 1999 17/40 9/39 35.67% 1.84[0.94,3.62]
Thibaudin 1998 15/47 7/42 25.88% 1.91[0.86,4.24]
   
Total (95% CI) 424 424 100% 2.41[1.61,3.61]
Total events: 71 (ATG), 27 (Control)  
Heterogeneity: Tau2=0; Chi2=2.49, df=3(P=0.48); I2=0%  
Test for overall effect: Z=4.26(P<0.0001)  
Less with ATG 100.1 50.2 20.5 1 Less with control
 
 
Analysis 1.9.   Comparison 1 ATG versus placebo/no treatment, Outcome 9 Malignancy or PTLD.
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.9.1 Malignancy at 1 to 2 years (+ CNI)  
Charpentier 2002 2/186 1/185 35.91% 1.99[0.18,21.75]
Thibaudin 1998 1/47 3/42 41.52% 0.3[0.03,2.76]
TRIMS Study 2010 2/103 0/48 22.57% 2.36[0.12,48.14]
Subtotal (95% CI) 336 275 100% 0.94[0.22,3.94]
Total events: 5 (ATG), 4 (Control)  
Heterogeneity: Tau2=0; Chi2=1.76, df=2(P=0.42); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
1.9.2 Malignancy at 5 years (+ CNI)  
Samsel 1999 1/40 0/39 35.65% 2.93[0.12,69.74]
Sheashaa 2008 1/40 2/40 64.35% 0.5[0.05,5.3]
Subtotal (95% CI) 80 79 100% 0.94[0.14,6.23]
Less with ATG 1000.01 100.1 1 Less with control
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Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 2 (ATG), 2 (Control)  
Heterogeneity: Tau2=0; Chi2=0.77, df=1(P=0.38); I2=0%  
Test for overall effect: Z=0.07(P=0.95)  
   
1.9.3 Malignancy at 1 to 2 years (no CNI)  
Chatterjee 1976 0/26 0/24   Not estimable
Turcotte 1973 0/36 0/35   Not estimable
Subtotal (95% CI) 62 59 Not estimable
Total events: 0 (ATG), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.9.4 PTLD at 1 to 2 years (+ CNI)  
TRIMS Study 2010 0/103 0/48   Not estimable
Subtotal (95% CI) 103 48 Not estimable
Total events: 0 (ATG), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=0, df=1 (P=1), I2=0%  
Less with ATG 1000.01 100.1 1 Less with control
 
 
Analysis 1.10.   Comparison 1 ATG versus placebo/no treatment, Outcome 10 Other adverse outcomes.
Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.10.1 NODAT  
Charpentier 2002 13/177 7/173 22.09% 1.82[0.74,4.44]
Mourad 1998 5/145 7/154 17.16% 0.76[0.25,2.34]
Sheashaa 2008 4/40 7/40 16.75% 0.57[0.18,1.8]
TRIMS Study 2010 6/76 6/38 18.37% 0.5[0.17,1.45]
van den Hoogen 2013 12/28 4/24 19.85% 2.57[0.95,6.93]
Wechter 1979 1/20 2/20 5.78% 0.5[0.05,5.08]
Subtotal (95% CI) 486 449 100% 1.01[0.56,1.84]
Total events: 41 (ATG), 33 (Control)  
Heterogeneity: Tau2=0.21; Chi2=8.24, df=5(P=0.14); I2=39.3%  
Test for overall effect: Z=0.03(P=0.97)  
   
1.10.2 Serum sickness  
Charpentier 2002 30/186 0/185 100% 60.67[3.74,984.93]
Subtotal (95% CI) 186 185 100% 60.67[3.74,984.93]
Total events: 30 (ATG), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.89(P=0)  
   
1.10.3 Tremor  
Charpentier 2002 14/186 15/185 100% 0.93[0.46,1.87]
Subtotal (95% CI) 186 185 100% 0.93[0.46,1.87]
Total events: 14 (ATG), 15 (Control)  
Heterogeneity: Not applicable  
Less with ATG 10000.001 100.1 1 Less with control
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Study or subgroup ATG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.21(P=0.83)  
Test for subgroup differences: Chi2=8.25, df=1 (P=0.02), I2=75.77%  
Less with ATG 10000.001 100.1 1 Less with control
 
 
Analysis 1.11.   Comparison 1 ATG versus placebo/no treatment, Outcome 11 Serum creatinine.
Study or subgroup ATG Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.11.1 At 6 months (+ CNI)  
Charpentier 2002 179 132.5 (39) 175 134 (68.7) 48.09% -1.5[-13.17,10.17]
TRIMS Study 2010 101 114.9 (34.5) 48 123.8 (31.8) 51.91% -8.9[-20.13,2.33]
Subtotal *** 280   223   100% -5.34[-13.44,2.75]
Heterogeneity: Tau2=0; Chi2=0.8, df=1(P=0.37); I2=0%  
Test for overall effect: Z=1.29(P=0.2)  
   
1.11.2 At 1 year (+ CNI)  
Thibaudin 1998 42 146 (56) 32 168 (77) 12.68% -22[-53.6,9.6]
TRIMS Study 2010 101 114.9 (35.4) 47 123.8 (34.5) 87.32% -8.9[-20.94,3.14]
Subtotal *** 143   79   100% -10.56[-21.81,0.69]
Heterogeneity: Tau2=0; Chi2=0.58, df=1(P=0.45); I2=0%  
Test for overall effect: Z=1.84(P=0.07)  
   
1.11.3 At 1 year: LD recipients (no CNI)  
Turcotte 1973 17 153.8 (50.4) 13 163.5 (96.4) 100% -9.7[-67.32,47.92]
Subtotal *** 17   13   100% -9.7[-67.32,47.92]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
   
1.11.4 At 1 year: DD recipients (no CNI)  
Turcotte 1973 8 122 (25.6) 11 145 (60.1) 100% -23[-62.7,16.7]
Subtotal *** 8   11   100% -23[-62.7,16.7]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.26)  
   
1.11.5 At 5 years (+ CNI)  
Samsel 1999 28 145.9 (40.7) 27 178.6 (87.5) 100% -32.7[-68.98,3.58]
Subtotal *** 28   27   100% -32.7[-68.98,3.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.77(P=0.08)  
Test for subgroup differences: Chi2=2.93, df=1 (P=0.57), I2=0%  
Lower with ATG 10050-100 -50 0 Lower with control
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Comparison 2.   Rabbit ATG versus horse ATG
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Main outcomes 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death at 1 year 2 139 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.07, 2.30]
1.2 Death at 10 years 1 72 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.35, 1.59]
1.3 GraB loss (all cause) at 1 year 2 139 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.08, 1.27]
1.4 GraB loss (all cause) at 10 years 1 72 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.58, 1.58]
1.5 Acute rejection at 1 month 1 16 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.6 Acute rejection at 1 year 1 72 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.04, 0.76]
1.7 Delayed graB function 1 16 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.06, 4.47]
2 Other adverse outcomes 3   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Infection (all cause) 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 CMV disease at 1 year 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Leucopenia 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Malignancy at 10 years 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Headache 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Serum creatinine 1   Mean Difference (IV, Random, 95%
CI)
Totals not selected
3.1 At 6 months 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
3.2 At 10 years 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Rabbit ATG versus horse ATG, Outcome 1 Main outcomes.
Study or subgroup rATG hATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 Death at 1 year  
Bock 1999 1/32 3/35 60.34% 0.36[0.04,3.33]
Brennan 1999 1/48 1/24 39.66% 0.5[0.03,7.65]
Subtotal (95% CI) 80 59 100% 0.41[0.07,2.3]
Total events: 2 (rATG), 4 (hATG)  
Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.86); I2=0%  
Less with rATG 1000.01 100.1 1 Less with hATG
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Study or subgroup rATG hATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.01(P=0.31)  
   
2.1.2 Death at 10 years  
Brennan 1999 12/48 8/24 100% 0.75[0.35,1.59]
Subtotal (95% CI) 48 24 100% 0.75[0.35,1.59]
Total events: 12 (rATG), 8 (hATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.75(P=0.45)  
   
2.1.3 GraB loss (all cause) at 1 year  
Bock 1999 2/32 4/35 61.35% 0.55[0.11,2.79]
Brennan 1999 1/48 4/24 38.65% 0.13[0.01,1.06]
Subtotal (95% CI) 80 59 100% 0.31[0.08,1.27]
Total events: 3 (rATG), 8 (hATG)  
Heterogeneity: Tau2=0.16; Chi2=1.17, df=1(P=0.28); I2=14.3%  
Test for overall effect: Z=1.63(P=0.1)  
   
2.1.4 GraB loss (all cause) at 10 years  
Brennan 1999 23/48 12/24 100% 0.96[0.58,1.58]
Subtotal (95% CI) 48 24 100% 0.96[0.58,1.58]
Total events: 23 (rATG), 12 (hATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.17(P=0.87)  
   
2.1.5 Acute rejection at 1 month  
Rostaing 2010 0/8 0/8   Not estimable
Subtotal (95% CI) 8 8 Not estimable
Total events: 0 (rATG), 0 (hATG)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.1.6 Acute rejection at 1 year  
Brennan 1999 2/48 6/24 100% 0.17[0.04,0.76]
Subtotal (95% CI) 48 24 100% 0.17[0.04,0.76]
Total events: 2 (rATG), 6 (hATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.31(P=0.02)  
   
2.1.7 Delayed graB function  
Rostaing 2010 1/8 2/8 100% 0.5[0.06,4.47]
Subtotal (95% CI) 8 8 100% 0.5[0.06,4.47]
Total events: 1 (rATG), 2 (hATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.62(P=0.54)  
Test for subgroup differences: Chi2=6.71, df=1 (P=0.24), I2=25.44%  
Less with rATG 1000.01 100.1 1 Less with hATG
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Analysis 2.2.   Comparison 2 Rabbit ATG versus horse ATG, Outcome 2 Other adverse outcomes.
Study or subgroup rATG hATG Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
2.2.1 Infection (all cause)  
Rostaing 2010 5/8 3/8 1.67[0.59,4.73]
   
2.2.2 CMV disease at 1 year  
Brennan 1999 6/48 8/24 0.38[0.15,0.96]
   
2.2.3 Leucopenia  
Brennan 1999 27/48 1/24 13.5[1.95,93.46]
   
2.2.4 Malignancy at 10 years  
Brennan 1999 4/48 5/24 0.4[0.12,1.35]
   
2.2.5 Headache  
Bock 1999 15/32 7/35 2.34[1.1,5]
Less with rATG 1000.01 100.1 1 Less with hATG
 
 
Analysis 2.3.   Comparison 2 Rabbit ATG versus horse ATG, Outcome 3 Serum creatinine.
Study or subgroup rATG hATG Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
2.3.1 At 6 months  
Brennan 1999 47 141 (35) 21 133 (35) 8[-10.01,26.01]
   
2.3.2 At 10 years  
Brennan 1999 23 150 (44) 12 106 (27) 44[20.41,67.59]
Lower with rATG 10050-100 -50 0 Lower with hATG
 
 
Comparison 3.   Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death and graB loss 6   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Death at 1 year 2 41 Risk Ratio (M-H, Random,
95% CI)
0.39 [0.06, 2.42]
1.2 Death at 2 to 3 years 3 225 Risk Ratio (M-H, Random,
95% CI)
0.67 [0.15, 2.95]
1.3 GraB loss (all cause) at 1 year 2 41 Risk Ratio (M-H, Random,
95% CI)
0.39 [0.12, 1.30]
1.4 GraB loss (all cause) at 2 to 3 years 3 379 Risk Ratio (M-H, Random,
95% CI)
0.98 [0.47, 2.06]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.5 GraB loss (death censored) at 1 year 2 37 Risk Ratio (M-H, Random,
95% CI)
0.38 [0.08, 1.81]
1.6 GraB loss (death censored) at 2 to 3 years 2 186 Risk Ratio (M-H, Random,
95% CI)
2.45 [0.67, 8.97]
1.7 Delayed graB function 2 86 Risk Ratio (M-H, Random,
95% CI)
0.62 [0.13, 3.07]
2 Rejection 6   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Acute rejection at 3 to 6 months (ESW
both arms)
3 341 Risk Ratio (M-H, Random,
95% CI)
0.47 [0.17, 1.30]
2.2 Acute rejection ≥ 1 year (all studies) 6 446 Risk Ratio (M-H, Random,
95% CI)
0.68 [0.44, 1.05]
2.3 Acute rejection ≥ 1 year (ESW both arms) 4 360 Risk Ratio (M-H, Random,
95% CI)
0.57 [0.35, 0.93]
2.4 Acute rejection ≥ 1 year (ESW with alem-
tuzumab only)
2 86 Risk Ratio (M-H, Random,
95% CI)
1.27 [0.50, 3.19]
2.5 CAN (biopsy proven) (ESW with alem-
tuzumab only)
2 86 Risk Ratio (M-H, Random,
95% CI)
2.45 [1.02, 5.94]
3 Infection 4   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 All cause (moderate-severe) 4 247 Risk Ratio (M-H, Random,
95% CI)
0.94 [0.63, 1.41]
3.2 CMV infection 3 225 Risk Ratio (M-H, Random,
95% CI)
1.08 [0.46, 2.56]
3.3 BK virus infection 2 86 Risk Ratio (M-H, Random,
95% CI)
3.0 [0.13, 70.83]
4 Other adverse effects 4   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
4.1 Leucopenia at 1 month 1 60 Risk Ratio (M-H, Random,
95% CI)
21.0 [1.29, 342.93]
4.2 Leucopenia at 2 years 1 53 Risk Ratio (M-H, Random,
95% CI)
3.12 [0.35, 28.06]
4.3 NODAT 2 69 Risk Ratio (M-H, Random,
95% CI)
0.41 [0.12, 1.40]
4.4 Malignancy 3 187 Risk Ratio (M-H, Random,
95% CI)
4.93 [0.59, 41.11]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.5 PTLD 2 165 Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
4.6 Cytokine release syndrome 1 22 Risk Ratio (M-H, Random,
95% CI)
0.2 [0.01, 3.74]
4.7 Any serious adverse event 1 139 Risk Ratio (M-H, Random,
95% CI)
0.81 [0.59, 1.12]
5 Creatinine clearance 2   Mean Difference (IV, Random,
95% CI)
Subtotals only
5.1 At 6 months 2 83 Mean Difference (IV, Random,
95% CI)
-13.35 [-23.91, -2.80]
5.2 At 24 months 2 77 Mean Difference (IV, Random,
95% CI)
-12.86 [-23.73, -2.00]
 
 
Analysis 3.1.   Comparison 3 Alemtuzumab + early steroid withdrawal
(ESW) or minimisation versus ATG ± ESW, Outcome 1 Death and graB loss.
Study or subgroup Alemtuzumab ATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 Death at 1 year  
Lu 2011 1/11 2/11 65.22% 0.5[0.05,4.75]
Thomas 2007 0/11 1/8 34.78% 0.25[0.01,5.45]
Subtotal (95% CI) 22 19 100% 0.39[0.06,2.42]
Total events: 1 (Alemtuzumab), 3 (ATG)  
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=1.01(P=0.31)  
   
3.1.2 Death at 2 to 3 years  
Ciancio 2005 3/30 3/30 48.41% 1[0.22,4.56]
Ciancio 2010 1/13 0/13 18.37% 3[0.13,67.51]
Hanaway 2011 1/70 6/69 33.22% 0.16[0.02,1.33]
Subtotal (95% CI) 113 112 100% 0.67[0.15,2.95]
Total events: 5 (Alemtuzumab), 9 (ATG)  
Heterogeneity: Tau2=0.58; Chi2=2.97, df=2(P=0.23); I2=32.66%  
Test for overall effect: Z=0.53(P=0.6)  
   
3.1.3 GraB loss (all cause) at 1 year  
Lu 2011 2/11 4/11 66.29% 0.5[0.11,2.19]
Thomas 2007 1/11 3/8 33.71% 0.24[0.03,1.92]
Subtotal (95% CI) 22 19 100% 0.39[0.12,1.3]
Total events: 3 (Alemtuzumab), 7 (ATG)  
Heterogeneity: Tau2=0; Chi2=0.31, df=1(P=0.58); I2=0%  
Test for overall effect: Z=1.53(P=0.13)  
   
Less with alemtuzumab 1000.01 100.1 1 Less with ATG
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Study or subgroup Alemtuzumab ATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.4 GraB loss (all cause) at 2 to 3 years  
Ciancio 2005 9/30 4/30 30.16% 2.25[0.78,6.52]
Farney 2008 7/85 11/95 36.51% 0.71[0.29,1.75]
Hanaway 2011 6/70 9/69 33.33% 0.66[0.25,1.75]
Subtotal (95% CI) 185 194 100% 0.98[0.47,2.06]
Total events: 22 (Alemtuzumab), 24 (ATG)  
Heterogeneity: Tau2=0.18; Chi2=3.47, df=2(P=0.18); I2=42.3%  
Test for overall effect: Z=0.05(P=0.96)  
   
3.1.5 GraB loss (death censored) at 1 year  
Lu 2011 1/10 2/9 49.56% 0.45[0.05,4.16]
Thomas 2007 1/11 2/7 50.44% 0.32[0.04,2.89]
Subtotal (95% CI) 21 16 100% 0.38[0.08,1.81]
Total events: 2 (Alemtuzumab), 4 (ATG)  
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%  
Test for overall effect: Z=1.22(P=0.22)  
   
3.1.6 GraB loss (death censored) at 2 to 3 years  
Ciancio 2005 6/27 1/27 34.75% 6[0.77,46.55]
Hanaway 2011 5/69 3/63 65.25% 1.52[0.38,6.11]
Subtotal (95% CI) 96 90 100% 2.45[0.67,8.97]
Total events: 11 (Alemtuzumab), 4 (ATG)  
Heterogeneity: Tau2=0.17; Chi2=1.21, df=1(P=0.27); I2=17.46%  
Test for overall effect: Z=1.35(P=0.18)  
   
3.1.7 Delayed graB function  
Ciancio 2005 2/30 2/30 70.75% 1[0.15,6.64]
Ciancio 2010 0/13 2/13 29.25% 0.2[0.01,3.8]
Subtotal (95% CI) 43 43 100% 0.62[0.13,3.07]
Total events: 2 (Alemtuzumab), 4 (ATG)  
Heterogeneity: Tau2=0; Chi2=0.83, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.58(P=0.56)  
Test for subgroup differences: Chi2=6.1, df=1 (P=0.41), I2=1.58%  
Less with alemtuzumab 1000.01 100.1 1 Less with ATG
 
 
Analysis 3.2.   Comparison 3 Alemtuzumab + early steroid withdrawal
(ESW) or minimisation versus ATG ± ESW, Outcome 2 Rejection.
Study or subgroup Alemtuzumab ATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 Acute rejection at 3 to 6 months (ESW both arms)  
Farney 2008 2/85 13/95 33.21% 0.17[0.04,0.74]
Hanaway 2011 4/70 6/69 41.65% 0.66[0.19,2.23]
Lu 2011 2/11 2/11 25.15% 1[0.17,5.89]
Subtotal (95% CI) 166 175 100% 0.47[0.17,1.3]
Total events: 8 (Alemtuzumab), 21 (ATG)  
Heterogeneity: Tau2=0.27; Chi2=2.96, df=2(P=0.23); I2=32.36%  
Test for overall effect: Z=1.45(P=0.15)  
   
Less with alemtuzumab 2000.005 100.1 1 Less with ATG
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Study or subgroup Alemtuzumab ATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.2 Acute rejection ≥ 1 year (all studies)  
Ciancio 2005 7/30 6/30 20.22% 1.17[0.44,3.06]
Ciancio 2010 1/13 0/13 1.95% 3[0.13,67.51]
Farney 2008 10/85 23/95 40.53% 0.49[0.25,0.96]
Hanaway 2011 7/70 9/69 21.81% 0.77[0.3,1.94]
Lu 2011 2/11 3/11 7.54% 0.67[0.14,3.24]
Thomas 2007 2/11 3/8 7.95% 0.48[0.1,2.26]
Subtotal (95% CI) 220 226 100% 0.68[0.44,1.05]
Total events: 29 (Alemtuzumab), 44 (ATG)  
Heterogeneity: Tau2=0; Chi2=3.25, df=5(P=0.66); I2=0%  
Test for overall effect: Z=1.74(P=0.08)  
   
3.2.3 Acute rejection ≥ 1 year (ESW both arms)  
Farney 2008 10/85 23/95 52.07% 0.49[0.25,0.96]
Hanaway 2011 7/70 9/69 28.02% 0.77[0.3,1.94]
Lu 2011 2/11 3/11 9.69% 0.67[0.14,3.24]
Thomas 2007 2/11 3/8 10.22% 0.48[0.1,2.26]
Subtotal (95% CI) 177 183 100% 0.57[0.35,0.93]
Total events: 21 (Alemtuzumab), 38 (ATG)  
Heterogeneity: Tau2=0; Chi2=0.68, df=3(P=0.88); I2=0%  
Test for overall effect: Z=2.24(P=0.02)  
   
3.2.4 Acute rejection ≥ 1 year (ESW with alemtuzumab only)  
Ciancio 2005 7/30 6/30 91.22% 1.17[0.44,3.06]
Ciancio 2010 1/13 0/13 8.78% 3[0.13,67.51]
Subtotal (95% CI) 43 43 100% 1.27[0.5,3.19]
Total events: 8 (Alemtuzumab), 6 (ATG)  
Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.57); I2=0%  
Test for overall effect: Z=0.5(P=0.61)  
   
3.2.5 CAN (biopsy proven) (ESW with alemtuzumab only)  
Ciancio 2005 11/30 5/30 90.53% 2.2[0.87,5.57]
Ciancio 2010 3/13 0/13 9.47% 7[0.4,123.35]
Subtotal (95% CI) 43 43 100% 2.45[1.02,5.94]
Total events: 14 (Alemtuzumab), 5 (ATG)  
Heterogeneity: Tau2=0; Chi2=0.59, df=1(P=0.44); I2=0%  
Test for overall effect: Z=1.99(P=0.05)  
Test for subgroup differences: Chi2=10.39, df=1 (P=0.03), I2=61.49%  
Less with alemtuzumab 2000.005 100.1 1 Less with ATG
 
 
Analysis 3.3.   Comparison 3 Alemtuzumab + early steroid withdrawal
(ESW) or minimisation versus ATG ± ESW, Outcome 3 Infection.
Study or subgroup Alemtuzumab ATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 All cause (moderate-severe)  
Ciancio 2005 8/30 8/30 23.07% 1[0.43,2.31]
Ciancio 2010 3/13 1/13 3.59% 3[0.36,25.21]
Hanaway 2011 19/70 23/69 62.81% 0.81[0.49,1.35]
Less with alemtuzumab 1000.01 100.1 1 Less with ATG
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Study or subgroup Alemtuzumab ATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Lu 2011 4/11 3/11 10.53% 1.33[0.39,4.62]
Subtotal (95% CI) 124 123 100% 0.94[0.63,1.41]
Total events: 34 (Alemtuzumab), 35 (ATG)  
Heterogeneity: Tau2=0; Chi2=1.78, df=3(P=0.62); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
   
3.3.2 CMV infection  
Ciancio 2005 2/30 1/30 13.37% 2[0.19,20.9]
Ciancio 2010 0/13 0/13   Not estimable
Hanaway 2011 8/70 8/69 86.63% 0.99[0.39,2.48]
Subtotal (95% CI) 113 112 100% 1.08[0.46,2.56]
Total events: 10 (Alemtuzumab), 9 (ATG)  
Heterogeneity: Tau2=0; Chi2=0.3, df=1(P=0.58); I2=0%  
Test for overall effect: Z=0.18(P=0.85)  
   
3.3.3 BK virus infection  
Ciancio 2005 1/30 0/30 100% 3[0.13,70.83]
Ciancio 2010 0/13 0/13   Not estimable
Subtotal (95% CI) 43 43 100% 3[0.13,70.83]
Total events: 1 (Alemtuzumab), 0 (ATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
Test for subgroup differences: Chi2=0.57, df=1 (P=0.75), I2=0%  
Less with alemtuzumab 1000.01 100.1 1 Less with ATG
 
 
Analysis 3.4.   Comparison 3 Alemtuzumab + early steroid withdrawal
(ESW) or minimisation versus ATG ± ESW, Outcome 4 Other adverse e>ects.
Study or subgroup Alemtuzumab ATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.4.1 Leucopenia at 1 month  
Ciancio 2005 10/30 0/30 100% 21[1.29,342.93]
Subtotal (95% CI) 30 30 100% 21[1.29,342.93]
Total events: 10 (Alemtuzumab), 0 (ATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.14(P=0.03)  
   
3.4.2 Leucopenia at 2 years  
Ciancio 2005 3/26 1/27 100% 3.12[0.35,28.06]
Subtotal (95% CI) 26 27 100% 3.12[0.35,28.06]
Total events: 3 (Alemtuzumab), 1 (ATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
   
3.4.3 NODAT  
Ciancio 2005 2/18 6/27 67% 0.5[0.11,2.21]
Ciancio 2010 1/13 3/11 33% 0.28[0.03,2.34]
Subtotal (95% CI) 31 38 100% 0.41[0.12,1.4]
Total events: 3 (Alemtuzumab), 9 (ATG)  
Less with alemtuzumab 5000.002 100.1 1 Less with ATG
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Study or subgroup Alemtuzumab ATG Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.66); I2=0%  
Test for overall effect: Z=1.42(P=0.15)  
   
3.4.4 Malignancy  
Ciancio 2010 0/13 0/13   Not estimable
Hanaway 2011 5/70 1/69 100% 4.93[0.59,41.11]
Lu 2011 0/11 0/11   Not estimable
Subtotal (95% CI) 94 93 100% 4.93[0.59,41.11]
Total events: 5 (Alemtuzumab), 1 (ATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.47(P=0.14)  
   
3.4.5 PTLD  
Ciancio 2010 0/13 0/13   Not estimable
Hanaway 2011 0/70 0/69   Not estimable
Subtotal (95% CI) 83 82 Not estimable
Total events: 0 (Alemtuzumab), 0 (ATG)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
3.4.6 Cytokine release syndrome  
Lu 2011 0/11 2/11 100% 0.2[0.01,3.74]
Subtotal (95% CI) 11 11 100% 0.2[0.01,3.74]
Total events: 0 (Alemtuzumab), 2 (ATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
   
3.4.7 Any serious adverse event  
Hanaway 2011 33/70 40/69 100% 0.81[0.59,1.12]
Subtotal (95% CI) 70 69 100% 0.81[0.59,1.12]
Total events: 33 (Alemtuzumab), 40 (ATG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
Test for subgroup differences: Chi2=11.4, df=1 (P=0.04), I2=56.14%  
Less with alemtuzumab 5000.002 100.1 1 Less with ATG
 
 
Analysis 3.5.   Comparison 3 Alemtuzumab + early steroid withdrawal
(ESW) or minimisation versus ATG ± ESW, Outcome 5 Creatinine clearance.
Study or subgroup Alemtuzumab ATG Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.5.1 At 6 months  
Ciancio 2005 29 64.7 (26.4) 28 78.4 (27.5) 56.87% -13.7[-27.7,0.3]
Ciancio 2010 13 69.9 (14.1) 13 82.8 (26) 43.13% -12.9[-28.98,3.18]
Subtotal *** 42   41   100% -13.35[-23.91,-2.8]
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%  
Test for overall effect: Z=2.48(P=0.01)  
   
3.5.2 At 24 months  
Higher with ATG 5025-50 -25 0 Higher with alemtuzumab
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Study or subgroup Alemtuzumab ATG Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Ciancio 2005 26 64.4 (22.9) 27 81.1 (28.6) 60.86% -16.7[-30.62,-2.78]
Ciancio 2010 12 72.7 (16.3) 12 79.6 (26) 39.14% -6.9[-24.26,10.46]
Subtotal *** 38   39   100% -12.86[-23.73,-2]
Heterogeneity: Tau2=0; Chi2=0.74, df=1(P=0.39); I2=0%  
Test for overall effect: Z=2.32(P=0.02)  
Test for subgroup differences: Chi2=0, df=1 (P=0.95), I2=0%  
Higher with ATG 5025-50 -25 0 Higher with alemtuzumab
 
 
Comparison 4.   Alemtuzumab + early steroid withdrawal (ESW) versus no induction
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Main outcomes 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death at 6 to 12 months 4 296 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.60, 4.00]
1.2 GraB loss (all cause) at 6 to 12
months
4 296 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.47, 1.59]
1.3 Acute rejection at 6 months 3 213 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.48, 1.08]
1.4 Acute rejection ≥ 1 year 3 244 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.42, 1.87]
1.5 Delayed graB function 1 30 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.26, 15.62]
2 Other adverse outcomes 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 CMV infection 2 161 Risk Ratio (M-H, Random, 95% CI) 2.28 [1.18, 4.40]
2.2 Infection (all cause) 3 213 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.46, 2.89]
2.3 NODAT 2 161 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.13, 2.46]
2.4 Thrombocytopenia 1 30 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.45, 3.96]
2.5 Malignancy or PTLD 1 30 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Serum creatinine 3   Mean Difference (IV, Random, 95%
CI)
Subtotals only
3.1 6 months 1 27 Mean Difference (IV, Random, 95%
CI)
-5.0 [-28.90, 18.90]
3.2 1 year 2 108 Mean Difference (IV, Random, 95%
CI)
-2.89 [-43.29, 37.52]
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Analysis 4.1.   Comparison 4 Alemtuzumab + early steroid
withdrawal (ESW) versus no induction, Outcome 1 Main outcomes.
Study or subgroup Alemtuzumab Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Death at 6 to 12 months  
CAMPASIA Study 2005 1/20 0/10 9.33% 1.57[0.07,35.46]
Friend 1987 5/26 2/26 37.84% 2.5[0.53,11.74]
Margreiter 2008 1/65 1/66 11.97% 1.02[0.06,15.89]
Sharaf El Din 2006 7/63 2/20 40.86% 1.11[0.25,4.92]
Subtotal (95% CI) 174 122 100% 1.54[0.6,4]
Total events: 14 (Alemtuzumab), 5 (Control)  
Heterogeneity: Tau2=0; Chi2=0.65, df=3(P=0.88); I2=0%  
Test for overall effect: Z=0.89(P=0.37)  
   
4.1.2 GraB loss (all cause) at 6 to 12 months  
CAMPASIA Study 2005 3/20 0/10 4.49% 3.67[0.21,64.8]
Friend 1987 8/26 8/26 55.75% 1[0.44,2.26]
Margreiter 2008 2/65 6/66 15.17% 0.34[0.07,1.62]
Sharaf El Din 2006 8/63 3/20 24.59% 0.85[0.25,2.89]
Subtotal (95% CI) 174 122 100% 0.86[0.47,1.59]
Total events: 21 (Alemtuzumab), 17 (Control)  
Heterogeneity: Tau2=0; Chi2=2.48, df=3(P=0.48); I2=0%  
Test for overall effect: Z=0.47(P=0.64)  
   
4.1.3 Acute rejection at 6 months  
CAMPASIA Study 2005 5/20 2/10 7.67% 1.25[0.29,5.35]
Friend 1987 12/26 15/26 57.76% 0.8[0.47,1.36]
Margreiter 2008 10/65 19/66 34.57% 0.53[0.27,1.06]
Subtotal (95% CI) 111 102 100% 0.72[0.48,1.08]
Total events: 27 (Alemtuzumab), 36 (Control)  
Heterogeneity: Tau2=0; Chi2=1.46, df=2(P=0.48); I2=0%  
Test for overall effect: Z=1.6(P=0.11)  
   
4.1.4 Acute rejection ≥ 1 year  
CAMPASIA Study 2005 9/20 2/10 23.59% 2.25[0.59,8.52]
Margreiter 2008 13/65 21/66 57.98% 0.63[0.34,1.15]
Sharaf El Din 2006 5/63 2/20 18.43% 0.79[0.17,3.78]
Subtotal (95% CI) 148 96 100% 0.89[0.42,1.87]
Total events: 27 (Alemtuzumab), 25 (Control)  
Heterogeneity: Tau2=0.16; Chi2=2.95, df=2(P=0.23); I2=32.17%  
Test for overall effect: Z=0.32(P=0.75)  
   
4.1.5 Delayed graB function  
CAMPASIA Study 2005 4/20 1/10 100% 2[0.26,15.62]
Subtotal (95% CI) 20 10 100% 2[0.26,15.62]
Total events: 4 (Alemtuzumab), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Test for subgroup differences: Chi2=2.84, df=1 (P=0.59), I2=0%  
Less with alemtuzumab 1000.01 100.1 1 Favours control
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Analysis 4.2.   Comparison 4 Alemtuzumab + early steroid withdrawal
(ESW) versus no induction, Outcome 2 Other adverse outcomes.
Study or subgroup Alemtuzumab Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.2.1 CMV infection  
CAMPASIA Study 2005 9/20 2/10 24.55% 2.25[0.59,8.52]
Margreiter 2008 18/65 8/66 75.45% 2.28[1.07,4.88]
Subtotal (95% CI) 85 76 100% 2.28[1.18,4.4]
Total events: 27 (Alemtuzumab), 10 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Test for overall effect: Z=2.44(P=0.01)  
   
4.2.2 Infection (all cause)  
CAMPASIA Study 2005 8/20 3/10 28.49% 1.33[0.45,3.96]
Friend 1987 10/26 4/26 29.84% 2.5[0.9,6.96]
Margreiter 2008 17/65 29/66 41.67% 0.6[0.36,0.97]
Subtotal (95% CI) 111 102 100% 1.15[0.46,2.89]
Total events: 35 (Alemtuzumab), 36 (Control)  
Heterogeneity: Tau2=0.47; Chi2=6.99, df=2(P=0.03); I2=71.4%  
Test for overall effect: Z=0.3(P=0.77)  
   
4.2.3 NODAT  
CAMPASIA Study 2005 1/20 2/10 41.8% 0.25[0.03,2.44]
Margreiter 2008 2/65 2/66 58.2% 1.02[0.15,6.99]
Subtotal (95% CI) 85 76 100% 0.57[0.13,2.46]
Total events: 3 (Alemtuzumab), 4 (Control)  
Heterogeneity: Tau2=0; Chi2=0.85, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.76(P=0.45)  
   
4.2.4 Thrombocytopenia  
CAMPASIA Study 2005 8/20 3/10 100% 1.33[0.45,3.96]
Subtotal (95% CI) 20 10 100% 1.33[0.45,3.96]
Total events: 8 (Alemtuzumab), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.52(P=0.6)  
   
4.2.5 Malignancy or PTLD  
CAMPASIA Study 2005 0/20 0/10   Not estimable
Subtotal (95% CI) 20 10 Not estimable
Total events: 0 (Alemtuzumab), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=3.58, df=1 (P=0.31), I2=16.26%  
Less with alemtuzumab 1000.01 100.1 1 Less with control
 
 
Analysis 4.3.   Comparison 4 Alemtuzumab + early steroid
withdrawal (ESW) versus no induction, Outcome 3 Serum creatinine.
Study or subgroup Alemtuzumab Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.3.1 6 months  
Lower with alemtuzumab 10050-100 -50 0 Lower with control
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Study or subgroup Alemtuzumab Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
CAMPASIA Study 2005 17 126 (26) 10 131 (33) 100% -5[-28.9,18.9]
Subtotal *** 17   10   100% -5[-28.9,18.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
   
4.3.2 1 year  
Friend 1987 18 165 (78) 18 168 (78) 62.87% -3[-53.96,47.96]
Sharaf El Din 2006 55 130.8
(137.7)
17 133.5
(116.6)
37.13% -2.7[-69.01,63.61]
Subtotal *** 73   35   100% -2.89[-43.29,37.52]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=0.14(P=0.89)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.93), I2=0%  
Lower with alemtuzumab 10050-100 -50 0 Lower with control
 
 
Comparison 5.   Rituximab versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Main outcomes 3   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 Death at 6 months 3 447 Risk Ratio (M-H, Random, 95%
CI)
0.55 [0.18, 1.71]
1.2 Death at 3 to 4 years 2 381 Risk Ratio (M-H, Random, 95%
CI)
2.06 [0.27, 15.64]
1.3 GraB loss (all cause) at 6 months 2 416 Risk Ratio (M-H, Random, 95%
CI)
0.58 [0.26, 1.28]
1.4 GraB loss (death censored) at 6 months 2 405 Risk Ratio (M-H, Random, 95%
CI)
0.55 [0.21, 1.46]
1.5 Acute rejection at 6 months 3 447 Risk Ratio (M-H, Random, 95%
CI)
0.73 [0.48, 1.10]
1.6 Delayed graB function 1 280 Risk Ratio (M-H, Random, 95%
CI)
1.07 [0.65, 1.76]
2 Other adverse outcomes 3   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 CMV infection 2 416 Risk Ratio (M-H, Random, 95%
CI)
1.36 [0.75, 2.47]
2.2 BK virus infection 1 136 Risk Ratio (M-H, Random, 95%
CI)
0.25 [0.03, 2.18]
2.3 Fungal infection at 6 months 3 447 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.50, 1.27]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.4 Leucopenia at 6 months 2 416 Risk Ratio (M-H, Random, 95%
CI)
8.15 [2.00, 33.15]
2.5 Malignancy at 2 years 1 280 Risk Ratio (M-H, Random, 95%
CI)
1.03 [0.40, 2.66]
3 GraB function at 6 months (eGFR) 2 388 Mean Difference (IV, Random,
95% CI)
0.32 [-3.34, 3.97]
 
 
Analysis 5.1.   Comparison 5 Rituximab versus placebo, Outcome 1 Main outcomes.
Study or subgroup Rituximab Placebo/no
induction
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.1.1 Death at 6 months  
Smeekens 2013 3/138 6/142 69.57% 0.51[0.13,2.02]
Tsai 2012 0/15 1/16 13.28% 0.35[0.02,8.08]
Tyden 2009 1/68 1/68 17.15% 1[0.06,15.66]
Subtotal (95% CI) 221 226 100% 0.55[0.18,1.71]
Total events: 4 (Rituximab), 8 (Placebo/no induction)  
Heterogeneity: Tau2=0; Chi2=0.27, df=2(P=0.88); I2=0%  
Test for overall effect: Z=1.03(P=0.3)  
   
5.1.2 Death at 3 to 4 years  
Smeekens 2013 18/138 20/142 61.06% 0.93[0.51,1.67]
Tyden 2009 8/53 1/48 38.94% 7.25[0.94,55.82]
Subtotal (95% CI) 191 190 100% 2.06[0.27,15.64]
Total events: 26 (Rituximab), 21 (Placebo/no induction)  
Heterogeneity: Tau2=1.66; Chi2=3.82, df=1(P=0.05); I2=73.81%  
Test for overall effect: Z=0.7(P=0.48)  
   
5.1.3 GraB loss (all cause) at 6 months  
Smeekens 2013 7/138 14/142 82.91% 0.51[0.21,1.24]
Tyden 2009 2/68 2/68 17.09% 1[0.15,6.9]
Subtotal (95% CI) 206 210 100% 0.58[0.26,1.28]
Total events: 9 (Rituximab), 16 (Placebo/no induction)  
Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%  
Test for overall effect: Z=1.35(P=0.18)  
   
5.1.4 GraB loss (death censored) at 6 months  
Smeekens 2013 5/135 10/136 87.35% 0.5[0.18,1.43]
Tyden 2009 1/67 1/67 12.65% 1[0.06,15.66]
Subtotal (95% CI) 202 203 100% 0.55[0.21,1.46]
Total events: 6 (Rituximab), 11 (Placebo/no induction)  
Heterogeneity: Tau2=0; Chi2=0.21, df=1(P=0.65); I2=0%  
Test for overall effect: Z=1.2(P=0.23)  
   
5.1.5 Acute rejection at 6 months  
Less with rituximab 2000.005 100.1 1 Less with control
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Study or subgroup Rituximab Placebo/no
induction
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Smeekens 2013 23/138 30/142 72.51% 0.79[0.48,1.29]
Tsai 2012 0/15 4/16 2.16% 0.12[0.01,2.02]
Tyden 2009 8/68 12/68 25.34% 0.67[0.29,1.53]
Subtotal (95% CI) 221 226 100% 0.73[0.48,1.1]
Total events: 31 (Rituximab), 46 (Placebo/no induction)  
Heterogeneity: Tau2=0; Chi2=1.77, df=2(P=0.41); I2=0%  
Test for overall effect: Z=1.51(P=0.13)  
   
5.1.6 Delayed graB function  
Smeekens 2013 26/138 25/142 100% 1.07[0.65,1.76]
Subtotal (95% CI) 138 142 100% 1.07[0.65,1.76]
Total events: 26 (Rituximab), 25 (Placebo/no induction)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.79)  
Test for subgroup differences: Chi2=3.97, df=1 (P=0.55), I2=0%  
Less with rituximab 2000.005 100.1 1 Less with control
 
 
Analysis 5.2.   Comparison 5 Rituximab versus placebo, Outcome 2 Other adverse outcomes.
Study or subgroup Rituximab Placebo/no
induction
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.2.1 CMV infection  
Smeekens 2013 20/138 16/142 93% 1.29[0.7,2.38]
Tyden 2009 3/68 1/68 7% 3[0.32,28.13]
Subtotal (95% CI) 206 210 100% 1.36[0.75,2.47]
Total events: 23 (Rituximab), 17 (Placebo/no induction)  
Heterogeneity: Tau2=0; Chi2=0.51, df=1(P=0.47); I2=0%  
Test for overall effect: Z=1.03(P=0.3)  
   
5.2.2 BK virus infection  
Tyden 2009 1/68 4/68 100% 0.25[0.03,2.18]
Subtotal (95% CI) 68 68 100% 0.25[0.03,2.18]
Total events: 1 (Rituximab), 4 (Placebo/no induction)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
5.2.3 Fungal infection at 6 months  
Smeekens 2013 23/138 28/142 86.63% 0.85[0.51,1.39]
Tsai 2012 0/15 1/16 2.21% 0.35[0.02,8.08]
Tyden 2009 3/68 5/68 11.16% 0.6[0.15,2.41]
Subtotal (95% CI) 221 226 100% 0.8[0.5,1.27]
Total events: 26 (Rituximab), 34 (Placebo/no induction)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.95(P=0.34)  
   
5.2.4 Leucopenia at 6 months  
Smeekens 2013 26/138 2/142 66.86% 13.38[3.24,55.29]
Tyden 2009 3/68 1/68 33.14% 3[0.32,28.13]
Less with rituximab 1000.01 100.1 1 Less with control
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Study or subgroup Rituximab Placebo/no
induction
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 206 210 100% 8.15[2,33.15]
Total events: 29 (Rituximab), 3 (Placebo/no induction)  
Heterogeneity: Tau2=0.24; Chi2=1.26, df=1(P=0.26); I2=20.95%  
Test for overall effect: Z=2.93(P=0)  
   
5.2.5 Malignancy at 2 years  
Smeekens 2013 8/138 8/142 100% 1.03[0.4,2.66]
Subtotal (95% CI) 138 142 100% 1.03[0.4,2.66]
Total events: 8 (Rituximab), 8 (Placebo/no induction)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
Test for subgroup differences: Chi2=11.96, df=1 (P=0.02), I2=66.56%  
Less with rituximab 1000.01 100.1 1 Less with control
 
 
Analysis 5.3.   Comparison 5 Rituximab versus placebo, Outcome 3 GraB function at 6 months (eGFR).
Study or subgroup Rituximab Placebo/no
induction
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Smeekens 2013 130 51.3 (16.9) 126 50.6 (17) 77.36% 0.7[-3.45,4.85]
Tyden 2009 66 66 (22) 66 67 (23) 22.64% -1[-8.68,6.68]
   
Total *** 196   192   100% 0.32[-3.34,3.97]
Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%  
Test for overall effect: Z=0.17(P=0.87)  
Higher with control 105-10 -5 0 Higher with rituximab
 
 
Comparison 6.   ATG versus OKT3
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Main outcomes 6   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 Death at 6 to 12 months 5 451 Risk Ratio (M-H, Random, 95%
CI)
1.29 [0.64, 2.60]
1.2 GraB loss (death censored) at 6 to 12
months
5 439 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.64, 1.57]
1.3 Acute rejection at 1 year 4 450 Risk Ratio (M-H, Random, 95%
CI)
0.76 [0.53, 1.09]
1.4 Delayed graB function 3 235 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.52, 1.24]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 Other adverse outcomes 5   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 CMV infection 3 274 Risk Ratio (M-H, Random, 95%
CI)
1.13 [0.88, 1.46]
2.2 Bacterial infection 1 50 Risk Ratio (M-H, Random, 95%
CI)
0.51 [0.20, 1.32]
2.3 Leucopenia 1 104 Risk Ratio (M-H, Random, 95%
CI)
1.92 [0.78, 4.74]
2.4 Thrombocytopenia 1 104 Risk Ratio (M-H, Random, 95%
CI)
4.81 [0.24, 97.91]
2.5 Malignancy at 1 year 1 104 Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
2.6 Unable to complete induction due to
side effects
2 131 Risk Ratio (M-H, Random, 95%
CI)
1.96 [0.10, 39.72]
3 Serum creatinine at 1 year 1   Mean Difference (IV, Random,
95% CI)
Subtotals only
 
 
Analysis 6.1.   Comparison 6 ATG versus OKT3, Outcome 1 Main outcomes.
Study or subgroup ATG OKT3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.1.1 Death at 6 to 12 months  
Bock 1995 2/53 4/51 17.96% 0.48[0.09,2.51]
Cole 1994 9/83 6/83 50.38% 1.5[0.56,4.03]
Fukuuchi 1996 5/37 1/44 11.11% 5.95[0.73,48.66]
Kumar 1998a 2/26 2/24 13.89% 0.92[0.14,6.05]
Perez-Tamajon 1996 1/26 1/24 6.66% 0.92[0.06,13.95]
Subtotal (95% CI) 225 226 100% 1.29[0.64,2.6]
Total events: 19 (ATG), 14 (OKT3)  
Heterogeneity: Tau2=0; Chi2=3.69, df=4(P=0.45); I2=0%  
Test for overall effect: Z=0.71(P=0.48)  
   
6.1.2 GraB loss (death censored) at 6 to 12 months  
Bock 1995 3/51 7/47 12.11% 0.39[0.11,1.44]
Cole 1994 19/83 16/83 57.92% 1.19[0.66,2.15]
Fukuuchi 1996 6/37 8/44 21.8% 0.89[0.34,2.34]
Kumar 1998a 2/24 2/22 5.78% 0.92[0.14,5.96]
Perez-Tamajon 1996 3/25 0/23 2.39% 6.46[0.35,118.71]
Subtotal (95% CI) 220 219 100% 1[0.64,1.57]
Total events: 33 (ATG), 33 (OKT3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.01(P=0.99)  
Less with ATG 2000.005 100.1 1 Less with OKT3
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Study or subgroup ATG OKT3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
6.1.3 Acute rejection at 1 year  
Bock 1995 14/53 23/51 21.38% 0.59[0.34,1.01]
Cole 1994 32/75 54/78 32.49% 0.62[0.46,0.83]
Kumar 1998a 6/26 6/24 9.97% 0.92[0.34,2.47]
Raffaele 1991 50/73 47/70 36.16% 1.02[0.81,1.28]
Subtotal (95% CI) 227 223 100% 0.76[0.53,1.09]
Total events: 102 (ATG), 130 (OKT3)  
Heterogeneity: Tau2=0.08; Chi2=9.08, df=3(P=0.03); I2=66.94%  
Test for overall effect: Z=1.5(P=0.13)  
   
6.1.4 Delayed graB function  
Bock 1995 14/53 15/51 48.98% 0.9[0.48,1.67]
Fukuuchi 1996 9/37 16/44 39.4% 0.67[0.34,1.33]
Perez-Tamajon 1996 4/26 4/24 11.62% 0.92[0.26,3.29]
Subtotal (95% CI) 116 119 100% 0.8[0.52,1.24]
Total events: 27 (ATG), 35 (OKT3)  
Heterogeneity: Tau2=0; Chi2=0.44, df=2(P=0.8); I2=0%  
Test for overall effect: Z=1(P=0.32)  
Test for subgroup differences: Chi2=2.26, df=1 (P=0.52), I2=0%  
Less with ATG 2000.005 100.1 1 Less with OKT3
 
 
Analysis 6.2.   Comparison 6 ATG versus OKT3, Outcome 2 Other adverse outcomes.
Study or subgroup ATG OKT3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.2.1 CMV infection  
Fukuuchi 1996 25/37 29/44 61.5% 1.03[0.75,1.4]
Kumar 1998a 3/26 4/24 3.29% 0.69[0.17,2.78]
Raffaele 1991 34/73 23/70 35.21% 1.42[0.94,2.15]
Subtotal (95% CI) 136 138 100% 1.13[0.88,1.46]
Total events: 62 (ATG), 56 (OKT3)  
Heterogeneity: Tau2=0; Chi2=2.07, df=2(P=0.35); I2=3.5%  
Test for overall effect: Z=0.98(P=0.33)  
   
6.2.2 Bacterial infection  
Kumar 1998a 5/26 9/24 100% 0.51[0.2,1.32]
Subtotal (95% CI) 26 24 100% 0.51[0.2,1.32]
Total events: 5 (ATG), 9 (OKT3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.39(P=0.16)  
   
6.2.3 Leucopenia  
Bock 1995 12/53 6/51 100% 1.92[0.78,4.74]
Subtotal (95% CI) 53 51 100% 1.92[0.78,4.74]
Total events: 12 (ATG), 6 (OKT3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.42(P=0.15)  
   
Less with ATG 2000.005 100.1 1 Less with OKT3
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Study or subgroup ATG OKT3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.2.4 Thrombocytopenia  
Bock 1995 2/53 0/51 100% 4.81[0.24,97.91]
Subtotal (95% CI) 53 51 100% 4.81[0.24,97.91]
Total events: 2 (ATG), 0 (OKT3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.02(P=0.31)  
   
6.2.5 Malignancy at 1 year  
Bock 1995 0/53 0/51   Not estimable
Subtotal (95% CI) 53 51 Not estimable
Total events: 0 (ATG), 0 (OKT3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.2.6 Unable to complete induction due to side effects  
Fukuuchi 1996 0/37 1/44 47.5% 0.39[0.02,9.41]
Perez-Tamajon 1996 4/26 0/24 52.5% 8.33[0.47,147.07]
Subtotal (95% CI) 63 68 100% 1.96[0.1,39.72]
Total events: 4 (ATG), 1 (OKT3)  
Heterogeneity: Tau2=2.35; Chi2=1.99, df=1(P=0.16); I2=49.65%  
Test for overall effect: Z=0.44(P=0.66)  
Test for subgroup differences: Chi2=5.06, df=1 (P=0.28), I2=20.95%  
Less with ATG 2000.005 100.1 1 Less with OKT3
 
 
Analysis 6.3.   Comparison 6 ATG versus OKT3, Outcome 3 Serum creatinine at 1 year.
Study or subgroup ATG OKT3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bock 1995 48 136 (10) 40 136 (7) 0% 0[-3.56,3.56]
Lower with ATG 42-4 -2 0 Lower with OKT3
 
 
Comparison 7.   OKT3 versus placebo/no induction
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Main outcomes 12   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death at 1 to 2 years 6 491 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.18, 0.97]
1.2 Death at 3 to 5 years 5 768 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.37, 1.44]
1.3 GraB loss (all cause) at 1 to 2 years 7 416 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.30, 1.02]
1.4 GraB loss (all cause) at 3 to 5 years 5 768 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.47, 1.14]
1.5 Acute rejection, any episode (+ CNI) 8 968 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.43, 0.83]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.6 Acute rejection at 3 months (no
CNI)
3 85 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.33, 1.46]
1.7 Delayed graB function 6 494 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.70, 1.65]
2 Other adverse effects 6   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Infection (all cause) 1 108 Risk Ratio (M-H, Random, 95% CI) 1.38 [1.04, 1.82]
2.2 Bacterial infection 3 366 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.76, 1.34]
2.3 Viral infection (all cause) 2 353 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.72, 1.37]
2.4 CMV infection 3 332 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.82, 2.84]
2.5 HSV infection 1 215 Risk Ratio (M-H, Random, 95% CI) 1.45 [0.89, 2.38]
2.6 Fungal infection 3 568 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.33, 4.89]
2.7 Malignancy or PTLD 3 610 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.52, 3.50]
3 Serum creatinine 5   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.1 3 months 3 226 Mean Difference (IV, Random,
95% CI)
-0.93 [-15.78, 13.93]
3.2 1 year 2 261 Mean Difference (IV, Random,
95% CI)
-6.22 [-18.21, 5.76]
3.3 3 to 4 years 2 38 Mean Difference (IV, Random,
95% CI)
-21.10 [-49.81, 7.61]
 
 
Analysis 7.1.   Comparison 7 OKT3 versus placebo/no induction, Outcome 1 Main outcomes.
Study or subgroup OKT3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.1.1 Death at 1 to 2 years  
Ackermann 1988 0/33 0/33   Not estimable
Henry 2001 2/55 3/49 23.92% 0.59[0.1,3.41]
Kreis 1986 0/19 1/18 7.42% 0.32[0.01,7.3]
Morales 1994a 2/41 4/41 27.11% 0.5[0.1,2.58]
Norman 1988 0/34 0/38   Not estimable
Shield 1993 4/99 4/31 41.55% 0.31[0.08,1.18]
Subtotal (95% CI) 281 210 100% 0.41[0.18,0.97]
Total events: 8 (OKT3), 12 (Control)  
Heterogeneity: Tau2=0; Chi2=0.42, df=3(P=0.94); I2=0%  
Test for overall effect: Z=2.02(P=0.04)  
   
Less with OKT3 1000.01 100.1 1 Less with control
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Study or subgroup OKT3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.1.2 Death at 3 to 5 years  
Abramowicz 1992 3/56 3/52 14.35% 0.93[0.2,4.4]
Benfield 1999 8/147 4/140 20.99% 1.9[0.59,6.18]
Debure 1987 0/18 1/18 4.38% 0.33[0.01,7.68]
Norman 1993 10/105 12/102 31.76% 0.81[0.37,1.79]
Shield 1993 8/99 8/31 28.52% 0.31[0.13,0.76]
Subtotal (95% CI) 425 343 100% 0.72[0.37,1.44]
Total events: 29 (OKT3), 28 (Control)  
Heterogeneity: Tau2=0.22; Chi2=6.45, df=4(P=0.17); I2=37.99%  
Test for overall effect: Z=0.92(P=0.36)  
   
7.1.3 GraB loss (all cause) at 1 to 2 years  
Ackermann 1988 0/33 0/33   Not estimable
De Pauw 1990 2/21 3/21 13.03% 0.67[0.12,3.59]
Henry 2001 2/55 4/49 13.51% 0.45[0.09,2.33]
Kreis 1986 1/19 3/18 7.85% 0.32[0.04,2.76]
Morales 1994a 6/41 7/41 36.87% 0.86[0.32,2.33]
Norman 1988 3/34 9/38 24.73% 0.37[0.11,1.26]
Vigeral 1986 0/6 1/7 4.01% 0.38[0.02,7.93]
Subtotal (95% CI) 209 207 100% 0.55[0.3,1.02]
Total events: 14 (OKT3), 27 (Control)  
Heterogeneity: Tau2=0; Chi2=1.58, df=5(P=0.9); I2=0%  
Test for overall effect: Z=1.91(P=0.06)  
   
7.1.4 GraB loss (all cause) at 3 to 5 years  
Abramowicz 1992 9/56 13/52 16.91% 0.64[0.3,1.38]
Benfield 1999 39/147 27/140 25.64% 1.38[0.89,2.12]
Debure 1987 2/18 5/18 6.87% 0.4[0.09,1.8]
Norman 1993 28/105 37/102 26.34% 0.74[0.49,1.11]
Shield 1993 25/99 16/31 24.24% 0.49[0.3,0.79]
Subtotal (95% CI) 425 343 100% 0.73[0.47,1.14]
Total events: 103 (OKT3), 98 (Control)  
Heterogeneity: Tau2=0.15; Chi2=11.44, df=4(P=0.02); I2=65.04%  
Test for overall effect: Z=1.38(P=0.17)  
   
7.1.5 Acute rejection, any episode (+ CNI)  
Abramowicz 1992 21/56 41/52 15.49% 0.48[0.33,0.69]
Ackermann 1988 5/33 20/33 8.39% 0.25[0.11,0.59]
Benfield 1999 82/147 72/140 17.7% 1.08[0.87,1.35]
De Pauw 1990 10/21 14/21 12.63% 0.71[0.42,1.23]
Henry 2001 6/55 13/49 8.02% 0.41[0.17,1]
Morales 1994a 22/41 30/41 15.92% 0.73[0.52,1.03]
Norman 1988 2/34 19/38 4.39% 0.12[0.03,0.47]
Norman 1993 54/105 67/102 17.48% 0.78[0.62,0.99]
Subtotal (95% CI) 492 476 100% 0.6[0.43,0.83]
Total events: 202 (OKT3), 276 (Control)  
Heterogeneity: Tau2=0.15; Chi2=33.93, df=7(P<0.0001); I2=79.37%  
Test for overall effect: Z=3.07(P=0)  
   
7.1.6 Acute rejection at 3 months (no CNI)  
Debure 1987 11/18 13/17 34.21% 0.8[0.51,1.26]
Kreis 1986 6/19 18/18 30.43% 0.33[0.18,0.63]
Less with OKT3 1000.01 100.1 1 Less with control
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Study or subgroup OKT3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Vigeral 1986 6/6 6/7 35.36% 1.14[0.77,1.69]
Subtotal (95% CI) 43 42 100% 0.7[0.33,1.46]
Total events: 23 (OKT3), 37 (Control)  
Heterogeneity: Tau2=0.36; Chi2=14.08, df=2(P=0); I2=85.79%  
Test for overall effect: Z=0.96(P=0.34)  
   
7.1.7 Delayed graB function  
Abramowicz 1992 35/56 21/52 22.62% 1.55[1.05,2.28]
Ackermann 1988 8/33 6/33 11.82% 1.33[0.52,3.42]
De Pauw 1990 14/21 6/21 15.14% 2.33[1.11,4.89]
Morales 1994a 10/41 13/41 15.88% 0.77[0.38,1.55]
Norman 1988 11/34 19/38 18.36% 0.65[0.36,1.16]
Shield 1993 21/99 8/25 16.19% 0.66[0.33,1.32]
Subtotal (95% CI) 284 210 100% 1.08[0.7,1.65]
Total events: 99 (OKT3), 73 (Control)  
Heterogeneity: Tau2=0.17; Chi2=13.38, df=5(P=0.02); I2=62.62%  
Test for overall effect: Z=0.33(P=0.74)  
Test for subgroup differences: Chi2=6.86, df=1 (P=0.33), I2=12.53%  
Less with OKT3 1000.01 100.1 1 Less with control
 
 
Analysis 7.2.   Comparison 7 OKT3 versus placebo/no induction, Outcome 2 Other adverse e>ects.
Study or subgroup OKT3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.2.1 Infection (all cause)  
Abramowicz 1992 43/56 29/52 100% 1.38[1.04,1.82]
Subtotal (95% CI) 56 52 100% 1.38[1.04,1.82]
Total events: 43 (OKT3), 29 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.23(P=0.03)  
   
7.2.2 Bacterial infection  
Ackermann 1988 20/33 19/33 51.19% 1.05[0.7,1.57]
Benfield 1999 34/147 33/140 47% 0.98[0.65,1.49]
Vigeral 1986 1/6 2/7 1.81% 0.58[0.07,4.95]
Subtotal (95% CI) 186 180 100% 1.01[0.76,1.34]
Total events: 55 (OKT3), 54 (Control)  
Heterogeneity: Tau2=0; Chi2=0.32, df=2(P=0.85); I2=0%  
Test for overall effect: Z=0.05(P=0.96)  
   
7.2.3 Viral infection (all cause)  
Ackermann 1988 7/33 6/33 10.76% 1.17[0.44,3.1]
Benfield 1999 46/147 45/140 89.24% 0.97[0.69,1.37]
Subtotal (95% CI) 180 173 100% 0.99[0.72,1.37]
Total events: 53 (OKT3), 51 (Control)  
Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%  
Test for overall effect: Z=0.04(P=0.96)  
   
7.2.4 CMV infection  
Less with OKT3 2000.005 100.1 1 Less with control
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Study or subgroup OKT3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Henry 2001 11/55 8/49 56.81% 1.23[0.54,2.8]
Norman 1993 13/111 5/104 39% 2.44[0.9,6.6]
Vigeral 1986 0/6 1/7 4.2% 0.38[0.02,7.93]
Subtotal (95% CI) 172 160 100% 1.52[0.82,2.84]
Total events: 24 (OKT3), 14 (Control)  
Heterogeneity: Tau2=0; Chi2=1.93, df=2(P=0.38); I2=0%  
Test for overall effect: Z=1.33(P=0.18)  
   
7.2.5 HSV infection  
Norman 1993 31/111 20/104 100% 1.45[0.89,2.38]
Subtotal (95% CI) 111 104 100% 1.45[0.89,2.38]
Total events: 31 (OKT3), 20 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.48(P=0.14)  
   
7.2.6 Fungal infection  
Ackermann 1988 12/33 3/33 38.23% 4[1.24,12.88]
Benfield 1999 0/147 3/140 15.09% 0.14[0.01,2.61]
Norman 1993 14/111 13/104 46.69% 1.01[0.5,2.04]
Subtotal (95% CI) 291 277 100% 1.26[0.33,4.89]
Total events: 26 (OKT3), 19 (Control)  
Heterogeneity: Tau2=0.89; Chi2=6.28, df=2(P=0.04); I2=68.17%  
Test for overall effect: Z=0.34(P=0.74)  
   
7.2.7 Malignancy or PTLD  
Abramowicz 1992 1/56 1/52 12.11% 0.93[0.06,14.47]
Benfield 1999 5/147 3/140 45.78% 1.59[0.39,6.52]
Norman 1993 4/111 3/104 42.11% 1.25[0.29,5.45]
Subtotal (95% CI) 314 296 100% 1.34[0.52,3.5]
Total events: 10 (OKT3), 7 (Control)  
Heterogeneity: Tau2=0; Chi2=0.13, df=2(P=0.94); I2=0%  
Test for overall effect: Z=0.61(P=0.54)  
Test for subgroup differences: Chi2=4.84, df=1 (P=0.56), I2=0%  
Less with OKT3 2000.005 100.1 1 Less with control
 
 
Analysis 7.3.   Comparison 7 OKT3 versus placebo/no induction, Outcome 3 Serum creatinine.
Study or subgroup OKT3 Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.3.1 3 months  
Abramowicz 1992 48 127 (36) 40 133 (56) 54.49% -6[-26.12,14.12]
Ackermann 1988 33 141.4 (61.9) 33 150.3 (70.7) 21.47% -8.9[-40.96,23.16]
Norman 1988 34 150.3 (77.3) 38 132.6 (49) 24.04% 17.7[-12.6,48]
Subtotal *** 115   111   100% -0.93[-15.78,13.93]
Heterogeneity: Tau2=0; Chi2=1.93, df=2(P=0.38); I2=0%  
Test for overall effect: Z=0.12(P=0.9)  
   
7.3.2 1 year  
Abramowicz 1992 45 128 (34) 37 133 (38) 57.78% -5[-20.77,10.77]
Lower with OKT3 10050-100 -50 0 Lower with control
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Study or subgroup OKT3 Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Norman 1993 95 145.9 (53.9) 84 153.8 (69.8) 42.22% -7.9[-26.35,10.55]
Subtotal *** 140   121   100% -6.22[-18.21,5.76]
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.81); I2=0%  
Test for overall effect: Z=1.02(P=0.31)  
   
7.3.3 3 to 4 years  
Abramowicz 1992 5 104 (11) 5 147 (43) 30.91% -43[-81.9,-4.1]
Debure 1987 16 123.1 (8.1) 12 134.4 (8.6) 69.09% -11.3[-17.58,-5.02]
Subtotal *** 21   17   100% -21.1[-49.81,7.61]
Heterogeneity: Tau2=300.31; Chi2=2.49, df=1(P=0.11); I2=59.77%  
Test for overall effect: Z=1.44(P=0.15)  
Test for subgroup differences: Chi2=1.51, df=1 (P=0.47), I2=0%  
Lower with OKT3 10050-100 -50 0 Lower with control
 
 
Comparison 8.   ALG versus OKT3
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Main outcomes 6   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death at 1 to 2 years 3 300 Risk Ratio (M-H, Random, 95% CI) 2.00 [0.62, 6.47]
1.2 Death at 3 years 2 265 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.13, 8.09]
1.3 GraB loss (all cause) at 1 to 2
years
3 300 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.57, 1.80]
1.4 GraB loss (all cause) at 3 years 2 265 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.68, 1.70]
1.5 Acute rejection (any episode) 6 593 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.83, 1.13]
1.6 Delayed graB function 3 310 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.61, 0.99]
2 Other adverse outcomes 6   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 CMV infection 4 431 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.82, 2.85]
2.2 Viral infection (not CMV) 1 148 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.34, 1.65]
2.3 Serious infection 1 124 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.19, 3.43]
2.4 Viral infection (all cause) 2 66 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.69, 2.64]
2.5 PCP 1 28 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.05, 4.90]
2.6 PTLD 1 124 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Serum creatinine 3   Mean Difference (IV, Random, 95%
CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3.1 1 year 2 245 Mean Difference (IV, Random, 95%
CI)
-15.85 [-28.55, -3.15]
3.2 2 years 2 223 Mean Difference (IV, Random, 95%
CI)
12.50 [-13.52, 38.52]
 
 
Analysis 8.1.   Comparison 8 ALG versus OKT3, Outcome 1 Main outcomes.
Study or subgroup ALG OKT3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.1.1 Death at 1 to 2 years  
Frey 1991 6/71 2/67 56.44% 2.83[0.59,13.54]
Grino 1991 2/60 1/64 24.52% 2.13[0.2,22.92]
Vela 1994 1/23 1/15 19.04% 0.65[0.04,9.65]
Subtotal (95% CI) 154 146 100% 2[0.62,6.47]
Total events: 9 (ALG), 4 (OKT3)  
Heterogeneity: Tau2=0; Chi2=0.86, df=2(P=0.65); I2=0%  
Test for overall effect: Z=1.15(P=0.25)  
   
8.1.2 Death at 3 years  
Broyer 1993 1/71 3/77 49.92% 0.36[0.04,3.4]
Hanto 1991 3/59 1/58 50.08% 2.95[0.32,27.54]
Subtotal (95% CI) 130 135 100% 1.03[0.13,8.09]
Total events: 4 (ALG), 4 (OKT3)  
Heterogeneity: Tau2=0.9; Chi2=1.69, df=1(P=0.19); I2=40.86%  
Test for overall effect: Z=0.03(P=0.97)  
   
8.1.3 GraB loss (all cause) at 1 to 2 years  
Frey 1991 14/71 9/67 42.96% 1.47[0.68,3.16]
Grino 1991 7/60 7/64 28.67% 1.07[0.4,2.86]
Vela 1994 5/23 6/15 28.37% 0.54[0.2,1.47]
Subtotal (95% CI) 154 146 100% 1.01[0.57,1.8]
Total events: 26 (ALG), 22 (OKT3)  
Heterogeneity: Tau2=0.05; Chi2=2.43, df=2(P=0.3); I2=17.8%  
Test for overall effect: Z=0.04(P=0.97)  
   
8.1.4 GraB loss (all cause) at 3 years  
Broyer 1993 16/71 16/77 56.28% 1.08[0.59,2]
Hanto 1991 13/59 12/58 43.72% 1.06[0.53,2.14]
Subtotal (95% CI) 130 135 100% 1.08[0.68,1.7]
Total events: 29 (ALG), 28 (OKT3)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%  
Test for overall effect: Z=0.31(P=0.76)  
   
8.1.5 Acute rejection (any episode)  
Broyer 1993 49/71 56/77 56.08% 0.95[0.77,1.17]
Frey 1991 32/71 23/67 13.73% 1.31[0.86,2]
Grino 1991 8/60 12/64 3.57% 0.71[0.31,1.62]
Less with ALG 1000.01 100.1 1 Less with OKT3
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Study or subgroup ALG OKT3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hanto 1991 19/59 26/58 11.03% 0.72[0.45,1.15]
Niaudet 1990 10/14 9/14 9.2% 1.11[0.67,1.85]
Vela 1994 12/23 8/15 6.39% 0.98[0.53,1.81]
Subtotal (95% CI) 298 295 100% 0.97[0.83,1.13]
Total events: 130 (ALG), 134 (OKT3)  
Heterogeneity: Tau2=0; Chi2=4.46, df=5(P=0.49); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
   
8.1.6 Delayed graB function  
Broyer 1993 37/71 53/77 80.55% 0.76[0.58,0.99]
Grino 1991 13/60 12/64 11.85% 1.16[0.57,2.33]
Vela 1994 6/23 7/15 7.6% 0.56[0.23,1.34]
Subtotal (95% CI) 154 156 100% 0.78[0.61,0.99]
Total events: 56 (ALG), 72 (OKT3)  
Heterogeneity: Tau2=0; Chi2=1.86, df=2(P=0.4); I2=0%  
Test for overall effect: Z=2.04(P=0.04)  
Test for subgroup differences: Chi2=4.46, df=1 (P=0.49), I2=0%  
Less with ALG 1000.01 100.1 1 Less with OKT3
 
 
Analysis 8.2.   Comparison 8 ALG versus OKT3, Outcome 2 Other adverse outcomes.
Study or subgroup ALG OKT3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.2.1 CMV infection  
Broyer 1993 11/71 14/77 28.3% 0.85[0.41,1.75]
Frey 1991 23/71 14/67 32.8% 1.55[0.87,2.75]
Hanto 1991 22/59 6/58 25.3% 3.6[1.58,8.24]
Niaudet 1990 3/14 3/14 13.6% 1[0.24,4.13]
Subtotal (95% CI) 215 216 100% 1.53[0.82,2.85]
Total events: 59 (ALG), 37 (OKT3)  
Heterogeneity: Tau2=0.22; Chi2=7.06, df=3(P=0.07); I2=57.49%  
Test for overall effect: Z=1.33(P=0.18)  
   
8.2.2 Viral infection (not CMV)  
Broyer 1993 9/71 13/77 100% 0.75[0.34,1.65]
Subtotal (95% CI) 71 77 100% 0.75[0.34,1.65]
Total events: 9 (ALG), 13 (OKT3)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.71(P=0.48)  
   
8.2.3 Serious infection  
Grino 1991 3/60 4/64 100% 0.8[0.19,3.43]
Subtotal (95% CI) 60 64 100% 0.8[0.19,3.43]
Total events: 3 (ALG), 4 (OKT3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.3(P=0.76)  
   
8.2.4 Viral infection (all cause)  
Niaudet 1990 4/14 4/14 32.66% 1[0.31,3.23]
Less with ALG 1000.01 100.1 1 Less with OKT3
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Study or subgroup ALG OKT3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Vela 1994 12/23 5/15 67.34% 1.57[0.69,3.54]
Subtotal (95% CI) 37 29 100% 1.35[0.69,2.64]
Total events: 16 (ALG), 9 (OKT3)  
Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%  
Test for overall effect: Z=0.88(P=0.38)  
   
8.2.5 PCP  
Niaudet 1990 1/14 2/14 100% 0.5[0.05,4.9]
Subtotal (95% CI) 14 14 100% 0.5[0.05,4.9]
Total events: 1 (ALG), 2 (OKT3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.55)  
   
8.2.6 PTLD  
Grino 1991 0/60 0/64   Not estimable
Subtotal (95% CI) 60 64 Not estimable
Total events: 0 (ALG), 0 (OKT3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=2.89, df=1 (P=0.58), I2=0%  
Less with ALG 1000.01 100.1 1 Less with OKT3
 
 
Analysis 8.3.   Comparison 8 ALG versus OKT3, Outcome 3 Serum creatinine.
Study or subgroup ALG OKT3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
8.3.1 1 year  
Broyer 1993 71 101 (58) 77 114 (21) 79.03% -13[-27.28,1.28]
Hanto 1991 48 141.4 (44.2) 49 168 (88.4) 20.97% -26.6[-54.33,1.13]
Subtotal *** 119   126   100% -15.85[-28.55,-3.15]
Heterogeneity: Tau2=0; Chi2=0.73, df=1(P=0.39); I2=0%  
Test for overall effect: Z=2.45(P=0.01)  
   
8.3.2 2 years  
Frey 1991 66 168 (74.5) 65 141.4 (72.4) 46.99% 26.6[1.44,51.76]
Hanto 1991 46 168 (53) 46 168 (53) 53.01% 0[-21.66,21.66]
Subtotal *** 112   111   100% 12.5[-13.52,38.52]
Heterogeneity: Tau2=210.35; Chi2=2.47, df=1(P=0.12); I2=59.46%  
Test for overall effect: Z=0.94(P=0.35)  
Test for subgroup differences: Chi2=3.68, df=1 (P=0.05), I2=72.85%  
Lower with ALG 10050-100 -50 0 Lower with OKT3
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Comparison 9.   ALG versus placebo/no induction
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Main outcomes 16   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death at 1 to 2 years 12 1180 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.96, 1.69]
1.2 Death at 3 to 5 years 2 406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.67, 1.50]
1.3 Death at 15 to 20 years 2 223 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.40, 2.10]
1.4 GraB loss (all cause) at 1 to 2 years 11 1049 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.09]
1.5 GraB loss (all cause) at 3 to 5 years 3 527 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.39]
1.6 GraB loss (all cause) at 15 to 20
years
2 223 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.67, 1.34]
1.7 Acute rejection 13 1575 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.53, 0.92]
1.8 Delayed graB function 5 615 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.31, 0.97]
2 Other adverse outcomes 10   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 CMV infection 3 289 Risk Ratio (M-H, Random, 95% CI) 2.45 [1.23, 4.85]
2.2 Any viral infection 2 324 Risk Ratio (M-H, Random, 95% CI) 2.71 [1.86, 3.95]
2.3 Bacterial infection 4 742 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.92, 1.52]
2.4 Fungal infection 1 230 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.63, 1.95]
2.5 Thrombocytopenia 1 67 Risk Ratio (M-H, Random, 95% CI) 12.19 [3.10, 47.92]
2.6 Leucopenia 2 297 Risk Ratio (M-H, Random, 95% CI) 20.31 [0.61, 676.54]
2.7 Malignancy or PTLD 4 623 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.27, 1.31]
2.8 NODAT 1 105 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.22, 3.93]
3 Serum creatinine 6   Mean Difference (IV, Random, 95%
CI)
Subtotals only
3.1 At 1 to 2 years 4 369 Mean Difference (IV, Random, 95%
CI)
-16.94 [-50.86, 16.97]
3.2 At 10 to 20 years 2 221 Mean Difference (IV, Random, 95%
CI)
-3.77 [-41.06, 33.53]
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Analysis 9.1.   Comparison 9 ALG versus placebo/no induction, Outcome 1 Main outcomes.
Study or subgroup ALG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
9.1.1 Death at 1 to 2 years  
Belitsky 1991 2/57 3/53 2.62% 0.62[0.11,3.57]
Bell 1983 19/86 17/87 23.64% 1.13[0.63,2.02]
Gianello 1987 6/58 2/66 3.29% 3.41[0.72,16.26]
Grundmann 1984 5/47 2/47 3.18% 2.5[0.51,12.25]
Halloran 1982 1/31 0/37 0.8% 3.56[0.15,84.46]
Jakobsen 1981 13/30 7/30 13.64% 1.86[0.86,4]
Launois 1977 3/21 2/15 2.9% 1.07[0.2,5.65]
Maiorca 1984 1/30 0/33 0.8% 3.29[0.14,77.82]
Novick 1983 4/31 9/36 6.94% 0.52[0.18,1.51]
Sansom 1976 17/43 10/42 18.69% 1.66[0.86,3.2]
Slakey 1993 4/61 6/60 5.44% 0.66[0.19,2.21]
Taylor 1976 15/87 14/92 18.05% 1.13[0.58,2.21]
Subtotal (95% CI) 582 598 100% 1.27[0.96,1.69]
Total events: 90 (ALG), 72 (Control)  
Heterogeneity: Tau2=0; Chi2=9.36, df=11(P=0.59); I2=0%  
Test for overall effect: Z=1.67(P=0.1)  
   
9.1.2 Death at 3 to 5 years  
Condie 1985 17/81 18/79 47.63% 0.92[0.51,1.65]
Minnesota Study 1982 20/115 21/131 52.37% 1.08[0.62,1.9]
Subtotal (95% CI) 196 210 100% 1[0.67,1.5]
Total events: 37 (ALG), 39 (Control)  
Heterogeneity: Tau2=0; Chi2=0.16, df=1(P=0.69); I2=0%  
Test for overall effect: Z=0.02(P=0.99)  
   
9.1.3 Death at 15 to 20 years  
Cantarovich 2008 28/60 23/63 61.41% 1.28[0.84,1.95]
Grino 1990 6/50 11/50 38.59% 0.55[0.22,1.36]
Subtotal (95% CI) 110 113 100% 0.92[0.4,2.1]
Total events: 34 (ALG), 34 (Control)  
Heterogeneity: Tau2=0.24; Chi2=2.83, df=1(P=0.09); I2=64.72%  
Test for overall effect: Z=0.2(P=0.84)  
   
9.1.4 GraB loss (all cause) at 1 to 2 years  
Belitsky 1991 11/57 7/53 4.16% 1.46[0.61,3.49]
Bell 1983 40/86 36/87 18.06% 1.12[0.8,1.58]
Gianello 1987 14/58 12/56 6.47% 1.13[0.57,2.22]
Grundmann 1984 14/47 19/47 8.89% 0.74[0.42,1.29]
Halloran 1982 4/31 10/37 2.92% 0.48[0.17,1.37]
Jakobsen 1981 20/30 15/30 12.86% 1.33[0.86,2.07]
Launois 1977 10/21 11/15 9.34% 0.65[0.38,1.12]
Maiorca 1984 7/30 7/33 3.74% 1.1[0.44,2.77]
Novick 1983 10/31 21/36 8.39% 0.55[0.31,0.99]
Sansom 1976 13/43 16/42 8.04% 0.79[0.44,1.44]
Taylor 1976 33/87 41/92 17.15% 0.85[0.6,1.21]
Subtotal (95% CI) 521 528 100% 0.91[0.75,1.09]
Total events: 176 (ALG), 195 (Control)  
Heterogeneity: Tau2=0.02; Chi2=12.74, df=10(P=0.24); I2=21.49%  
Test for overall effect: Z=1.05(P=0.3)  
Less with ALG 10000.001 100.1 1 Less with control
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Study or subgroup ALG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
9.1.5 GraB loss (all cause) at 3 to 5 years  
Condie 1985 36/81 61/79 38.34% 0.58[0.44,0.76]
Minnesota Study 1982 40/115 37/131 35.45% 1.23[0.85,1.78]
Slakey 1993 12/61 16/60 26.21% 0.74[0.38,1.42]
Subtotal (95% CI) 257 270 100% 0.8[0.47,1.39]
Total events: 88 (ALG), 114 (Control)  
Heterogeneity: Tau2=0.18; Chi2=10.93, df=2(P=0); I2=81.71%  
Test for overall effect: Z=0.78(P=0.43)  
   
9.1.6 GraB loss (all cause) at 15 to 20 years  
Cantarovich 2008 41/60 39/63 56.41% 1.1[0.85,1.43]
Grino 1990 24/50 31/50 43.59% 0.77[0.54,1.11]
Subtotal (95% CI) 110 113 100% 0.95[0.67,1.34]
Total events: 65 (ALG), 70 (Control)  
Heterogeneity: Tau2=0.04; Chi2=2.49, df=1(P=0.11); I2=59.91%  
Test for overall effect: Z=0.31(P=0.75)  
   
9.1.7 Acute rejection  
Belitsky 1991 22/56 24/52 7.57% 0.85[0.55,1.32]
Bell 1983 29/86 38/87 7.94% 0.77[0.53,1.13]
Cantarovich 2008 17/60 47/63 7.64% 0.38[0.25,0.58]
Condie 1985 7/81 49/79 5.68% 0.14[0.07,0.29]
Gianello 1987 44/58 39/66 8.69% 1.28[1,1.64]
Grino 1990 10/50 22/50 6.26% 0.45[0.24,0.86]
Grundmann 1984 14/47 25/47 7.07% 0.56[0.33,0.94]
Jakobsen 1981 21/30 24/30 8.44% 0.88[0.65,1.17]
Launois 1977 9/21 13/15 6.95% 0.49[0.29,0.84]
Minnesota Study 1982 65/109 41/121 8.45% 1.76[1.31,2.36]
Novick 1983 22/31 33/36 8.7% 0.77[0.61,0.99]
Slakey 1993 30/61 32/60 8.14% 0.92[0.65,1.31]
Taylor 1976 36/87 59/92 8.45% 0.65[0.48,0.86]
Subtotal (95% CI) 777 798 100% 0.69[0.53,0.92]
Total events: 326 (ALG), 446 (Control)  
Heterogeneity: Tau2=0.22; Chi2=89.95, df=12(P<0.0001); I2=86.66%  
Test for overall effect: Z=2.58(P=0.01)  
   
9.1.8 Delayed graB function  
Belitsky 1991 3/57 5/53 10.81% 0.56[0.14,2.22]
Gianello 1987 15/58 21/66 22.75% 0.81[0.46,1.42]
Grundmann 1984 9/47 36/47 21.91% 0.25[0.14,0.46]
Halloran 1982 8/31 22/34 21.23% 0.4[0.21,0.76]
Minnesota Study 1982 21/104 23/118 23.3% 1.04[0.61,1.76]
Subtotal (95% CI) 297 318 100% 0.55[0.31,0.97]
Total events: 56 (ALG), 107 (Control)  
Heterogeneity: Tau2=0.29; Chi2=14.66, df=4(P=0.01); I2=72.72%  
Test for overall effect: Z=2.05(P=0.04)  
Test for subgroup differences: Chi2=12.5, df=1 (P=0.09), I2=43.99%  
Less with ALG 10000.001 100.1 1 Less with control
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Analysis 9.2.   Comparison 9 ALG versus placebo/no induction, Outcome 2 Other adverse outcomes.
Study or subgroup ALG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
9.2.1 CMV infection  
Cantarovich 2008 11/60 6/63 54.15% 1.93[0.76,4.88]
Halloran 1982 2/19 0/26 5.27% 6.75[0.34,133]
Slakey 1993 12/61 4/60 40.58% 2.95[1.01,8.64]
Subtotal (95% CI) 140 149 100% 2.45[1.23,4.85]
Total events: 25 (ALG), 10 (Control)  
Heterogeneity: Tau2=0; Chi2=0.83, df=2(P=0.66); I2=0%  
Test for overall effect: Z=2.56(P=0.01)  
   
9.2.2 Any viral infection  
Grundmann 1984 9/47 2/47 6.5% 4.5[1.03,19.73]
Minnesota Study 1982 59/109 25/121 93.5% 2.62[1.77,3.87]
Subtotal (95% CI) 156 168 100% 2.71[1.86,3.95]
Total events: 68 (ALG), 27 (Control)  
Heterogeneity: Tau2=0; Chi2=0.49, df=1(P=0.48); I2=0%  
Test for overall effect: Z=5.19(P<0.0001)  
   
9.2.3 Bacterial infection  
Bell 1983 13/86 10/87 9.07% 1.32[0.61,2.84]
Condie 1985 40/81 44/79 32.78% 0.89[0.66,1.19]
Minnesota Study 1982 34/109 28/121 21.89% 1.35[0.88,2.07]
Taylor 1976 57/87 44/92 36.26% 1.37[1.05,1.78]
Subtotal (95% CI) 363 379 100% 1.18[0.92,1.52]
Total events: 144 (ALG), 126 (Control)  
Heterogeneity: Tau2=0.03; Chi2=5.3, df=3(P=0.15); I2=43.39%  
Test for overall effect: Z=1.29(P=0.2)  
   
9.2.4 Fungal infection  
Minnesota Study 1982 20/109 20/121 100% 1.11[0.63,1.95]
Subtotal (95% CI) 109 121 100% 1.11[0.63,1.95]
Total events: 20 (ALG), 20 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
   
9.2.5 Thrombocytopenia  
Novick 1983 21/31 2/36 100% 12.19[3.1,47.92]
Subtotal (95% CI) 31 36 100% 12.19[3.1,47.92]
Total events: 21 (ALG), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.58(P=0)  
   
9.2.6 Leucopenia  
Minnesota Study 1982 44/109 0/121 43.22% 98.71[6.15,1583.79]
Novick 1983 21/31 4/36 56.78% 6.1[2.35,15.85]
Subtotal (95% CI) 140 157 100% 20.31[0.61,676.54]
Total events: 65 (ALG), 4 (Control)  
Heterogeneity: Tau2=5.4; Chi2=5.81, df=1(P=0.02); I2=82.8%  
Test for overall effect: Z=1.68(P=0.09)  
   
9.2.7 Malignancy or PTLD  
Less with ALG 10000.001 100.1 1 Less with control
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Study or subgroup ALG Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Belitsky 1991 2/57 0/53 6.86% 4.66[0.23,94.79]
Cantarovich 2008 7/60 14/63 87.02% 0.53[0.23,1.21]
Condie 1985 0/81 0/79   Not estimable
Minnesota Study 1982 0/109 1/121 6.12% 0.37[0.02,8.98]
Subtotal (95% CI) 307 316 100% 0.6[0.27,1.31]
Total events: 9 (ALG), 15 (Control)  
Heterogeneity: Tau2=0; Chi2=2.01, df=2(P=0.37); I2=0.36%  
Test for overall effect: Z=1.28(P=0.2)  
   
9.2.8 NODAT  
Minnesota Study 1982 3/47 4/58 100% 0.93[0.22,3.93]
Subtotal (95% CI) 47 58 100% 0.93[0.22,3.93]
Total events: 3 (ALG), 4 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.1(P=0.92)  
Test for subgroup differences: Chi2=32.87, df=1 (P<0.0001), I2=78.71%  
Less with ALG 10000.001 100.1 1 Less with control
 
 
Analysis 9.3.   Comparison 9 ALG versus placebo/no induction, Outcome 3 Serum creatinine.
Study or subgroup ALG Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
9.3.1 At 1 to 2 years  
Belitsky 1991 57 144 (44) 53 165 (49) 31.03% -21[-38.45,-3.55]
Gianello 1987 44 133 (141) 54 130 (137) 17.77% 3[-52.42,58.42]
Halloran 1982 27 150.3 (61.9) 27 221 (88.4) 22.74% -70.72[-111.43,-30.01]
Slakey 1993 56 159.1 (68.1) 51 141.1 (65.4) 28.46% 18[-7.3,43.3]
Subtotal *** 184   185   100% -16.94[-50.86,16.97]
Heterogeneity: Tau2=885.64; Chi2=14.58, df=3(P=0); I2=79.42%  
Test for overall effect: Z=0.98(P=0.33)  
   
9.3.2 At 10 to 20 years  
Cantarovich 2008 28 145 (47) 27 128 (56) 45.64% 17[-10.37,44.37]
Minnesota Study 1982 72 131.7 (52.2) 94 152.9 (53) 54.36% -21.2[-37.33,-5.07]
Subtotal *** 100   121   100% -3.77[-41.06,33.53]
Heterogeneity: Tau2=598.24; Chi2=5.55, df=1(P=0.02); I2=81.99%  
Test for overall effect: Z=0.2(P=0.84)  
Test for subgroup differences: Chi2=0.26, df=1 (P=0.61), I2=0%  
Lower with ALG 200100-200 -100 0 Lower with control
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CENTRAL 1. MeSH descriptor Kidney Transplantation explode all trees
2. (kidney transplant* or renal transplant*):ti,ab,kw in Clinical Trials
3. (1 OR 2)
4. MeSH descriptor Antibodies, Monoclonal explode all trees
5. MeSH descriptor Antilymphocyte Serum explode all trees
6. (monoclonal or polyclonal) and antibod*:ti,ab,kw in Clinical Trials
7. (muromonab CD3):ti,ab,kw in Clinical Trials
8. (antilymphocyte* and (globulin* or serum$* or sera* or antibod* or immunoglobulin*)):ti,ab,kw
in Clinical Trials
9. (antithymocyte globulin*):ti,ab,kw in Clinical Trials
10.(atg or alg or okt3 or malg or mabthera* or campath* or atgam*):ti,ab,kw in Clinical Trials
11.(alemtuzumab*):ti,ab,kw in Clinical Trials
12.(rituximab*):ti,ab,kw in Clinical Trials
13.(4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12)
14.(induction):ti,ab,kw in Clinical Trials
15.(13 AND 14)
16.(3 AND 5)
MEDLINE (OvidSP) 1. kidney transplantation/
2. exp antibodies, monoclonal/
3. ((monoclonal or polyclonal) and antibod$).tw.
4. muromonab-CD3.tw.
5. exp Antilymphocyte Serum/
6. (antilymphocyte$ and (globulin$ or serum$ or sera$ or antibod$ or immunoglobulin$)).tw.
7. antithymocyte globulin$.tw.
8. (atg or alg or okt3 or malg or mabthera$ or campath$ or atgam$).tw.
9. alemtuzumab.tw.
10.rituximab.tw.
11.or/2-10
12.induction.tw.
13.and/11-12
14.and/1,13
EMBASE (OvidSP) 1. kidney transplantation/
2. exp monoclonal antibody/
3. polyclonal antibody/
4. lymphocyte antibody/
5. thymocyte antibody/
6. (atg or alg or okt3 or malg or mabthera$ or campath$ or atgam$).tw.
7. (alemtuzumab or rituximab).tw.
8. or/2-7
9. induction.tw.
10.and/8-9
11.and/1,10
  (Continued)
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Low risk of bias: Random number table; computer ran-
dom number generator; coin tossing; shuffling cards or en-
velopes; throwing dice; drawing of lots; minimization (mini-
mization may be implemented without a random element,
and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date
of birth; date (or day) of admission; sequence generated by
hospital or clinic record number; allocation by judgement
of the clinician; by preference of the participant; based on
the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence generation
Selection bias (biased allocation to interventions) due to inadequate
generation of a randomised sequence
Unclear: Insufficient information about the sequence gen-
eration process to permit judgement.
Low risk of bias: Randomisation method described that
would not allow investigator/participant to know or influ-
ence intervention group before eligible participant entered
in the study (e.g. central allocation, including telephone,
web-based, and pharmacy-controlled, randomisation; se-
quentially numbered drug containers of identical appear-
ance; sequentially numbered, opaque, sealed envelopes).
High risk of bias: Using an open random allocation schedule
(e.g. a list of random numbers); assignment envelopes were
used without appropriate safeguards (e.g. if envelopes
were unsealed or non-opaque or not sequentially num-
bered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
Allocation concealment
Selection bias (biased allocation to interventions) due to inadequate
concealment of allocations prior to assignment
Unclear: Randomisation stated but no information on
method used is available.
Low risk of bias: No blinding or incomplete blinding, but the
review authors judge that the outcome is not likely to be in-
fluenced by lack of blinding; blinding of participants and
key study personnel ensured, and unlikely that the blinding
could have been broken.
High risk of bias: No blinding or incomplete blinding, and
the outcome is likely to be influenced by lack of blinding;
blinding of key study participants and personnel attempt-
ed, but likely that the blinding could have been broken, and
the outcome is likely to be influenced by lack of blinding.
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions by
participants and personnel during the study
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but
the review authors judge that the outcome measurement
is not likely to be influenced by lack of blinding; blinding of
outcome assessment ensured, and unlikely that the blind-
ing could have been broken.
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by out-
come assessors.
High risk of bias: No blinding of outcome assessment, and
the outcome measurement is likely to be influenced by lack
of blinding; blinding of outcome assessment, but likely that
  (Continued)
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the blinding could have been broken, and the outcome
measurement is likely to be influenced by lack of blinding.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for miss-
ing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing
bias); missing outcome data balanced in numbers across
intervention groups, with similar reasons for missing data
across groups; for dichotomous outcome data, the propor-
tion of missing outcomes compared with observed event
risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data,
plausible effect size (difference in means or standardized
difference in means) among missing outcomes not enough
to have a clinically relevant impact on observed effect size;
missing data have been imputed using appropriate meth-
ods.
High risk of bias: Reason for missing outcome data like-
ly to be related to true outcome, with either imbalance
in numbers or reasons for missing data across interven-
tion groups; for dichotomous outcome data, the propor-
tion of missing outcomes compared with observed event
risk enough to induce clinically relevant bias in interven-
tion effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized differ-
ence in means) among missing outcomes enough to induce
clinically relevant bias in observed effect size; ‘as-treated’
analysis done with substantial departure of the interven-
tion received from that assigned at randomisation; poten-
tially inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete out-
come data.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study protocol is available and all of
the study’s pre-specified (primary and secondary) out-
comes that are of interest in the review have been reported
in the pre-specified way; the study protocol is not available
but it is clear that the published reports include all expect-
ed outcomes, including those that were pre-specified (con-
vincing text of this nature may be uncommon).
High risk of bias: Not all of the study’s pre-specified prima-
ry outcomes have been reported; one or more primary out-
comes is reported using measurements, analysis methods
or subsets of the data (e.g. subscales) that were not pre-
specified; one or more reported primary outcomes were
not pre-specified (unless clear justification for their report-
ing is provided, such as an unexpected adverse effect); one
or more outcomes of interest in the review are reported in-
completely so that they cannot be entered in a meta-analy-
sis; the study report fails to include results for a key out-
come that would be expected to have been reported for
such a study.
Selective reporting
Reporting bias due to selective outcome reporting
Unclear: Insufficient information to permit judgement
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Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Low risk of bias: The study appears to be free of other
sources of bias.
High risk of bias: Had a potential source of bias related to
the specific study design used; stopped early due to some
data-dependent process (including a formal-stopping rule);
had extreme baseline imbalance; has been claimed to have
been fraudulent; had some other problem.
Other bias
Bias due to problems not covered elsewhere in the table
Unclear: Insufficient information to assess whether an im-
portant risk of bias exists; insufficient rationale or evidence
that an identified problem will introduce bias.
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